Companies:
11,400
total market cap:
$139.540 T
Sign In
๐บ๐ธ
EN
English
$ USD
โฌ
EUR
๐ช๐บ
โน
INR
๐ฎ๐ณ
ยฃ
GBP
๐ฌ๐ง
$
CAD
๐จ๐ฆ
$
AUD
๐ฆ๐บ
$
NZD
๐ณ๐ฟ
$
HKD
๐ญ๐ฐ
$
SGD
๐ธ๐ฌ
Global ranking
Ranking by countries
America
๐บ๐ธ United States
๐จ๐ฆ Canada
๐ฒ๐ฝ Mexico
๐ง๐ท Brazil
๐จ๐ฑ Chile
Europe
๐ช๐บ European Union
๐ฉ๐ช Germany
๐ฌ๐ง United Kingdom
๐ซ๐ท France
๐ช๐ธ Spain
๐ณ๐ฑ Netherlands
๐ธ๐ช Sweden
๐ฎ๐น Italy
๐จ๐ญ Switzerland
๐ต๐ฑ Poland
๐ซ๐ฎ Finland
Asia
๐จ๐ณ China
๐ฏ๐ต Japan
๐ฐ๐ท South Korea
๐ญ๐ฐ Hong Kong
๐ธ๐ฌ Singapore
๐ฎ๐ฉ Indonesia
๐ฎ๐ณ India
๐ฒ๐พ Malaysia
๐น๐ผ Taiwan
๐น๐ญ Thailand
๐ป๐ณ Vietnam
Others
๐ฆ๐บ Australia
๐ณ๐ฟ New Zealand
๐ฎ๐ฑ Israel
๐ธ๐ฆ Saudi Arabia
๐น๐ท Turkey
๐ท๐บ Russia
๐ฟ๐ฆ South Africa
>> All Countries
Ranking by categories
๐ All assets by Market Cap
๐ Automakers
โ๏ธ Airlines
๐ซ Airports
โ๏ธ Aircraft manufacturers
๐ฆ Banks
๐จ Hotels
๐ Pharmaceuticals
๐ E-Commerce
โ๏ธ Healthcare
๐ฆ Courier services
๐ฐ Media/Press
๐ท Alcoholic beverages
๐ฅค Beverages
๐ Clothing
โ๏ธ Mining
๐ Railways
๐ฆ Insurance
๐ Real estate
โ Ports
๐ผ Professional services
๐ด Food
๐ Restaurant chains
โ๐ป Software
๐ Semiconductors
๐ฌ Tobacco
๐ณ Financial services
๐ข Oil&Gas
๐ Electricity
๐งช Chemicals
๐ฐ Investment
๐ก Telecommunication
๐๏ธ Retail
๐ฅ๏ธ Internet
๐ Construction
๐ฎ Video Game
๐ป Tech
๐ฆพ AI
>> All Categories
ETFs
๐ All ETFs
๐๏ธ Bond ETFs
๏ผ Dividend ETFs
โฟ Bitcoin ETFs
โข Ethereum ETFs
๐ช Crypto Currency ETFs
๐ฅ Gold ETFs & ETCs
๐ฅ Silver ETFs & ETCs
๐ข๏ธ Oil ETFs & ETCs
๐ฝ Commodities ETFs & ETNs
๐ Emerging Markets ETFs
๐ Small-Cap ETFs
๐ Low volatility ETFs
๐ Inverse/Bear ETFs
โฌ๏ธ Leveraged ETFs
๐ Global/World ETFs
๐บ๐ธ USA ETFs
๐บ๐ธ S&P 500 ETFs
๐บ๐ธ Dow Jones ETFs
๐ช๐บ Europe ETFs
๐จ๐ณ China ETFs
๐ฏ๐ต Japan ETFs
๐ฎ๐ณ India ETFs
๐ฌ๐ง UK ETFs
๐ฉ๐ช Germany ETFs
๐ซ๐ท France ETFs
โ๏ธ Mining ETFs
โ๏ธ Gold Mining ETFs
โ๏ธ Silver Mining ETFs
๐งฌ Biotech ETFs
๐ฉโ๐ป Tech ETFs
๐ Real Estate ETFs
โ๏ธ Healthcare ETFs
โก Energy ETFs
๐ Renewable Energy ETFs
๐ก๏ธ Insurance ETFs
๐ฐ Water ETFs
๐ด Food & Beverage ETFs
๐ฑ Socially Responsible ETFs
๐ฃ๏ธ Infrastructure ETFs
๐ก Innovation ETFs
๐ Semiconductors ETFs
๐ Aerospace & Defense ETFs
๐ Cybersecurity ETFs
๐ฆพ Artificial Intelligence ETFs
Watchlist
Account
CVS Health
CVS
#209
Rank
$103.43 B
Marketcap
๐บ๐ธ
United States
Country
$80.84
Share price
1.00%
Change (1 day)
6.31%
Change (1 year)
๐ Pharmaceuticals
โ๏ธ Healthcare
๐๏ธ Retail
๐ Drugstore
Categories
Market cap
Revenue
Earnings
Price history
P/E ratio
P/S ratio
More
Price history
P/E ratio
P/S ratio
P/B ratio
Operating margin
EPS
Stock Splits
Dividends
Dividend yield
Shares outstanding
Fails to deliver
Cost to borrow
Total assets
Total liabilities
Total debt
Cash on Hand
Net Assets
Annual Reports
Annual Reports (10-K)
ESG Reports
CVS Health
Quarterly Reports (10-Q)
Financial Year FY2026 Q3
CVS Health - 10-Q quarterly report FY2026 Q3
Text size:
Small
Medium
Large
0000064803
12/31
2026
Q3
false
http://fasb.org/us-gaap/2026#ProductMember
http://fasb.org/us-gaap/2026#ProductMember
http://fasb.org/us-gaap/2026#ProductMember
http://fasb.org/us-gaap/2026#ProductMember
xbrli:shares
iso4217:USD
iso4217:USD
xbrli:shares
cvs:store
cvs:clinic
cvs:people
cvs:segment
cvs:state
cvs:program
cvs:security
xbrli:pure
cvs:lease
cvs:claim
0000064803
2026-01-01
2026-09-30
0000064803
2026-10-28
0000064803
us-gaap:ProductMember
2026-07-01
2026-09-30
0000064803
us-gaap:ProductMember
2025-07-01
2025-09-30
0000064803
us-gaap:ProductMember
2026-01-01
2026-09-30
0000064803
us-gaap:ProductMember
2025-01-01
2025-09-30
0000064803
2026-07-01
2026-09-30
0000064803
2025-07-01
2025-09-30
0000064803
2025-01-01
2025-09-30
0000064803
us-gaap:ServiceMember
2026-07-01
2026-09-30
0000064803
us-gaap:ServiceMember
2025-07-01
2025-09-30
0000064803
us-gaap:ServiceMember
2026-01-01
2026-09-30
0000064803
us-gaap:ServiceMember
2025-01-01
2025-09-30
0000064803
us-gaap:RetainedEarningsMember
2026-07-01
2026-09-30
0000064803
2026-09-30
0000064803
2025-12-31
0000064803
2024-12-31
0000064803
2025-09-30
0000064803
us-gaap:CommonStockMember
2025-12-31
0000064803
us-gaap:TreasuryStockCommonMember
2025-12-31
0000064803
us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember
2025-12-31
0000064803
us-gaap:RetainedEarningsMember
2025-12-31
0000064803
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2025-12-31
0000064803
us-gaap:ParentMember
2025-12-31
0000064803
us-gaap:NoncontrollingInterestMember
2025-12-31
0000064803
us-gaap:RetainedEarningsMember
2026-01-01
2026-03-31
0000064803
us-gaap:ParentMember
2026-01-01
2026-03-31
0000064803
us-gaap:NoncontrollingInterestMember
2026-01-01
2026-03-31
0000064803
2026-01-01
2026-03-31
0000064803
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2026-01-01
2026-03-31
0000064803
us-gaap:CommonStockMember
2026-01-01
2026-03-31
0000064803
us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember
2026-01-01
2026-03-31
0000064803
us-gaap:TreasuryStockCommonMember
2026-01-01
2026-03-31
0000064803
us-gaap:CommonStockMember
2026-03-31
0000064803
us-gaap:TreasuryStockCommonMember
2026-03-31
0000064803
us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember
2026-03-31
0000064803
us-gaap:RetainedEarningsMember
2026-03-31
0000064803
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2026-03-31
0000064803
us-gaap:ParentMember
2026-03-31
0000064803
us-gaap:NoncontrollingInterestMember
2026-03-31
0000064803
2026-03-31
0000064803
us-gaap:RetainedEarningsMember
2026-04-01
2026-06-30
0000064803
us-gaap:ParentMember
2026-04-01
2026-06-30
0000064803
us-gaap:NoncontrollingInterestMember
2026-04-01
2026-06-30
0000064803
2026-04-01
2026-06-30
0000064803
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2026-04-01
2026-06-30
0000064803
us-gaap:CommonStockMember
2026-04-01
2026-06-30
0000064803
us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember
2026-04-01
2026-06-30
0000064803
us-gaap:TreasuryStockCommonMember
2026-04-01
2026-06-30
0000064803
us-gaap:CommonStockMember
2026-06-30
0000064803
us-gaap:TreasuryStockCommonMember
2026-06-30
0000064803
us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember
2026-06-30
0000064803
us-gaap:RetainedEarningsMember
2026-06-30
0000064803
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2026-06-30
0000064803
us-gaap:ParentMember
2026-06-30
0000064803
us-gaap:NoncontrollingInterestMember
2026-06-30
0000064803
2026-06-30
0000064803
us-gaap:ParentMember
2026-07-01
2026-09-30
0000064803
us-gaap:NoncontrollingInterestMember
2026-07-01
2026-09-30
0000064803
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2026-07-01
2026-09-30
0000064803
us-gaap:CommonStockMember
2026-07-01
2026-09-30
0000064803
us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember
2026-07-01
2026-09-30
0000064803
us-gaap:TreasuryStockCommonMember
2026-07-01
2026-09-30
0000064803
us-gaap:CommonStockMember
2026-09-30
0000064803
us-gaap:TreasuryStockCommonMember
2026-09-30
0000064803
us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember
2026-09-30
0000064803
us-gaap:RetainedEarningsMember
2026-09-30
0000064803
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2026-09-30
0000064803
us-gaap:ParentMember
2026-09-30
0000064803
us-gaap:NoncontrollingInterestMember
2026-09-30
0000064803
us-gaap:CommonStockMember
2024-12-31
0000064803
us-gaap:TreasuryStockCommonMember
2024-12-31
0000064803
us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember
2024-12-31
0000064803
us-gaap:RetainedEarningsMember
2024-12-31
0000064803
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2024-12-31
0000064803
us-gaap:ParentMember
2024-12-31
0000064803
us-gaap:NoncontrollingInterestMember
2024-12-31
0000064803
us-gaap:RetainedEarningsMember
2025-01-01
2025-03-31
0000064803
us-gaap:ParentMember
2025-01-01
2025-03-31
0000064803
us-gaap:NoncontrollingInterestMember
2025-01-01
2025-03-31
0000064803
2025-01-01
2025-03-31
0000064803
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2025-01-01
2025-03-31
0000064803
us-gaap:CommonStockMember
2025-01-01
2025-03-31
0000064803
us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember
2025-01-01
2025-03-31
0000064803
us-gaap:TreasuryStockCommonMember
2025-01-01
2025-03-31
0000064803
us-gaap:CommonStockMember
2025-03-31
0000064803
us-gaap:TreasuryStockCommonMember
2025-03-31
0000064803
us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember
2025-03-31
0000064803
us-gaap:RetainedEarningsMember
2025-03-31
0000064803
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2025-03-31
0000064803
us-gaap:ParentMember
2025-03-31
0000064803
us-gaap:NoncontrollingInterestMember
2025-03-31
0000064803
2025-03-31
0000064803
us-gaap:RetainedEarningsMember
2025-04-01
2025-06-30
0000064803
us-gaap:ParentMember
2025-04-01
2025-06-30
0000064803
us-gaap:NoncontrollingInterestMember
2025-04-01
2025-06-30
0000064803
2025-04-01
2025-06-30
0000064803
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2025-04-01
2025-06-30
0000064803
us-gaap:CommonStockMember
2025-04-01
2025-06-30
0000064803
us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember
2025-04-01
2025-06-30
0000064803
us-gaap:TreasuryStockCommonMember
2025-04-01
2025-06-30
0000064803
us-gaap:CommonStockMember
2025-06-30
0000064803
us-gaap:TreasuryStockCommonMember
2025-06-30
0000064803
us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember
2025-06-30
0000064803
us-gaap:RetainedEarningsMember
2025-06-30
0000064803
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2025-06-30
0000064803
us-gaap:ParentMember
2025-06-30
0000064803
us-gaap:NoncontrollingInterestMember
2025-06-30
0000064803
2025-06-30
0000064803
us-gaap:RetainedEarningsMember
2025-07-01
2025-09-30
0000064803
us-gaap:ParentMember
2025-07-01
2025-09-30
0000064803
us-gaap:NoncontrollingInterestMember
2025-07-01
2025-09-30
0000064803
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2025-07-01
2025-09-30
0000064803
us-gaap:CommonStockMember
2025-07-01
2025-09-30
0000064803
us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember
2025-07-01
2025-09-30
0000064803
us-gaap:TreasuryStockCommonMember
2025-07-01
2025-09-30
0000064803
us-gaap:CommonStockMember
2025-09-30
0000064803
us-gaap:TreasuryStockCommonMember
2025-09-30
0000064803
us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember
2025-09-30
0000064803
us-gaap:RetainedEarningsMember
2025-09-30
0000064803
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2025-09-30
0000064803
us-gaap:ParentMember
2025-09-30
0000064803
us-gaap:NoncontrollingInterestMember
2025-09-30
0000064803
cvs:PharmacyAndConsumerHealthSegmentMember
2026-09-30
0000064803
cvs:HealthServicesSegmentMember
2026-09-30
0000064803
cvs:HealthCareBenefitsSegmentMember
2026-09-30
0000064803
cvs:MedicaidProductLineMember
2026-04-01
2026-06-30
0000064803
cvs:IndividualExchangeProductLineMember
2025-01-01
2025-03-31
0000064803
cvs:IndividualExchangeProductLineMember
us-gaap:OtherCostAndExpenseOperating
2025-01-01
2025-03-31
0000064803
cvs:IndividualExchangeProductLineMember
us-gaap:PolicyholderBenefitsAndClaimsIncurredNet
2025-01-01
2025-03-31
0000064803
cvs:GroupMedicareAdvantageProductLineMember
2025-04-01
2025-06-30
0000064803
cvs:HealthCareBenefitsSegmentMember
cvs:PharmacyRevenueMember
us-gaap:OperatingSegmentsMember
2026-07-01
2026-09-30
0000064803
cvs:HealthServicesSegmentMember
cvs:PharmacyRevenueMember
us-gaap:OperatingSegmentsMember
2026-07-01
2026-09-30
0000064803
cvs:PharmacyAndConsumerHealthSegmentMember
cvs:PharmacyRevenueMember
us-gaap:OperatingSegmentsMember
2026-07-01
2026-09-30
0000064803
cvs:CorporateAndOtherSegmentMember
cvs:PharmacyRevenueMember
cvs:CorporateAndReconcilingItemsMember
2026-07-01
2026-09-30
0000064803
cvs:PharmacyRevenueMember
us-gaap:IntersegmentEliminationMember
2026-07-01
2026-09-30
0000064803
cvs:PharmacyRevenueMember
2026-07-01
2026-09-30
0000064803
cvs:HealthCareBenefitsSegmentMember
cvs:FrontStoreRevenueMember
us-gaap:OperatingSegmentsMember
2026-07-01
2026-09-30
0000064803
cvs:HealthServicesSegmentMember
cvs:FrontStoreRevenueMember
us-gaap:OperatingSegmentsMember
2026-07-01
2026-09-30
0000064803
cvs:PharmacyAndConsumerHealthSegmentMember
cvs:FrontStoreRevenueMember
us-gaap:OperatingSegmentsMember
2026-07-01
2026-09-30
0000064803
cvs:CorporateAndOtherSegmentMember
cvs:FrontStoreRevenueMember
cvs:CorporateAndReconcilingItemsMember
2026-07-01
2026-09-30
0000064803
cvs:FrontStoreRevenueMember
us-gaap:IntersegmentEliminationMember
2026-07-01
2026-09-30
0000064803
cvs:FrontStoreRevenueMember
2026-07-01
2026-09-30
0000064803
cvs:HealthCareBenefitsSegmentMember
cvs:PremiumsMember
us-gaap:OperatingSegmentsMember
2026-07-01
2026-09-30
0000064803
cvs:HealthServicesSegmentMember
cvs:PremiumsMember
us-gaap:OperatingSegmentsMember
2026-07-01
2026-09-30
0000064803
cvs:PharmacyAndConsumerHealthSegmentMember
cvs:PremiumsMember
us-gaap:OperatingSegmentsMember
2026-07-01
2026-09-30
0000064803
cvs:CorporateAndOtherSegmentMember
cvs:PremiumsMember
cvs:CorporateAndReconcilingItemsMember
2026-07-01
2026-09-30
0000064803
cvs:PremiumsMember
us-gaap:IntersegmentEliminationMember
2026-07-01
2026-09-30
0000064803
cvs:PremiumsMember
2026-07-01
2026-09-30
0000064803
cvs:HealthCareBenefitsSegmentMember
us-gaap:OperatingSegmentsMember
2026-07-01
2026-09-30
0000064803
cvs:HealthServicesSegmentMember
us-gaap:OperatingSegmentsMember
2026-07-01
2026-09-30
0000064803
cvs:PharmacyAndConsumerHealthSegmentMember
us-gaap:OperatingSegmentsMember
2026-07-01
2026-09-30
0000064803
cvs:CorporateAndOtherSegmentMember
cvs:CorporateAndReconcilingItemsMember
2026-07-01
2026-09-30
0000064803
us-gaap:IntersegmentEliminationMember
2026-07-01
2026-09-30
0000064803
cvs:HealthCareBenefitsSegmentMember
us-gaap:ProductAndServiceOtherMember
us-gaap:OperatingSegmentsMember
2026-07-01
2026-09-30
0000064803
cvs:HealthServicesSegmentMember
us-gaap:ProductAndServiceOtherMember
us-gaap:OperatingSegmentsMember
2026-07-01
2026-09-30
0000064803
cvs:PharmacyAndConsumerHealthSegmentMember
us-gaap:ProductAndServiceOtherMember
us-gaap:OperatingSegmentsMember
2026-07-01
2026-09-30
0000064803
cvs:CorporateAndOtherSegmentMember
us-gaap:ProductAndServiceOtherMember
cvs:CorporateAndReconcilingItemsMember
2026-07-01
2026-09-30
0000064803
us-gaap:ProductAndServiceOtherMember
us-gaap:IntersegmentEliminationMember
2026-07-01
2026-09-30
0000064803
us-gaap:ProductAndServiceOtherMember
2026-07-01
2026-09-30
0000064803
cvs:HealthServicesSegmentMember
us-gaap:SalesChannelThroughIntermediaryMember
us-gaap:OperatingSegmentsMember
2026-07-01
2026-09-30
0000064803
cvs:HealthServicesSegmentMember
us-gaap:SalesChannelDirectlyToConsumerMember
us-gaap:OperatingSegmentsMember
2026-07-01
2026-09-30
0000064803
cvs:HealthServicesSegmentMember
cvs:SalesChannelOtherMember
us-gaap:OperatingSegmentsMember
2026-07-01
2026-09-30
0000064803
cvs:HealthCareBenefitsSegmentMember
cvs:PharmacyRevenueMember
us-gaap:OperatingSegmentsMember
2025-07-01
2025-09-30
0000064803
cvs:HealthServicesSegmentMember
cvs:PharmacyRevenueMember
us-gaap:OperatingSegmentsMember
2025-07-01
2025-09-30
0000064803
cvs:PharmacyAndConsumerHealthSegmentMember
cvs:PharmacyRevenueMember
us-gaap:OperatingSegmentsMember
2025-07-01
2025-09-30
0000064803
cvs:CorporateAndOtherSegmentMember
cvs:PharmacyRevenueMember
cvs:CorporateAndReconcilingItemsMember
2025-07-01
2025-09-30
0000064803
cvs:PharmacyRevenueMember
us-gaap:IntersegmentEliminationMember
2025-07-01
2025-09-30
0000064803
cvs:PharmacyRevenueMember
2025-07-01
2025-09-30
0000064803
cvs:HealthCareBenefitsSegmentMember
cvs:FrontStoreRevenueMember
us-gaap:OperatingSegmentsMember
2025-07-01
2025-09-30
0000064803
cvs:HealthServicesSegmentMember
cvs:FrontStoreRevenueMember
us-gaap:OperatingSegmentsMember
2025-07-01
2025-09-30
0000064803
cvs:PharmacyAndConsumerHealthSegmentMember
cvs:FrontStoreRevenueMember
us-gaap:OperatingSegmentsMember
2025-07-01
2025-09-30
0000064803
cvs:CorporateAndOtherSegmentMember
cvs:FrontStoreRevenueMember
cvs:CorporateAndReconcilingItemsMember
2025-07-01
2025-09-30
0000064803
cvs:FrontStoreRevenueMember
us-gaap:IntersegmentEliminationMember
2025-07-01
2025-09-30
0000064803
cvs:FrontStoreRevenueMember
2025-07-01
2025-09-30
0000064803
cvs:HealthCareBenefitsSegmentMember
cvs:PremiumsMember
us-gaap:OperatingSegmentsMember
2025-07-01
2025-09-30
0000064803
cvs:HealthServicesSegmentMember
cvs:PremiumsMember
us-gaap:OperatingSegmentsMember
2025-07-01
2025-09-30
0000064803
cvs:PharmacyAndConsumerHealthSegmentMember
cvs:PremiumsMember
us-gaap:OperatingSegmentsMember
2025-07-01
2025-09-30
0000064803
cvs:CorporateAndOtherSegmentMember
cvs:PremiumsMember
cvs:CorporateAndReconcilingItemsMember
2025-07-01
2025-09-30
0000064803
cvs:PremiumsMember
us-gaap:IntersegmentEliminationMember
2025-07-01
2025-09-30
0000064803
cvs:PremiumsMember
2025-07-01
2025-09-30
0000064803
cvs:HealthCareBenefitsSegmentMember
us-gaap:OperatingSegmentsMember
2025-07-01
2025-09-30
0000064803
cvs:HealthServicesSegmentMember
us-gaap:OperatingSegmentsMember
2025-07-01
2025-09-30
0000064803
cvs:PharmacyAndConsumerHealthSegmentMember
us-gaap:OperatingSegmentsMember
2025-07-01
2025-09-30
0000064803
cvs:CorporateAndOtherSegmentMember
cvs:CorporateAndReconcilingItemsMember
2025-07-01
2025-09-30
0000064803
us-gaap:IntersegmentEliminationMember
2025-07-01
2025-09-30
0000064803
cvs:HealthCareBenefitsSegmentMember
us-gaap:ProductAndServiceOtherMember
us-gaap:OperatingSegmentsMember
2025-07-01
2025-09-30
0000064803
cvs:HealthServicesSegmentMember
us-gaap:ProductAndServiceOtherMember
us-gaap:OperatingSegmentsMember
2025-07-01
2025-09-30
0000064803
cvs:PharmacyAndConsumerHealthSegmentMember
us-gaap:ProductAndServiceOtherMember
us-gaap:OperatingSegmentsMember
2025-07-01
2025-09-30
0000064803
cvs:CorporateAndOtherSegmentMember
us-gaap:ProductAndServiceOtherMember
cvs:CorporateAndReconcilingItemsMember
2025-07-01
2025-09-30
0000064803
us-gaap:ProductAndServiceOtherMember
us-gaap:IntersegmentEliminationMember
2025-07-01
2025-09-30
0000064803
us-gaap:ProductAndServiceOtherMember
2025-07-01
2025-09-30
0000064803
cvs:HealthServicesSegmentMember
us-gaap:SalesChannelThroughIntermediaryMember
us-gaap:OperatingSegmentsMember
2025-07-01
2025-09-30
0000064803
cvs:HealthServicesSegmentMember
us-gaap:SalesChannelDirectlyToConsumerMember
us-gaap:OperatingSegmentsMember
2025-07-01
2025-09-30
0000064803
cvs:HealthServicesSegmentMember
cvs:SalesChannelOtherMember
us-gaap:OperatingSegmentsMember
2025-07-01
2025-09-30
0000064803
cvs:HealthCareBenefitsSegmentMember
cvs:PharmacyRevenueMember
us-gaap:OperatingSegmentsMember
2026-01-01
2026-09-30
0000064803
cvs:HealthServicesSegmentMember
cvs:PharmacyRevenueMember
us-gaap:OperatingSegmentsMember
2026-01-01
2026-09-30
0000064803
cvs:PharmacyAndConsumerHealthSegmentMember
cvs:PharmacyRevenueMember
us-gaap:OperatingSegmentsMember
2026-01-01
2026-09-30
0000064803
cvs:CorporateAndOtherSegmentMember
cvs:PharmacyRevenueMember
cvs:CorporateAndReconcilingItemsMember
2026-01-01
2026-09-30
0000064803
cvs:PharmacyRevenueMember
us-gaap:IntersegmentEliminationMember
2026-01-01
2026-09-30
0000064803
cvs:PharmacyRevenueMember
2026-01-01
2026-09-30
0000064803
cvs:HealthCareBenefitsSegmentMember
cvs:FrontStoreRevenueMember
us-gaap:OperatingSegmentsMember
2026-01-01
2026-09-30
0000064803
cvs:HealthServicesSegmentMember
cvs:FrontStoreRevenueMember
us-gaap:OperatingSegmentsMember
2026-01-01
2026-09-30
0000064803
cvs:PharmacyAndConsumerHealthSegmentMember
cvs:FrontStoreRevenueMember
us-gaap:OperatingSegmentsMember
2026-01-01
2026-09-30
0000064803
cvs:CorporateAndOtherSegmentMember
cvs:FrontStoreRevenueMember
cvs:CorporateAndReconcilingItemsMember
2026-01-01
2026-09-30
0000064803
cvs:FrontStoreRevenueMember
us-gaap:IntersegmentEliminationMember
2026-01-01
2026-09-30
0000064803
cvs:FrontStoreRevenueMember
2026-01-01
2026-09-30
0000064803
cvs:HealthCareBenefitsSegmentMember
cvs:PremiumsMember
us-gaap:OperatingSegmentsMember
2026-01-01
2026-09-30
0000064803
cvs:HealthServicesSegmentMember
cvs:PremiumsMember
us-gaap:OperatingSegmentsMember
2026-01-01
2026-09-30
0000064803
cvs:PharmacyAndConsumerHealthSegmentMember
cvs:PremiumsMember
us-gaap:OperatingSegmentsMember
2026-01-01
2026-09-30
0000064803
cvs:CorporateAndOtherSegmentMember
cvs:PremiumsMember
cvs:CorporateAndReconcilingItemsMember
2026-01-01
2026-09-30
0000064803
cvs:PremiumsMember
us-gaap:IntersegmentEliminationMember
2026-01-01
2026-09-30
0000064803
cvs:PremiumsMember
2026-01-01
2026-09-30
0000064803
cvs:HealthCareBenefitsSegmentMember
us-gaap:OperatingSegmentsMember
2026-01-01
2026-09-30
0000064803
cvs:HealthServicesSegmentMember
us-gaap:OperatingSegmentsMember
2026-01-01
2026-09-30
0000064803
cvs:PharmacyAndConsumerHealthSegmentMember
us-gaap:OperatingSegmentsMember
2026-01-01
2026-09-30
0000064803
cvs:CorporateAndOtherSegmentMember
cvs:CorporateAndReconcilingItemsMember
2026-01-01
2026-09-30
0000064803
us-gaap:IntersegmentEliminationMember
2026-01-01
2026-09-30
0000064803
cvs:HealthCareBenefitsSegmentMember
us-gaap:ProductAndServiceOtherMember
us-gaap:OperatingSegmentsMember
2026-01-01
2026-09-30
0000064803
cvs:HealthServicesSegmentMember
us-gaap:ProductAndServiceOtherMember
us-gaap:OperatingSegmentsMember
2026-01-01
2026-09-30
0000064803
cvs:PharmacyAndConsumerHealthSegmentMember
us-gaap:ProductAndServiceOtherMember
us-gaap:OperatingSegmentsMember
2026-01-01
2026-09-30
0000064803
cvs:CorporateAndOtherSegmentMember
us-gaap:ProductAndServiceOtherMember
cvs:CorporateAndReconcilingItemsMember
2026-01-01
2026-09-30
0000064803
us-gaap:ProductAndServiceOtherMember
us-gaap:IntersegmentEliminationMember
2026-01-01
2026-09-30
0000064803
us-gaap:ProductAndServiceOtherMember
2026-01-01
2026-09-30
0000064803
cvs:HealthServicesSegmentMember
us-gaap:SalesChannelThroughIntermediaryMember
us-gaap:OperatingSegmentsMember
2026-01-01
2026-09-30
0000064803
cvs:HealthServicesSegmentMember
us-gaap:SalesChannelDirectlyToConsumerMember
us-gaap:OperatingSegmentsMember
2026-01-01
2026-09-30
0000064803
cvs:HealthServicesSegmentMember
cvs:SalesChannelOtherMember
us-gaap:OperatingSegmentsMember
2026-01-01
2026-09-30
0000064803
cvs:HealthCareBenefitsSegmentMember
cvs:PharmacyRevenueMember
us-gaap:OperatingSegmentsMember
2025-01-01
2025-09-30
0000064803
cvs:HealthServicesSegmentMember
cvs:PharmacyRevenueMember
us-gaap:OperatingSegmentsMember
2025-01-01
2025-09-30
0000064803
cvs:PharmacyAndConsumerHealthSegmentMember
cvs:PharmacyRevenueMember
us-gaap:OperatingSegmentsMember
2025-01-01
2025-09-30
0000064803
cvs:CorporateAndOtherSegmentMember
cvs:PharmacyRevenueMember
cvs:CorporateAndReconcilingItemsMember
2025-01-01
2025-09-30
0000064803
cvs:PharmacyRevenueMember
us-gaap:IntersegmentEliminationMember
2025-01-01
2025-09-30
0000064803
cvs:PharmacyRevenueMember
2025-01-01
2025-09-30
0000064803
cvs:HealthCareBenefitsSegmentMember
cvs:FrontStoreRevenueMember
us-gaap:OperatingSegmentsMember
2025-01-01
2025-09-30
0000064803
cvs:HealthServicesSegmentMember
cvs:FrontStoreRevenueMember
us-gaap:OperatingSegmentsMember
2025-01-01
2025-09-30
0000064803
cvs:PharmacyAndConsumerHealthSegmentMember
cvs:FrontStoreRevenueMember
us-gaap:OperatingSegmentsMember
2025-01-01
2025-09-30
0000064803
cvs:CorporateAndOtherSegmentMember
cvs:FrontStoreRevenueMember
cvs:CorporateAndReconcilingItemsMember
2025-01-01
2025-09-30
0000064803
cvs:FrontStoreRevenueMember
us-gaap:IntersegmentEliminationMember
2025-01-01
2025-09-30
0000064803
cvs:FrontStoreRevenueMember
2025-01-01
2025-09-30
0000064803
cvs:HealthCareBenefitsSegmentMember
cvs:PremiumsMember
us-gaap:OperatingSegmentsMember
2025-01-01
2025-09-30
0000064803
cvs:HealthServicesSegmentMember
cvs:PremiumsMember
us-gaap:OperatingSegmentsMember
2025-01-01
2025-09-30
0000064803
cvs:PharmacyAndConsumerHealthSegmentMember
cvs:PremiumsMember
us-gaap:OperatingSegmentsMember
2025-01-01
2025-09-30
0000064803
cvs:CorporateAndOtherSegmentMember
cvs:PremiumsMember
cvs:CorporateAndReconcilingItemsMember
2025-01-01
2025-09-30
0000064803
cvs:PremiumsMember
us-gaap:IntersegmentEliminationMember
2025-01-01
2025-09-30
0000064803
cvs:PremiumsMember
2025-01-01
2025-09-30
0000064803
cvs:HealthCareBenefitsSegmentMember
us-gaap:OperatingSegmentsMember
2025-01-01
2025-09-30
0000064803
cvs:HealthServicesSegmentMember
us-gaap:OperatingSegmentsMember
2025-01-01
2025-09-30
0000064803
cvs:PharmacyAndConsumerHealthSegmentMember
us-gaap:OperatingSegmentsMember
2025-01-01
2025-09-30
0000064803
cvs:CorporateAndOtherSegmentMember
cvs:CorporateAndReconcilingItemsMember
2025-01-01
2025-09-30
0000064803
us-gaap:IntersegmentEliminationMember
2025-01-01
2025-09-30
0000064803
cvs:HealthCareBenefitsSegmentMember
us-gaap:ProductAndServiceOtherMember
us-gaap:OperatingSegmentsMember
2025-01-01
2025-09-30
0000064803
cvs:HealthServicesSegmentMember
us-gaap:ProductAndServiceOtherMember
us-gaap:OperatingSegmentsMember
2025-01-01
2025-09-30
0000064803
cvs:PharmacyAndConsumerHealthSegmentMember
us-gaap:ProductAndServiceOtherMember
us-gaap:OperatingSegmentsMember
2025-01-01
2025-09-30
0000064803
cvs:CorporateAndOtherSegmentMember
us-gaap:ProductAndServiceOtherMember
cvs:CorporateAndReconcilingItemsMember
2025-01-01
2025-09-30
0000064803
us-gaap:ProductAndServiceOtherMember
us-gaap:IntersegmentEliminationMember
2025-01-01
2025-09-30
0000064803
us-gaap:ProductAndServiceOtherMember
2025-01-01
2025-09-30
0000064803
cvs:HealthServicesSegmentMember
us-gaap:SalesChannelThroughIntermediaryMember
us-gaap:OperatingSegmentsMember
2025-01-01
2025-09-30
0000064803
cvs:HealthServicesSegmentMember
us-gaap:SalesChannelDirectlyToConsumerMember
us-gaap:OperatingSegmentsMember
2025-01-01
2025-09-30
0000064803
cvs:HealthServicesSegmentMember
cvs:SalesChannelOtherMember
us-gaap:OperatingSegmentsMember
2025-01-01
2025-09-30
0000064803
cvs:HealthServicesSegmentMember
2024-12-31
0000064803
cvs:HealthServicesSegmentMember
2025-01-01
2025-09-30
0000064803
cvs:MedicareSharedSavingsProgramMember
cvs:HealthServicesSegmentMember
us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember
2025-01-01
2025-09-30
0000064803
2025-09-22
2025-09-22
0000064803
cvs:OmnicareLLCMember
2025-09-30
0000064803
cvs:DebtAndEquitySecuritiesAvailableForSaleMember
2026-09-30
0000064803
cvs:DebtAndEquitySecuritiesAvailableForSaleMember
2025-12-31
0000064803
cvs:MortgageLoansMember
2026-09-30
0000064803
cvs:MortgageLoansMember
2025-12-31
0000064803
cvs:InvestmentsOtherMember
2026-09-30
0000064803
cvs:InvestmentsOtherMember
2025-12-31
0000064803
us-gaap:USGovernmentAgenciesDebtSecuritiesMember
2026-09-30
0000064803
us-gaap:USStatesAndPoliticalSubdivisionsMember
2026-09-30
0000064803
us-gaap:DomesticCorporateDebtSecuritiesMember
2026-09-30
0000064803
us-gaap:ForeignCorporateDebtSecuritiesMember
2026-09-30
0000064803
us-gaap:ResidentialMortgageBackedSecuritiesMember
2026-09-30
0000064803
us-gaap:CommercialMortgageBackedSecuritiesMember
2026-09-30
0000064803
cvs:OtherAssetBackedSecuritiesMember
2026-09-30
0000064803
us-gaap:RedeemablePreferredStockMember
2026-09-30
0000064803
us-gaap:USGovernmentAgenciesDebtSecuritiesMember
2025-12-31
0000064803
us-gaap:USStatesAndPoliticalSubdivisionsMember
2025-12-31
0000064803
us-gaap:DomesticCorporateDebtSecuritiesMember
2025-12-31
0000064803
us-gaap:ForeignCorporateDebtSecuritiesMember
2025-12-31
0000064803
us-gaap:ResidentialMortgageBackedSecuritiesMember
2025-12-31
0000064803
us-gaap:CommercialMortgageBackedSecuritiesMember
2025-12-31
0000064803
cvs:OtherAssetBackedSecuritiesMember
2025-12-31
0000064803
us-gaap:RedeemablePreferredStockMember
2025-12-31
0000064803
cvs:SupportingExperienceRatedProductsMember
2026-09-30
0000064803
cvs:SupportingExperienceRatedProductsMember
2025-12-31
0000064803
us-gaap:DebtSecuritiesMember
2026-07-01
2026-09-30
0000064803
us-gaap:DebtSecuritiesMember
2025-07-01
2025-09-30
0000064803
us-gaap:DebtSecuritiesMember
2026-01-01
2026-09-30
0000064803
us-gaap:DebtSecuritiesMember
2025-01-01
2025-09-30
0000064803
cvs:MortgageLoansMember
2026-07-01
2026-09-30
0000064803
cvs:MortgageLoansMember
2025-07-01
2025-09-30
0000064803
cvs:MortgageLoansMember
2026-01-01
2026-09-30
0000064803
cvs:MortgageLoansMember
2025-01-01
2025-09-30
0000064803
cvs:InvestmentsOtherMember
2026-07-01
2026-09-30
0000064803
cvs:InvestmentsOtherMember
2025-07-01
2025-09-30
0000064803
cvs:InvestmentsOtherMember
2026-01-01
2026-09-30
0000064803
cvs:InvestmentsOtherMember
2025-01-01
2025-09-30
0000064803
us-gaap:FairValueInputsLevel1Member
2026-09-30
0000064803
us-gaap:FairValueInputsLevel2Member
2026-09-30
0000064803
us-gaap:FairValueInputsLevel3Member
2026-09-30
0000064803
us-gaap:USGovernmentAgenciesDebtSecuritiesMember
us-gaap:FairValueInputsLevel1Member
2026-09-30
0000064803
us-gaap:USGovernmentAgenciesDebtSecuritiesMember
us-gaap:FairValueInputsLevel2Member
2026-09-30
0000064803
us-gaap:USGovernmentAgenciesDebtSecuritiesMember
us-gaap:FairValueInputsLevel3Member
2026-09-30
0000064803
us-gaap:USStatesAndPoliticalSubdivisionsMember
us-gaap:FairValueInputsLevel1Member
2026-09-30
0000064803
us-gaap:USStatesAndPoliticalSubdivisionsMember
us-gaap:FairValueInputsLevel2Member
2026-09-30
0000064803
us-gaap:USStatesAndPoliticalSubdivisionsMember
us-gaap:FairValueInputsLevel3Member
2026-09-30
0000064803
us-gaap:DomesticCorporateDebtSecuritiesMember
us-gaap:FairValueInputsLevel1Member
2026-09-30
0000064803
us-gaap:DomesticCorporateDebtSecuritiesMember
us-gaap:FairValueInputsLevel2Member
2026-09-30
0000064803
us-gaap:DomesticCorporateDebtSecuritiesMember
us-gaap:FairValueInputsLevel3Member
2026-09-30
0000064803
us-gaap:ForeignCorporateDebtSecuritiesMember
us-gaap:FairValueInputsLevel1Member
2026-09-30
0000064803
us-gaap:ForeignCorporateDebtSecuritiesMember
us-gaap:FairValueInputsLevel2Member
2026-09-30
0000064803
us-gaap:ForeignCorporateDebtSecuritiesMember
us-gaap:FairValueInputsLevel3Member
2026-09-30
0000064803
us-gaap:ResidentialMortgageBackedSecuritiesMember
us-gaap:FairValueInputsLevel1Member
2026-09-30
0000064803
us-gaap:ResidentialMortgageBackedSecuritiesMember
us-gaap:FairValueInputsLevel2Member
2026-09-30
0000064803
us-gaap:ResidentialMortgageBackedSecuritiesMember
us-gaap:FairValueInputsLevel3Member
2026-09-30
0000064803
us-gaap:CommercialMortgageBackedSecuritiesMember
us-gaap:FairValueInputsLevel1Member
2026-09-30
0000064803
us-gaap:CommercialMortgageBackedSecuritiesMember
us-gaap:FairValueInputsLevel2Member
2026-09-30
0000064803
us-gaap:CommercialMortgageBackedSecuritiesMember
us-gaap:FairValueInputsLevel3Member
2026-09-30
0000064803
cvs:OtherAssetBackedSecuritiesMember
us-gaap:FairValueInputsLevel1Member
2026-09-30
0000064803
cvs:OtherAssetBackedSecuritiesMember
us-gaap:FairValueInputsLevel2Member
2026-09-30
0000064803
cvs:OtherAssetBackedSecuritiesMember
us-gaap:FairValueInputsLevel3Member
2026-09-30
0000064803
us-gaap:RedeemablePreferredStockMember
us-gaap:FairValueInputsLevel1Member
2026-09-30
0000064803
us-gaap:RedeemablePreferredStockMember
us-gaap:FairValueInputsLevel2Member
2026-09-30
0000064803
us-gaap:RedeemablePreferredStockMember
us-gaap:FairValueInputsLevel3Member
2026-09-30
0000064803
us-gaap:FairValueInputsLevel1Member
2025-12-31
0000064803
us-gaap:FairValueInputsLevel2Member
2025-12-31
0000064803
us-gaap:FairValueInputsLevel3Member
2025-12-31
0000064803
us-gaap:USGovernmentAgenciesDebtSecuritiesMember
us-gaap:FairValueInputsLevel1Member
2025-12-31
0000064803
us-gaap:USGovernmentAgenciesDebtSecuritiesMember
us-gaap:FairValueInputsLevel2Member
2025-12-31
0000064803
us-gaap:USGovernmentAgenciesDebtSecuritiesMember
us-gaap:FairValueInputsLevel3Member
2025-12-31
0000064803
us-gaap:USStatesAndPoliticalSubdivisionsMember
us-gaap:FairValueInputsLevel1Member
2025-12-31
0000064803
us-gaap:USStatesAndPoliticalSubdivisionsMember
us-gaap:FairValueInputsLevel2Member
2025-12-31
0000064803
us-gaap:USStatesAndPoliticalSubdivisionsMember
us-gaap:FairValueInputsLevel3Member
2025-12-31
0000064803
us-gaap:DomesticCorporateDebtSecuritiesMember
us-gaap:FairValueInputsLevel1Member
2025-12-31
0000064803
us-gaap:DomesticCorporateDebtSecuritiesMember
us-gaap:FairValueInputsLevel2Member
2025-12-31
0000064803
us-gaap:DomesticCorporateDebtSecuritiesMember
us-gaap:FairValueInputsLevel3Member
2025-12-31
0000064803
us-gaap:ForeignCorporateDebtSecuritiesMember
us-gaap:FairValueInputsLevel1Member
2025-12-31
0000064803
us-gaap:ForeignCorporateDebtSecuritiesMember
us-gaap:FairValueInputsLevel2Member
2025-12-31
0000064803
us-gaap:ForeignCorporateDebtSecuritiesMember
us-gaap:FairValueInputsLevel3Member
2025-12-31
0000064803
us-gaap:ResidentialMortgageBackedSecuritiesMember
us-gaap:FairValueInputsLevel1Member
2025-12-31
0000064803
us-gaap:ResidentialMortgageBackedSecuritiesMember
us-gaap:FairValueInputsLevel2Member
2025-12-31
0000064803
us-gaap:ResidentialMortgageBackedSecuritiesMember
us-gaap:FairValueInputsLevel3Member
2025-12-31
0000064803
us-gaap:CommercialMortgageBackedSecuritiesMember
us-gaap:FairValueInputsLevel1Member
2025-12-31
0000064803
us-gaap:CommercialMortgageBackedSecuritiesMember
us-gaap:FairValueInputsLevel2Member
2025-12-31
0000064803
us-gaap:CommercialMortgageBackedSecuritiesMember
us-gaap:FairValueInputsLevel3Member
2025-12-31
0000064803
cvs:OtherAssetBackedSecuritiesMember
us-gaap:FairValueInputsLevel1Member
2025-12-31
0000064803
cvs:OtherAssetBackedSecuritiesMember
us-gaap:FairValueInputsLevel2Member
2025-12-31
0000064803
cvs:OtherAssetBackedSecuritiesMember
us-gaap:FairValueInputsLevel3Member
2025-12-31
0000064803
us-gaap:RedeemablePreferredStockMember
us-gaap:FairValueInputsLevel1Member
2025-12-31
0000064803
us-gaap:RedeemablePreferredStockMember
us-gaap:FairValueInputsLevel2Member
2025-12-31
0000064803
us-gaap:RedeemablePreferredStockMember
us-gaap:FairValueInputsLevel3Member
2025-12-31
0000064803
us-gaap:CarryingReportedAmountFairValueDisclosureMember
2026-09-30
0000064803
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:FairValueInputsLevel1Member
2026-09-30
0000064803
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:FairValueInputsLevel2Member
2026-09-30
0000064803
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:FairValueInputsLevel3Member
2026-09-30
0000064803
us-gaap:EstimateOfFairValueFairValueDisclosureMember
2026-09-30
0000064803
us-gaap:CarryingReportedAmountFairValueDisclosureMember
2025-12-31
0000064803
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:FairValueInputsLevel1Member
2025-12-31
0000064803
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:FairValueInputsLevel2Member
2025-12-31
0000064803
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:FairValueInputsLevel3Member
2025-12-31
0000064803
us-gaap:EstimateOfFairValueFairValueDisclosureMember
2025-12-31
0000064803
us-gaap:CashAndCashEquivalentsMember
us-gaap:FairValueInputsLevel1Member
2026-09-30
0000064803
us-gaap:CashAndCashEquivalentsMember
us-gaap:FairValueInputsLevel2Member
2026-09-30
0000064803
us-gaap:CashAndCashEquivalentsMember
us-gaap:FairValueInputsLevel3Member
2026-09-30
0000064803
us-gaap:CashAndCashEquivalentsMember
2026-09-30
0000064803
us-gaap:CashAndCashEquivalentsMember
us-gaap:FairValueInputsLevel1Member
2025-12-31
0000064803
us-gaap:CashAndCashEquivalentsMember
us-gaap:FairValueInputsLevel2Member
2025-12-31
0000064803
us-gaap:CashAndCashEquivalentsMember
us-gaap:FairValueInputsLevel3Member
2025-12-31
0000064803
us-gaap:CashAndCashEquivalentsMember
2025-12-31
0000064803
us-gaap:DebtSecuritiesMember
us-gaap:FairValueInputsLevel1Member
2026-09-30
0000064803
us-gaap:DebtSecuritiesMember
us-gaap:FairValueInputsLevel2Member
2026-09-30
0000064803
us-gaap:DebtSecuritiesMember
us-gaap:FairValueInputsLevel3Member
2026-09-30
0000064803
us-gaap:DebtSecuritiesMember
2026-09-30
0000064803
us-gaap:DebtSecuritiesMember
us-gaap:FairValueInputsLevel1Member
2025-12-31
0000064803
us-gaap:DebtSecuritiesMember
us-gaap:FairValueInputsLevel2Member
2025-12-31
0000064803
us-gaap:DebtSecuritiesMember
us-gaap:FairValueInputsLevel3Member
2025-12-31
0000064803
us-gaap:DebtSecuritiesMember
2025-12-31
0000064803
us-gaap:EquitySecuritiesMember
us-gaap:FairValueInputsLevel1Member
2026-09-30
0000064803
us-gaap:EquitySecuritiesMember
us-gaap:FairValueInputsLevel2Member
2026-09-30
0000064803
us-gaap:EquitySecuritiesMember
us-gaap:FairValueInputsLevel3Member
2026-09-30
0000064803
us-gaap:EquitySecuritiesMember
2026-09-30
0000064803
us-gaap:EquitySecuritiesMember
us-gaap:FairValueInputsLevel1Member
2025-12-31
0000064803
us-gaap:EquitySecuritiesMember
us-gaap:FairValueInputsLevel2Member
2025-12-31
0000064803
us-gaap:EquitySecuritiesMember
us-gaap:FairValueInputsLevel3Member
2025-12-31
0000064803
us-gaap:EquitySecuritiesMember
2025-12-31
0000064803
cvs:CommonAndCollectiveTrustsMember
us-gaap:FairValueInputsLevel1Member
2026-09-30
0000064803
cvs:CommonAndCollectiveTrustsMember
us-gaap:FairValueInputsLevel2Member
2026-09-30
0000064803
cvs:CommonAndCollectiveTrustsMember
us-gaap:FairValueInputsLevel3Member
2026-09-30
0000064803
cvs:CommonAndCollectiveTrustsMember
2026-09-30
0000064803
cvs:CommonAndCollectiveTrustsMember
us-gaap:FairValueInputsLevel1Member
2025-12-31
0000064803
cvs:CommonAndCollectiveTrustsMember
us-gaap:FairValueInputsLevel2Member
2025-12-31
0000064803
cvs:CommonAndCollectiveTrustsMember
us-gaap:FairValueInputsLevel3Member
2025-12-31
0000064803
cvs:CommonAndCollectiveTrustsMember
2025-12-31
0000064803
cvs:SeparateAccountExcludingOtherReceivablesAndOtherPayablesMember
us-gaap:FairValueInputsLevel1Member
2026-09-30
0000064803
cvs:SeparateAccountExcludingOtherReceivablesAndOtherPayablesMember
us-gaap:FairValueInputsLevel2Member
2026-09-30
0000064803
cvs:SeparateAccountExcludingOtherReceivablesAndOtherPayablesMember
us-gaap:FairValueInputsLevel3Member
2026-09-30
0000064803
cvs:SeparateAccountExcludingOtherReceivablesAndOtherPayablesMember
2026-09-30
0000064803
cvs:SeparateAccountExcludingOtherReceivablesAndOtherPayablesMember
us-gaap:FairValueInputsLevel1Member
2025-12-31
0000064803
cvs:SeparateAccountExcludingOtherReceivablesAndOtherPayablesMember
us-gaap:FairValueInputsLevel2Member
2025-12-31
0000064803
cvs:SeparateAccountExcludingOtherReceivablesAndOtherPayablesMember
us-gaap:FairValueInputsLevel3Member
2025-12-31
0000064803
cvs:SeparateAccountExcludingOtherReceivablesAndOtherPayablesMember
2025-12-31
0000064803
us-gaap:OtherAssetsNoncurrent
2026-09-30
0000064803
cvs:HealthCareBenefitsSegmentMember
2026-01-01
2026-09-30
0000064803
cvs:HealthCareBenefitsSegmentMember
2025-01-01
2025-09-30
0000064803
cvs:CorporateAndOtherSegmentMember
2026-01-01
2026-09-30
0000064803
cvs:CorporateAndOtherSegmentMember
2025-01-01
2025-09-30
0000064803
cvs:MedicaidProductLineMember
2026-01-01
2026-09-30
0000064803
cvs:LargeCasePensionsMember
2026-09-30
0000064803
cvs:LargeCasePensionsMember
2025-09-30
0000064803
cvs:LongTermCareMember
2026-09-30
0000064803
cvs:LongTermCareMember
2025-09-30
0000064803
cvs:A2022RepurchaseProgramMember
2022-11-17
0000064803
cvs:A2022RepurchaseProgramMember
2026-09-30
0000064803
cvs:A2021RepurchaseProgramMember
2021-12-09
0000064803
cvs:A2021RepurchaseProgramMember
2026-09-30
0000064803
cvs:A2021RepurchaseProgramMember
2026-01-01
2026-09-30
0000064803
cvs:A2021RepurchaseProgramMember
2025-01-01
2025-09-30
0000064803
us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember
2026-06-30
0000064803
us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember
2025-06-30
0000064803
us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember
2025-12-31
0000064803
us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember
2024-12-31
0000064803
us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember
2026-07-01
2026-09-30
0000064803
us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember
2025-07-01
2025-09-30
0000064803
us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember
2026-01-01
2026-09-30
0000064803
us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember
2025-01-01
2025-09-30
0000064803
us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember
2026-09-30
0000064803
us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember
2025-09-30
0000064803
cvs:AOCIChangeInDiscountRateOnInsuranceReservesMember
2026-06-30
0000064803
cvs:AOCIChangeInDiscountRateOnInsuranceReservesMember
2025-06-30
0000064803
cvs:AOCIChangeInDiscountRateOnInsuranceReservesMember
2025-12-31
0000064803
cvs:AOCIChangeInDiscountRateOnInsuranceReservesMember
2024-12-31
0000064803
cvs:AOCIChangeInDiscountRateOnInsuranceReservesMember
2026-07-01
2026-09-30
0000064803
cvs:AOCIChangeInDiscountRateOnInsuranceReservesMember
2025-07-01
2025-09-30
0000064803
cvs:AOCIChangeInDiscountRateOnInsuranceReservesMember
2026-01-01
2026-09-30
0000064803
cvs:AOCIChangeInDiscountRateOnInsuranceReservesMember
2025-01-01
2025-09-30
0000064803
cvs:AOCIChangeInDiscountRateOnInsuranceReservesMember
2026-09-30
0000064803
cvs:AOCIChangeInDiscountRateOnInsuranceReservesMember
2025-09-30
0000064803
us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
2026-06-30
0000064803
us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
2025-06-30
0000064803
us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
2025-12-31
0000064803
us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
2024-12-31
0000064803
us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
2026-07-01
2026-09-30
0000064803
us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
2025-07-01
2025-09-30
0000064803
us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
2026-01-01
2026-09-30
0000064803
us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
2025-01-01
2025-09-30
0000064803
us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
2026-09-30
0000064803
us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
2025-09-30
0000064803
us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember
2026-06-30
0000064803
us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember
2025-06-30
0000064803
us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember
2025-12-31
0000064803
us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember
2024-12-31
0000064803
us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember
2026-07-01
2026-09-30
0000064803
us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember
2025-07-01
2025-09-30
0000064803
us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember
2026-01-01
2026-09-30
0000064803
us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember
2025-01-01
2025-09-30
0000064803
us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember
2026-09-30
0000064803
us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember
2025-09-30
0000064803
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember
2026-06-30
0000064803
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember
2025-06-30
0000064803
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember
2025-12-31
0000064803
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember
2024-12-31
0000064803
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember
2026-07-01
2026-09-30
0000064803
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember
2025-07-01
2025-09-30
0000064803
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember
2026-01-01
2026-09-30
0000064803
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember
2025-01-01
2025-09-30
0000064803
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember
2026-09-30
0000064803
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember
2025-09-30
0000064803
us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember
2026-06-30
0000064803
us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember
2025-06-30
0000064803
us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember
2025-12-31
0000064803
us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember
2024-12-31
0000064803
us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember
2026-09-30
0000064803
us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember
2025-09-30
0000064803
cvs:StockOptionsAndStockAppreciationRightsMember
2026-07-01
2026-09-30
0000064803
cvs:StockOptionsAndStockAppreciationRightsMember
2026-01-01
2026-09-30
0000064803
cvs:StockOptionsAndStockAppreciationRightsMember
2025-07-01
2025-09-30
0000064803
cvs:StockOptionsAndStockAppreciationRightsMember
2025-01-01
2025-09-30
0000064803
cvs:CommonEquivalentSharesMember
2025-01-01
2025-09-30
0000064803
cvs:CommonEquivalentSharesMember
2025-07-01
2025-09-30
0000064803
cvs:RestrictedStockUnitsRSUsAndPerformanceStockUnitsPSUsMember
2026-07-01
2026-09-30
0000064803
cvs:RestrictedStockUnitsRSUsAndPerformanceStockUnitsPSUsMember
2025-07-01
2025-09-30
0000064803
cvs:RestrictedStockUnitsRSUsAndPerformanceStockUnitsPSUsMember
2026-01-01
2026-09-30
0000064803
cvs:RestrictedStockUnitsRSUsAndPerformanceStockUnitsPSUsMember
2025-01-01
2025-09-30
0000064803
cvs:UnitedStatesExRel.BehnkeV.CVSCaremarkCorporationEtAl.Member
2025-01-01
2025-12-31
0000064803
cvs:SettlementFrameworkMember
2026-09-30
0000064803
us-gaap:SubsequentEventMember
cvs:SettlementFrameworkMember
2026-10-01
2026-10-31
0000064803
cvs:OmnicareInc.Member
cvs:U.S.ExRel.BassanEtAl.V.OmnicareInc.AndCVSHealthCorp.Member
2025-04-01
2025-04-30
0000064803
cvs:OmnicareInc.Member
cvs:U.S.ExRel.BassanEtAl.V.OmnicareInc.AndCVSHealthCorp.Member
2025-07-01
2025-07-31
0000064803
cvs:OmnicareIncAndCVSHealthCorporationMember
cvs:U.S.ExRel.BassanEtAl.V.OmnicareInc.AndCVSHealthCorp.Member
2025-07-01
2025-07-31
0000064803
cvs:OmnicareIncAndCVSHealthCorporationMember
cvs:U.S.ExRel.BassanEtAl.V.OmnicareInc.AndCVSHealthCorp.Member
srt:MinimumMember
2026-07-01
2026-07-31
0000064803
cvs:U.S.ExRel.BassanEtAl.V.OmnicareInc.AndCVSHealthCorp.Member
2026-07-01
2026-07-31
0000064803
cvs:OmnicareInc.Member
cvs:U.S.ExRel.BassanEtAl.V.OmnicareInc.AndCVSHealthCorp.Member
2026-07-31
0000064803
cvs:U.S.ExRel.BassanEtAl.V.OmnicareInc.AndCVSHealthCorp.Member
2026-07-31
0000064803
cvs:U.S.ExRel.BassanEtAl.V.OmnicareInc.AndCVSHealthCorp.Member
2026-07-01
2026-09-30
0000064803
cvs:U.S.ExRel.BassanEtAl.V.OmnicareInc.AndCVSHealthCorp.Member
2026-01-01
2026-09-30
0000064803
cvs:StockholderMattersClassActionComplaintsMember
2024-07-01
2026-09-30
0000064803
cvs:InReCVSHealthCorporationDerivativeLitigationMember
2024-07-01
2026-09-30
0000064803
cvs:InReCVSHealthCorporationStockholderDerivativeLitigationMember
2024-07-01
2026-09-30
0000064803
cvs:InReCVSHealthCorporationStockholderDerivativeLitigationAndDavidowV.LynchEtAl.Member
2024-07-01
2026-09-30
0000064803
cvs:HealthCareBenefitsSegmentMember
2026-07-01
2026-09-30
0000064803
cvs:HealthServicesSegmentMember
2026-07-01
2026-09-30
0000064803
cvs:PharmacyAndConsumerHealthSegmentMember
2026-07-01
2026-09-30
0000064803
cvs:CorporateAndOtherSegmentMember
2026-07-01
2026-09-30
0000064803
cvs:HealthCareBenefitsSegmentMember
us-gaap:IntersegmentEliminationMember
2026-07-01
2026-09-30
0000064803
cvs:HealthServicesSegmentMember
us-gaap:IntersegmentEliminationMember
2026-07-01
2026-09-30
0000064803
cvs:PharmacyAndConsumerHealthSegmentMember
us-gaap:IntersegmentEliminationMember
2026-07-01
2026-09-30
0000064803
cvs:OperatingSegmentsAndCorporateNonSegmentMember
2026-07-01
2026-09-30
0000064803
cvs:HealthCareBenefitsSegmentMember
2025-07-01
2025-09-30
0000064803
cvs:HealthServicesSegmentMember
2025-07-01
2025-09-30
0000064803
cvs:PharmacyAndConsumerHealthSegmentMember
2025-07-01
2025-09-30
0000064803
cvs:CorporateAndOtherSegmentMember
2025-07-01
2025-09-30
0000064803
cvs:HealthCareBenefitsSegmentMember
us-gaap:IntersegmentEliminationMember
2025-07-01
2025-09-30
0000064803
cvs:HealthServicesSegmentMember
us-gaap:IntersegmentEliminationMember
2025-07-01
2025-09-30
0000064803
cvs:PharmacyAndConsumerHealthSegmentMember
us-gaap:IntersegmentEliminationMember
2025-07-01
2025-09-30
0000064803
cvs:OperatingSegmentsAndCorporateNonSegmentMember
2025-07-01
2025-09-30
0000064803
cvs:HealthServicesSegmentMember
2026-01-01
2026-09-30
0000064803
cvs:PharmacyAndConsumerHealthSegmentMember
2026-01-01
2026-09-30
0000064803
cvs:HealthCareBenefitsSegmentMember
us-gaap:IntersegmentEliminationMember
2026-01-01
2026-09-30
0000064803
cvs:HealthServicesSegmentMember
us-gaap:IntersegmentEliminationMember
2026-01-01
2026-09-30
0000064803
cvs:PharmacyAndConsumerHealthSegmentMember
us-gaap:IntersegmentEliminationMember
2026-01-01
2026-09-30
0000064803
cvs:OperatingSegmentsAndCorporateNonSegmentMember
2026-01-01
2026-09-30
0000064803
cvs:PharmacyAndConsumerHealthSegmentMember
2025-01-01
2025-09-30
0000064803
cvs:HealthCareBenefitsSegmentMember
us-gaap:IntersegmentEliminationMember
2025-01-01
2025-09-30
0000064803
cvs:HealthServicesSegmentMember
us-gaap:IntersegmentEliminationMember
2025-01-01
2025-09-30
0000064803
cvs:PharmacyAndConsumerHealthSegmentMember
us-gaap:IntersegmentEliminationMember
2025-01-01
2025-09-30
0000064803
cvs:OperatingSegmentsAndCorporateNonSegmentMember
2025-01-01
2025-09-30
0000064803
cvs:OpioidLitigationMember
2025-01-01
2025-09-30
0000064803
cvs:LegacyLitigationMember
2025-01-01
2025-09-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
10-Q
(Mark One)
☑
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended
September 30, 2026
or
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _________ to_________
Commission File Number:
001-01011
CVS HEALTH CORPORATION
(Exact name of registrant as specified in its charter)
Delaware
05-0494040
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification No.)
One CVS Drive
,
Woonsocket
,
Rhode Island
02895
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code:
(401)
765-1500
Former name, former address and former fiscal year, if changed since last report:
N/A
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.01 per share
CVS
New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
☑
Yes
☐
No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
☑
Yes
☐
No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☑
Accelerated filer
☐
Non-accelerated filer
☐
Smaller reporting company
☐
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
☐
Yes
☑
No
As of October 28, 2026, the registrant had
1,279,474,188
shares of common stock issued and outstanding.
TABLE OF CONTENTS
Page
Part I
Financial Information
Item 1.
Financial Statements
1
Item 2.
Management’s Discussion and Analysis of Financial Condition and Results of Operations
37
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
56
Item 4.
Controls and Procedures
56
Part II
Other Information
Item 1.
Legal Proceedings
57
Item 1A.
Risk Factors
57
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
58
Item 3
Defaults Upon Senior Securities
58
Item 4.
Mine Safety Disclosures
58
Item 5.
Other Information
58
Item 6.
Exhibits
59
Signatures
60
Form 10-Q Table of Contents
Part I.
Financial Information
Item 1.
Financial Statements
Index to Condensed Consolidated Financial Statements
Page
Condensed Consolidated Statements of Operations (Unaudited) for the three and nine months ended September 30, 2026 and 2025
2
Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) for the three and nine months ended September 30, 2026 and 2025
3
Condensed Consolidated Balance Sheets (Unaudited) as of September 30, 2026 and December 31, 2025
4
Condensed Consolidated Statements of Cash Flows (Unaudited) for the nine months ended September 30, 2026 and 2025
5
Condensed Consolidated Statements of Shareholders’ Equity (Unaudited) for the three months ended September 30, 2026 and 2025, the three months ended June 30, 2026 and 2025 and the three months ended March 31, 2026 and 2025
7
Notes to Condensed Consolidated Financial Statements (Unaudited)
9
Report of Independent Registered Public Accounting Firm
36
1
Index to Condensed Consolidated Financial Statements
CVS Health Corporation
Condensed Consolidated Statements of Operations
(Unaudited)
Three Months Ended
September 30,
Nine Months Ended
September 30,
In millions, except per share amounts
2026
2025
2026
2025
Revenues:
Products
$
69,225
$
64,590
$
197,670
$
182,866
Premiums
34,566
33,719
103,474
100,734
Services
3,961
3,930
11,915
11,135
Net investment income
647
632
1,862
1,639
Total revenues
108,399
102,871
314,921
296,374
Operating costs:
Cost of products sold
61,185
57,045
175,491
162,107
Health care costs
32,316
32,020
93,159
92,472
Operating expenses
11,332
11,288
33,322
33,522
Goodwill impairment
—
5,725
—
5,725
Total operating costs
104,833
106,078
301,972
293,826
Operating income (loss)
3,566
(
3,207
)
12,949
2,548
Gain on deconsolidation of subsidiary
—
483
—
483
Interest expense
(
747
)
(
784
)
(
2,278
)
(
2,332
)
Other income
30
26
93
83
Income (loss) before income tax provision
2,849
(
3,482
)
10,764
782
Income tax provision
678
508
2,641
1,977
Net income (loss)
2,171
(
3,990
)
8,123
(
1,195
)
Net (income) loss attributable to noncontrolling interests
1
15
(
29
)
20
Net income (loss) attributable to CVS Health
$
2,172
$
(
3,975
)
$
8,094
$
(
1,175
)
Net income (loss) per share attributable to CVS Health:
Basic
$
1.70
$
(
3.13
)
$
6.33
$
(
0.93
)
Diluted
$
1.68
$
(
3.13
)
$
6.29
$
(
0.93
)
Weighted average shares outstanding:
Basic
1,282
1,269
1,278
1,266
Diluted
1,291
1,269
1,286
1,266
See accompanying notes to condensed consolidated financial statements (unaudited).
2
Index to Condensed Consolidated Financial Statements
CVS Health Corporation
Condensed Consolidated Statements of Comprehensive Income (Loss)
(Unaudited)
Three Months Ended
September 30,
Nine Months Ended
September 30,
In millions
2026
2025
2026
2025
Net income (loss)
$
2,171
$
(
3,990
)
$
8,123
$
(
1,195
)
Other comprehensive income (loss), net of tax:
Net unrealized investment gains (losses)
(
960
)
192
(
1,213
)
595
Change in discount rate on long-duration insurance reserves
181
(
50
)
225
(
60
)
Foreign currency translation adjustments
—
6
(
1
)
10
Net cash flow hedges
(
4
)
(
4
)
(
12
)
(
9
)
Other comprehensive income (loss)
(
783
)
144
(
1,001
)
536
Comprehensive income (loss)
1,388
(
3,846
)
7,122
(
659
)
Comprehensive (income) loss attributable to noncontrolling interests
1
15
(
29
)
20
Comprehensive income (loss) attributable to CVS Health
$
1,389
$
(
3,831
)
$
7,093
$
(
639
)
See accompanying notes to condensed consolidated financial statements (unaudited).
3
Index to Condensed Consolidated Financial Statements
CVS Health Corporation
Condensed Consolidated Balance Sheets
(Unaudited)
In millions, except per share amounts
September 30,
2026
December 31,
2025
Assets:
Cash and cash equivalents
$
11,738
$
8,453
Investments
3,149
2,145
Accounts receivable, net
42,073
39,779
Inventories
18,240
19,246
Other current assets
4,192
5,091
Total current assets
79,392
74,714
Long-term investments
34,066
32,669
Property and equipment, net
13,322
13,083
Operating lease right-of-use assets
14,226
14,973
Goodwill
85,478
85,478
Intangible assets, net
24,224
25,508
Other assets
7,367
7,113
Total assets
$
258,075
$
253,538
Liabilities:
Accounts payable
$
17,875
$
17,641
Pharmacy claims and discounts payable
26,296
26,344
Health care costs payable
16,858
15,399
Accrued expenses and other current liabilities
25,787
22,387
Other insurance liabilities
904
1,116
Current portion of operating lease liabilities
1,920
1,737
Current portion of long-term debt
3,457
4,068
Total current liabilities
93,097
88,692
Long-term operating lease liabilities
12,697
13,643
Long-term debt
57,223
60,502
Deferred income taxes
3,866
3,832
Other long-term insurance liabilities
4,231
4,716
Other long-term liabilities
6,272
6,771
Total liabilities
177,386
178,156
Shareholders’ equity:
Preferred stock, par value $
0.01
:
0.1
shares authorized;
no
ne issued or outstanding
—
—
Common stock, par value $
0.01
:
3,200
shares authorized;
1,796
shares issued and
1,280
shares outstanding as of September 30, 2026 and
1,787
shares issued and
1,271
shares outstanding as of December 31, 2025 and capital surplus
51,154
50,402
Treasury stock, at cost:
516
shares as of September 30, 2026 and December 31, 2025
(
36,769
)
(
36,790
)
Retained earnings
66,707
61,196
Accumulated other comprehensive income (loss)
(
595
)
406
Total CVS Health shareholders’ equity
80,497
75,214
Noncontrolling interests
192
168
Total shareholders’ equity
80,689
75,382
Total liabilities and shareholders’ equity
$
258,075
$
253,538
See accompanying notes to condensed consolidated financial statements (unaudited).
4
Index to Condensed Consolidated Financial Statements
CVS Health Corporation
Condensed Consolidated Statements of Cash Flows
(Unaudited)
Nine Months Ended
September 30,
In millions
2026
2025
Cash flows from operating activities:
Cash receipts from customers
$
303,060
$
283,378
Cash paid for inventory, prescriptions dispensed and health services rendered
(
165,790
)
(
157,849
)
Insurance benefits paid
(
89,377
)
(
88,769
)
Cash paid to other suppliers and employees
(
30,874
)
(
27,308
)
Interest and investment income received
1,593
1,494
Interest paid
(
2,586
)
(
2,529
)
Income taxes paid
(
708
)
(
1,168
)
Net cash provided by operating activities
15,318
7,249
Cash flows from investing activities:
Proceeds from sales and maturities of investments
10,382
9,640
Purchases of investments
(
13,592
)
(
11,045
)
Purchases of property and equipment
(
2,357
)
(
2,048
)
Acquisitions
(
15
)
(
429
)
Other
37
9
Net cash used in investing activities
(
5,545
)
(
3,873
)
Cash flows from financing activities:
Commercial paper borrowings (repayments), net
—
(
872
)
Proceeds from issuance of long-term debt
—
3,969
Repayments of long-term debt
(
4,057
)
(
3,609
)
Dividends paid
(
2,578
)
(
2,552
)
Proceeds from exercise of stock options
339
308
Payments for taxes related to net share settlement of equity awards
(
175
)
(
145
)
Other
(
66
)
(
7
)
Net cash used in financing activities
(
6,537
)
(
2,908
)
Net increase in cash, cash equivalents and restricted cash
3,236
468
Cash, cash equivalents and restricted cash at the beginning of the period
8,712
8,884
Cash, cash equivalents and restricted cash at the end of the period
$
11,948
$
9,352
5
Index to Condensed Consolidated Financial Statements
CVS Health Corporation
Condensed Consolidated Statements of Cash Flows
(Unaudited)
Nine Months Ended
September 30,
In millions
2026
2025
Reconciliation of net income (loss) to net cash provided by operating activities:
Net income (loss)
$
8,123
$
(
1,195
)
Adjustments required to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization
3,373
3,459
Goodwill impairment
—
5,725
Stock-based compensation
610
400
Loss on sale of subsidiary
—
236
Gain on deconsolidation of subsidiary
—
(
483
)
Deferred income taxes and other items
(
344
)
(
440
)
Change in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable, net
(
2,254
)
(
7,537
)
Inventories
1,006
(
982
)
Other assets
532
(
588
)
Accounts payable and pharmacy claims and discounts payable
409
5,052
Health care costs payable and other insurance liabilities
1,053
734
Other liabilities
2,810
2,868
Net cash provided by operating activities
$
15,318
$
7,249
See accompanying notes to condensed consolidated financial statements (unaudited).
6
Index to Condensed Consolidated Financial Statements
CVS Health Corporation
Condensed Consolidated Statements of Shareholders’ Equity
(Unaudited)
Attributable to CVS Health
Number of shares
outstanding
Common
Stock and
Capital
Surplus
(2)
Treasury
Stock
(1)
Retained
Earnings
Accumulated
Other
Comprehensive
Income (Loss)
Total
CVS Health
Shareholders’
Equity
Noncontrolling
Interests
Total
Shareholders’
Equity
Common
Shares
Treasury
Shares
(1)
In millions
Balance as of December 31, 2025
1,787
(
516
)
$
50,402
$
(
36,790
)
$
61,196
$
406
$
75,214
$
168
$
75,382
Net income
—
—
—
—
2,943
—
2,943
14
2,957
Other comprehensive loss
—
—
—
—
—
(
205
)
(
205
)
—
(
205
)
Stock option activity, stock awards and other
1
—
277
—
—
—
277
—
277
ESPP issuances, net of purchase of treasury shares
—
1
—
84
—
—
84
—
84
Common stock dividends
($
0.665
per share)
—
—
—
—
(
857
)
—
(
857
)
—
(
857
)
Other decreases in noncontrolling interests
—
—
—
—
—
—
—
(
1
)
(
1
)
Balance as of March 31, 2026
1,788
(
515
)
50,679
(
36,706
)
63,282
201
77,456
181
77,637
Net income
—
—
—
—
2,979
—
2,979
16
2,995
Other comprehensive loss
—
—
—
—
—
(
13
)
(
13
)
—
(
13
)
Stock option activity, stock awards and other
7
—
289
—
—
—
289
—
289
Purchase of treasury shares, net of ESPP issuances
—
(
2
)
—
(
146
)
—
—
(
146
)
—
(
146
)
Common stock dividends
($
0.665
per share)
—
—
—
—
(
863
)
—
(
863
)
—
(
863
)
Balance as of June 30, 2026
1,795
(
517
)
50,968
(
36,852
)
65,398
188
79,702
197
79,899
Net income
—
—
—
—
2,172
—
2,172
(
1
)
2,171
Other comprehensive loss (Note 6)
—
—
—
—
—
(
783
)
(
783
)
—
(
783
)
Stock option activity, stock awards and other
1
—
186
—
—
—
186
—
186
ESPP issuances, net of purchase of treasury shares
—
1
—
83
—
—
83
—
83
Common stock dividends
($
0.665
per share)
—
—
—
—
(
863
)
—
(
863
)
—
(
863
)
Other decreases in noncontrolling interests
—
—
—
—
—
—
—
(
4
)
(
4
)
Balance as of September 30, 2026
1,796
(
516
)
$
51,154
$
(
36,769
)
$
66,707
$
(
595
)
$
80,497
$
192
$
80,689
_____________________________________________
(1)
Treasury shares include
1
million shares held in trust and treasury stock includes $
29
million related to shares held in trust as of September 30, 2026, June 30, 2026, March 31, 2026 and December 31, 2025.
(2)
Common stock and capital surplus includes the par value of common stock of $
18
million as of September 30, 2026, June 30, 2026, March 31, 2026 and December 31, 2025.
See accompanying notes to condensed consolidated financial statements (unaudited).
7
Index to Condensed Consolidated Financial Statements
CVS Health Corporation
Condensed Consolidated Statements of Shareholders’ Equity
(Unaudited)
Attributable to CVS Health
Number of shares
outstanding
Common
Stock and
Capital
Surplus
(2)
Treasury
Stock
(1)
Retained
Earnings
Accumulated
Other
Comprehensive
Income (Loss)
Total
CVS Health
Shareholders’
Equity
Noncontrolling
Interests
Total
Shareholders’
Equity
Common
Shares
Treasury
Shares
(1)
In millions
Balance as of December 31, 2024
1,778
(
518
)
$
49,661
$
(
36,818
)
$
62,837
$
(
120
)
$
75,560
$
170
$
75,730
Net income
—
—
—
—
1,779
—
1,779
3
1,782
Other comprehensive income
—
—
—
—
—
179
179
—
179
Stock option activity, stock awards and other
1
—
176
—
—
—
176
—
176
ESPP issuances, net of purchase of treasury shares
—
1
—
83
—
—
83
—
83
Common stock dividends
($
0.665
per share)
—
—
—
—
(
848
)
—
(
848
)
—
(
848
)
Other increases in noncontrolling interests
—
—
—
—
—
—
—
8
8
Balance as of March 31, 2025
1,779
(
517
)
49,837
(
36,735
)
63,768
59
76,929
181
77,110
Net income
—
—
—
—
1,021
—
1,021
(
8
)
1,013
Other comprehensive income
—
—
—
—
—
213
213
—
213
Stock option activity, stock awards and other
6
—
183
—
—
—
183
—
183
Purchase of treasury shares, net of ESPP issuances
—
(
1
)
—
(
114
)
—
—
(
114
)
—
(
114
)
Common stock dividends
($
0.665
per share)
—
—
—
—
(
853
)
—
(
853
)
—
(
853
)
Other decreases in noncontrolling interests
—
—
—
—
—
—
—
(
1
)
(
1
)
Balance as of June 30, 2025
1,785
(
518
)
50,020
(
36,849
)
63,936
272
77,379
172
77,551
Net loss
—
—
—
—
(
3,975
)
—
(
3,975
)
(
15
)
(
3,990
)
Other comprehensive income (Note 6)
—
—
—
—
—
144
144
—
144
Stock option activity, stock awards and other
1
—
161
—
—
—
161
—
161
ESPP issuances, net of purchase of treasury shares
—
2
—
73
—
—
73
—
73
Common stock dividends
($
0.665
per share)
—
—
—
—
(
854
)
—
(
854
)
—
(
854
)
Other increases in noncontrolling interests
—
—
—
—
—
—
—
25
25
Balance as of September 30, 2025
1,786
(
516
)
$
50,181
$
(
36,776
)
$
59,107
$
416
$
72,928
$
182
$
73,110
_____________________________________________
(1)
Treasury shares include
1
million shares held in trust and treasury stock includes $
29
million related to shares held in trust as of September 30, 2025
,
June 30, 2025
,
March 31, 2025 and December 31, 2024.
(2)
Common stock and capital surplus includes the par value of common stock of $
18
million as of September 30, 2025
,
June 30, 2025, March 31, 2025 and December 31, 2024.
See accompanying notes to condensed consolidated financial statements (unaudited).
8
Index to Condensed Consolidated Financial Statements
Notes to Condensed Consolidated Financial Statements (Unaudited)
1.
Significant Accounting Policies
Description of Business
CVS Health Corporation, together with its subsidiaries (collectively, “CVS Health” or the “Company”), is a leading health solutions company simplifying health care one person, one family and one community at a time. As of September 30, 2026, the Company had approximately
9,000
retail locations, more than
1,000
walk-in and primary care medical clinics and a leading pharmacy benefits manager with approximately
87
million plan members and expanding specialty pharmacy solutions. The Company also serves an estimated
37
million people through a broad range of health insurance products and related services. The Company is creating new sources of value through its integrated model, allowing it to expand into personalized, technology driven care delivery and health services, increasing access to quality care, delivering better health outcomes and lowering overall health care costs.
The Company has
four
reportable segments: Health Care Benefits, Health Services, Pharmacy & Consumer Wellness and Corporate/Other, which are described below.
Health Care Benefits Segment
The Health Care Benefits segment operates as one of the nation’s leading diversified health care benefits providers through its Aetna
®
operations. The Health Care Benefits segment has the information and resources to help members, in consultation with their health care professionals, make more informed decisions about their health care. The Health Care Benefits segment offers a broad range of health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare Supplement plans, prescription drug plans (“PDPs”) and Medicaid health care management services. The Health Care Benefits segment’s primary customers, its members, primarily access the segment’s products and services through employer groups, government-sponsored plans or individually. The Health Care Benefits segment also serves customers who purchase products and services that are ancillary to its health insurance products. The Company refers to insurance products (where it assumes all or a majority of the risk for medical and dental care costs) as “Insured” and administrative services contract products (where the plan sponsor assumes all or a majority of the risk for medical and dental care costs) as “ASC.”
Health Services Segment
The Health Services segment provides a full range of pharmacy benefit management (“PBM”) solutions through its CVS Caremark
®
operations and delivers health care services in its medical clinics, virtually, and in the home. PBM solutions include plan design offerings and administration, formulary management, retail pharmacy network management services, and specialty and mail order pharmacy services. In addition, the Company provides clinical services, disease management services, medical spend management and pharmacy and/or other administrative services for providers and federal 340B drug pricing program covered entities (“Covered Entities”). The Company operates a group purchasing organization that negotiates pricing for the purchase of pharmaceuticals and rebates with pharmaceutical manufacturers on behalf of its participants and provides various administrative, management and reporting services to pharmaceutical manufacturers. The segment also works directly with pharmaceutical manufacturers to commercialize and/or co-produce high quality biosimilar products through its Cordavis
®
subsidiary. The Health Services segment’s health care delivery assets include Signify Health, Inc. (“Signify Health”), a leader in health risk assessments, and Oak Street Health, Inc. (“Oak Street Health”), a leading multi-payor operator of value-based primary care centers serving Medicare eligible patients. The Health Services segment’s clients and customers are primarily employers, insurance companies, unions, government employee groups, health plans, PDPs, Medicaid managed care plans, the U.S. Centers for Medicare & Medicaid Services (“
CMS”)
, plans offered on public and private health insurance exchanges and other sponsors of health benefit plans throughout the U.S., patients who receive care in the Health Services segment’s medical clinics, virtually or in the home, as well as Covered Entities.
Pharmacy & Consumer Wellness Segment
The Pharmacy & Consumer Wellness segment dispenses prescriptions in its CVS Pharmacy
®
retail locations and through its infusion operations, provides ancillary pharmacy services including pharmacy patient care programs and vaccination administration, and sells a wide assortment of health and wellness products and general merchandise. The segment also provides pharmacy fulfillment services to support the Health Services segment’s specialty and mail order pharmacy offerings. As of September 30, 2026, the Pharmacy & Consumer Wellness segment operated approximately
9,000
retail locations, as well as online retail pharmacy websites, retail specialty pharmacy stores, compounding pharmacies and branches for infusion and enteral nutrition services.
9
Corporate/Other Segment
The Company presents the remainder of its financial results in the Corporate/Other segment, which primarily consists of:
•
Management and administrative expenses to support the Company’s overall operations, which include certain aspects of executive management and the corporate relations, legal, compliance, human resources and finance departments, information technology, digital, data and analytics, as well as acquisition-related integration costs; and
•
Products for which the Company no longer solicits or accepts new customers, such as its large case pensions and long-term care insurance products.
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements of CVS Health and its subsidiaries have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. In accordance with such rules and regulations, certain information and accompanying note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been omitted, although the Company believes the disclosures included herein are adequate to make the information presented not misleading. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 (the “2025 Form 10-K”).
In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods presented. Because of the influence of various factors on the Company’s operations, including business combinations, certain holidays and other seasonal influences, net income (loss) for any interim period may not be comparable to the same interim period in previous years or necessarily indicative of income for the full year.
Principles of Consolidation
The unaudited condensed consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries and variable interest entities (“VIEs”) for which the Company is the primary beneficiary. All material intercompany balances and transactions have been eliminated.
The Company continually evaluates its investments to determine if they represent variable interests in a VIE. If the Company determines that it has a variable interest in a VIE, the Company then evaluates if it is the primary beneficiary of the VIE. The evaluation is a qualitative assessment as to whether the Company has the ability to direct the activities of a VIE that most significantly impact the entity’s economic performance. The Company consolidates a VIE if it is considered to be the primary beneficiary.
Assets and liabilities of VIEs for which the Company is the primary beneficiary were not significant to the Company’s unaudited condensed consolidated financial statements. VIE creditors do not have recourse against the general credit of the Company.
Reclassifications
Certain prior year amounts within the unaudited condensed consolidated balance sheet have been reclassified to conform with the current year presentation.
Restricted Cash
Restricted cash included in other current assets on the unaudited condensed consolidated balance sheets primarily represents funds held on behalf of members. Restricted cash included in other assets on the unaudited condensed consolidated balance sheets represents amounts held in a trust in one of the Company’s captive insurance companies to satisfy collateral requirements associated with the assignment of certain insurance policies. All restricted cash is invested in demand deposits, time deposits and money market funds.
10
The following is a reconciliation of cash and cash equivalents on the unaudited condensed consolidated balance sheets to total cash, cash equivalents and restricted cash on the unaudited condensed consolidated statements of cash flows:
In millions
September 30,
2026
December 31,
2025
Cash and cash equivalents
$
11,738
$
8,453
Restricted cash (included in other current assets)
—
59
Restricted cash (included in other assets)
210
200
Total cash, cash equivalents and restricted cash in the statements of cash flows
$
11,948
$
8,712
Accounts Receivable
Accounts receivable are stated net of allowances for credit losses, customer credit allowances, contractual allowances and estimated terminations.
Accounts receivable, net as of September 30, 2026 and December 31, 2025 was composed of the following:
In millions
September 30,
2026
December 31,
2025
Trade receivables
$
14,150
$
10,563
Vendor and manufacturer receivables
16,188
15,564
Premium receivables
5,445
5,753
Other receivables
6,290
7,899
Total accounts receivable, net
$
42,073
$
39,779
The Company’s allowance for credit losses was $
173
million and $
182
million as of September 30, 2026 and December 31, 2025, respectively.
When developing an estimate of the Company’s expected credit losses, the Company considers all available relevant information regarding the collectability of cash flows, including historical information, current conditions and reasonable and supportable forecasts of future economic conditions over the contractual life of the receivable. The Company’s accounts receivable are short duration in nature and typically settle in less than 30 days.
Premium Deficiency Reserves
The Company evaluates its short-duration insurance contracts to determine if it is probable that a loss will be incurred. For purposes of determining premium deficiency losses, contracts are grouped consistent with the Company’s method of acquiring, servicing and measuring the profitability of such contracts. For each contract grouping, a premium deficiency reserve is recognized when it is probable that expected future incurred claims, including costs to maintain the contract grouping, exceed anticipated future premiums and reinsurance recoveries. Anticipated investment income is not considered in the calculation of premium deficiency reserves. A premium deficiency is first recognized by charging any unamortized acquisition costs to operating expenses, and to the extent the premium deficiency is greater than the unamortized acquisition costs, a premium deficiency reserve liability is established and reflected in health care costs payable on the unaudited condensed consolidated balance sheets. Losses recognized as a premium deficiency reserve result in a beneficial effect in subsequent periods as subsequent costs under these contracts are then charged to this previously established liability.
During the second quarter of 2026, the Company recorded a premium deficiency reserve of $
15
million to health care costs related to
one
state in its Medicaid product line. As of September 30, 2026, the remaining premium deficiency reserve reflected in health care costs payable was $
13
million. The Company did not establish any other premium deficiency reserves during the three and nine months ended September 30, 2026.
During the first quarter of 2025, the Company determined it had a premium deficiency in its individual exchange product line related to the remainder of the 2025 coverage year and, accordingly, recorded a premium deficiency reserve of $
448
million. The premium deficiency reserve consisted of a $
17
million write-off of unamortized acquisition costs, which was recorded in operating expenses, and $
431
million recorded in health care costs. Additionally, during the second quarter of 2025, the Company recorded a premium deficiency reserve of $
471
million to health care costs related to its Group Medicare Advantage product line for the remainder of the 2025 coverage year. The premium deficiency reserves were subsequently utilized throughout the remainder of 2025. The Company did not establish any other premium deficiency reserves during the three and nine months ended September 30, 2025.
11
Revenue Recognition
Disaggregation of Revenue
The following tables disaggregate the Company’s revenue by major source in each segment for the three and nine months ended September 30, 2026 and 2025:
In millions
Health Care
Benefits
Health
Services
Pharmacy &
Consumer
Wellness
Corporate/
Other
Intersegment
Eliminations
Consolidated
Totals
Three Months Ended September 30, 2026
Major goods/services lines:
Pharmacy
$
—
$
51,411
$
29,725
$
—
$
(
17,073
)
$
64,063
Front Store
—
—
5,164
—
—
5,164
Premiums
34,569
—
—
11
(
14
)
34,566
Net investment income
455
—
—
192
—
647
Other
1,831
2,553
609
2
(
1,036
)
3,959
Total
$
36,855
$
53,964
$
35,498
$
205
$
(
18,123
)
$
108,399
Health Services distribution channel:
Pharmacy network
(1)
$
28,258
Mail & specialty
(2)
23,153
Other
2,553
Total
$
53,964
Three Months Ended September 30, 2025
Major goods/services lines:
Pharmacy
$
—
$
46,800
$
30,428
$
—
$
(
17,680
)
$
59,548
Front Store
—
—
5,192
—
—
5,192
Premiums
33,739
—
—
11
(
31
)
33,719
Net investment income (loss)
513
(
1
)
—
120
—
632
Other
1,741
2,467
594
2
(
1,024
)
3,780
Total
$
35,993
$
49,266
$
36,214
$
133
$
(
18,735
)
$
102,871
Health Services distribution channel:
Pharmacy network
(1)
$
26,408
Mail & specialty
(2)
20,392
Net investment income (loss)
(
1
)
Other
2,467
Total
$
49,266
12
In millions
Health Care
Benefits
Health
Services
Pharmacy &
Consumer
Wellness
Corporate/
Other
Intersegment
Eliminations
Consolidated
Totals
Nine Months Ended September 30, 2026
Major goods/services lines:
Pharmacy
$
—
$
146,260
$
83,629
$
—
$
(
48,061
)
$
181,828
Front Store
—
—
15,830
—
—
15,830
Premiums
103,480
—
—
34
(
40
)
103,474
Net investment income (loss)
1,425
(
1
)
—
438
—
1,862
Other
5,459
7,737
1,844
6
(
3,119
)
11,927
Total
$
110,364
$
153,996
$
101,303
$
478
$
(
51,220
)
$
314,921
Health Services distribution channel:
Pharmacy network
(1)
$
80,024
Mail & specialty
(2)
66,236
Net investment income (loss)
(
1
)
Other
7,737
Total
$
153,996
Nine Months Ended September 30, 2025
Major goods/services lines:
Pharmacy
$
—
$
132,258
$
84,135
$
—
$
(
48,989
)
$
167,404
Front Store
—
—
15,803
—
—
15,803
Premiums
100,731
—
—
34
(
31
)
100,734
Net investment income
1,307
10
—
322
—
1,639
Other
5,023
6,913
1,769
6
(
2,917
)
10,794
Total
$
107,061
$
139,181
$
101,707
$
362
$
(
51,937
)
$
296,374
Health Services distribution channel:
Pharmacy network
(1)
$
74,187
Mail & specialty
(2)
58,071
Net investment income
10
Other
6,913
Total
$
139,181
_____________________________________________
(1)
Health Services pharmacy network is defined as claims filled at retail and specialty retail pharmacies, including pharmacies owned by the Company, as well as activity associated with Maintenance Choice
®
, which permits eligible client plan members to fill their maintenance prescriptions through mail order delivery or at a CVS pharmacy retail store for the same price as mail order.
(2)
Health Services mail & specialty is defined as specialty mail claims inclusive of Specialty Connect
®
claims picked up at a retail pharmacy, as well as mail order and specialty claims fulfilled by the Pharmacy & Consumer Wellness segment.
ACO REACH and MSSP Exit
Prior to the first quarter of 2025, the Company’s Health Services segment provided enablement services to health systems primarily through
two
programs administered by CMS: the Accountable Care Organization Realizing Equity, Access and Community Health (“ACO REACH”) program and the Medicare Shared Savings Program (“MSSP”). During the first quarter of 2025, the Company determined that it would substantially exit both the ACO REACH program and the MSSP as further described below. In connection with these actions, during the nine months ended September 30, 2025, the Company recorded expenses of $
288
million, which were included in the loss on Accountable Care assets and reflected in operating expenses within the Health Services segment.
13
ACO REACH
In February 2025, the Company informed CMS of its plans to voluntarily terminate substantially all of its participation in the ACO REACH program effective March 31, 2025. In connection with the process of winding down its ACO REACH operations, the Company incurred costs of $
52
million during the nine months ended September 30, 2025.
MSSP
In March 2025, the Company also divested its MSSP operations to Wellvana Health, LLC. The Company recorded a pre-tax loss on the divestiture of $
236
million during the nine months ended September 30, 2025, which included the removal of intangible assets and goodwill totaling $
342
million. The consideration received related to this agreement was not material.
Omnicare Bankruptcy
On September 22, 2025, Omnicare, LLC (“Omnicare”), a wholly-owned indirect subsidiary of CVS Health Corporation, and certain of Omnicare’s subsidiary entities (collectively, the “Omnicare Entities”) voluntarily initiated Chapter 11 proceedings under the U.S. Bankruptcy Code. As a result of the initiation of Chapter 11 proceedings, the Company determined that it no longer retained control of the Omnicare Entities and deconsolidated the subsidiaries on September 22, 2025. The Omnicare Entities conduct long-term care pharmacy (“LTC”) operations, which distribute prescription drugs and provide related pharmacy consulting and ancillary services to long-term care facilities and other care settings. Prior to deconsolidation, the financial results of the Omnicare Entities were not material and were included in the Pharmacy & Consumer Wellness segment. As a result of the deconsolidation, the Company recorded a gain on deconsolidation of subsidiary of $
483
million. Subsequent to deconsolidation, the Company’s retained investment related to its equity ownership of the Omnicare Entities had both a carrying value and a fair value of $
0
.
New Accounting Pronouncements Not Yet Adopted
Disaggregation of Income Statement Expenses
In November 2024, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2024-03,
Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses
. The standard requires the Company to provide further disaggregated information of relevant expense captions within its consolidated statements of operations, including the purchases of inventory, employee compensation, depreciation and intangible asset amortization, as well as the inclusion of other specific expenses, gains and losses required by existing GAAP. The new standard also requires the Company to disclose its total selling expenses and, on an annual basis, provide a qualitative description of its selling expenses. The standard is effective for fiscal years beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The standard may be applied prospectively or retrospectively. While the standard will require additional disclosures related to certain expenses included in the consolidated statements of operations, the standard is not expected to have any impact on the Company’s consolidated operating results, financial condition or cash flows.
Internal-Use Software
In September 2025, the FASB issued ASU 2025-06,
Targeted Improvements to the Accounting for Internal-Use Software
. This standard is intended to modernize the accounting for internal-use software. Under the new standard, the Company will capitalize eligible costs when (i) management has authorized and committed to funding the software project, and (ii) it is probable that the project will be completed and the software will be used to perform the function intended. The standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2027, with early adoption permitted as of the beginning of a fiscal year. The standard may be applied prospectively, retrospectively or using a modified transition approach. The Company is currently evaluating the impact that this standard will have on the Company’s consolidated operating results, cash flows, financial condition and related disclosures.
14
2.
Investments
Total investments as of September 30, 2026 and December 31, 2025 were as follows:
September 30, 2026
December 31, 2025
In millions
Current
Long-term
Total
Current
Long-term
Total
Debt securities available for sale
$
2,868
$
27,303
$
30,171
$
1,997
$
26,721
$
28,718
Mortgage loans
281
1,205
1,486
148
1,376
1,524
Other investments
—
5,558
5,558
—
4,572
4,572
Total investments
$
3,149
$
34,066
$
37,215
$
2,145
$
32,669
$
34,814
Debt Securities
Debt securities available for sale as of September 30, 2026 and December 31, 2025 were as follows:
In millions
Amortized
Cost
(1)
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair
Value
September 30, 2026
Debt securities:
U.S. government securities
$
3,133
$
1
$
(
74
)
$
3,060
States, municipalities and political subdivisions
258
—
(
17
)
241
U.S. corporate securities
16,758
25
(
775
)
16,008
Foreign securities
3,338
16
(
120
)
3,234
Residential mortgage-backed securities
1,251
—
(
88
)
1,163
Commercial mortgage-backed securities
2,045
—
(
96
)
1,949
Other asset-backed securities
4,523
4
(
25
)
4,502
Redeemable preferred securities
14
—
—
14
Total debt securities
(2)
$
31,320
$
46
$
(
1,195
)
$
30,171
December 31, 2025
Debt securities:
U.S. government securities
$
2,691
$
39
$
(
8
)
$
2,722
States, municipalities and political subdivisions
296
3
(
7
)
292
U.S. corporate securities
14,657
262
(
231
)
14,688
Foreign securities
2,981
78
(
31
)
3,028
Residential mortgage-backed securities
1,065
14
(
29
)
1,050
Commercial mortgage-backed securities
1,974
28
(
23
)
1,979
Other asset-backed securities
4,921
25
(
2
)
4,944
Redeemable preferred securities
15
—
—
15
Total debt securities
(2)
$
28,600
$
449
$
(
331
)
$
28,718
_____________________________________________
(1)
There was
no
allowance for expected credit losses recorded on available-for-sale debt securities as of September 30, 2026 or December 31, 2025.
(2)
Investment risks associated with the Company’s experience-rated products generally do not impact the Company’s consolidated operating results. As of September 30, 2026, debt securities with a fair value of $
430
million, gross unrealized capital gains of $
2
million and gross unrealized capital losses of $
36
million, and as of December 31, 2025, debt securities with a fair value of $
475
million, gross unrealized capital gains of $
10
million and gross unrealized capital losses of $
16
million were included in total debt securities, but support experience-rated products. Changes in net unrealized capital gains (losses) on these securities are not reflected in accumulated other comprehensive income (loss).
15
The amortized cost and fair value of debt securities as of September 30, 2026 are shown below by contractual maturity. Actual maturities may differ from contractual maturities because securities may be restructured, called or prepaid, or the Company intends to sell a security prior to maturity.
In millions
Amortized
Cost
Fair
Value
Due to mature:
Less than one year
$
1,394
$
1,393
One year through five years
12,666
12,409
After five years through ten years
6,338
6,040
Greater than ten years
3,103
2,715
Residential mortgage-backed securities
1,251
1,163
Commercial mortgage-backed securities
2,045
1,949
Other asset-backed securities
4,523
4,502
Total
$
31,320
$
30,171
16
Summarized below are the debt securities the Company held as of September 30, 2026 and December 31, 2025 that were in an unrealized capital loss position, aggregated by the length of time the investments have been in that position:
Less than 12 months
Greater than 12 months
Total
In millions, except number of securities
Number
of
Securities
Fair
Value
Unrealized
Losses
Number
of
Securities
Fair
Value
Unrealized
Losses
Number
of
Securities
Fair
Value
Unrealized
Losses
September 30, 2026
Debt securities:
U.S. government securities
538
$
2,305
$
66
62
$
106
$
8
600
$
2,411
$
74
States, municipalities and political subdivisions
85
154
7
50
66
10
135
220
17
U.S. corporate securities
8,322
12,590
481
1,141
1,506
294
9,463
14,096
775
Foreign securities
1,519
2,487
90
148
205
30
1,667
2,692
120
Residential mortgage-backed securities
471
965
50
264
187
38
735
1,152
88
Commercial mortgage-backed securities
607
1,764
71
74
154
25
681
1,918
96
Other asset-backed securities
727
2,018
24
19
22
1
746
2,040
25
Redeemable preferred securities
6
9
—
—
—
—
6
9
—
Total debt securities
12,275
$
22,292
$
789
1,758
$
2,246
$
406
14,033
$
24,538
$
1,195
December 31, 2025
Debt securities:
U.S. government securities
50
$
156
$
2
80
$
168
$
6
130
$
324
$
8
States, municipalities and political subdivisions
16
28
—
89
136
7
105
164
7
U.S. corporate securities
1,045
1,634
23
1,541
2,149
208
2,586
3,783
231
Foreign securities
180
310
2
303
449
29
483
759
31
Residential mortgage-backed securities
67
124
1
303
272
28
370
396
29
Commercial mortgage-backed securities
84
290
1
126
269
22
210
559
23
Other asset-backed securities
136
314
1
19
27
1
155
341
2
Redeemable preferred securities
—
—
—
4
6
—
4
6
—
Total debt securities
1,578
$
2,856
$
30
2,465
$
3,476
$
301
4,043
$
6,332
$
331
The Company reviewed the securities in the table above and concluded that they are performing assets generating investment income to support the needs of the Company’s business. In performing this review, the Company considered factors such as the quality of the investment security based on research performed by the Company’s internal credit analysts and external rating agencies and the prospects of realizing the carrying value of the security based on the investment’s current prospects for recovery. Unrealized capital losses as of September 30, 2026 were generally caused by interest rate increases and not by unfavorable changes in the credit quality associated with these securities. As of September 30, 2026, the Company did not intend to sell these securities, and did not believe it was more likely than not that it would be required to sell these securities prior to the anticipated recovery of their amortized cost basis.
17
Net Investment Income
Sources of net investment income for the three and nine months ended September 30, 2026 and 2025 were as follows:
Three Months Ended
September 30,
Nine Months Ended
September 30,
In millions
2026
2025
2026
2025
Debt securities
$
376
$
339
$
1,086
$
986
Mortgage loans
22
22
66
64
Other investments
260
298
775
687
Gross investment income
658
659
1,927
1,737
Investment expenses
(
14
)
(
16
)
(
39
)
(
39
)
Net investment income (excluding net realized capital gains or losses)
644
643
1,888
1,698
Net realized capital gains (losses)
3
(
11
)
(
26
)
(
59
)
Net investment income
$
647
$
632
$
1,862
$
1,639
Excluding amounts related to experience-rated products, proceeds from the sale of available-for-sale debt securities and the related gross realized capital gains and losses for the three and nine months ended September 30, 2026 and 2025 were as follows:
Three Months Ended
September 30,
Nine Months Ended
September 30,
In millions
2026
2025
2026
2025
Proceeds from sales
$
1,820
$
1,836
$
6,713
$
6,644
Gross realized capital gains
7
15
52
37
Gross realized capital losses
33
27
84
114
3.
Fair Value
The preparation of the Company’s unaudited condensed consolidated financial statements in accordance with GAAP requires certain assets and liabilities to be reflected at their fair value and others to be reflected on another basis, such as an adjusted historical cost basis. The Company’s assets and liabilities carried at fair value have been classified within one of three levels of a hierarchy established by GAAP. The following are the levels of the hierarchy and a brief description of the type of valuation information (“valuation inputs”) that qualifies a financial asset or liability for each level:
•
Level 1 – Unadjusted quoted prices for identical assets or liabilities in active markets.
•
Level 2 – Valuation inputs other than Level 1 that are based on observable market data. These include: quoted prices for similar assets in active markets, quoted prices for identical assets in inactive markets, valuation inputs that are observable that are not prices (such as interest rates and credit risks) and valuation inputs that are derived from or corroborated by observable markets.
•
Level 3 – Developed from unobservable data, reflecting the Company’s assumptions.
For a description of the methods and assumptions that are used to estimate the fair value and determine the fair value hierarchy classification of each class of financial instrument, see Note 5 ‘‘Fair Value’’ in the 2025 Form 10-K.
18
There were
no
financial liabilities measured at fair value on a recurring basis on the unaudited condensed consolidated balance sheets as of September 30, 2026 or December 31, 2025.
Financial assets measured at fair value on a recurring basis on the unaudited condensed consolidated balance sheets as of September 30, 2026 and December 31, 2025 were as follows:
In millions
Level 1
Level 2
Level 3
Total
September 30, 2026
Cash and cash equivalents
$
6,468
$
5,270
$
—
$
11,738
Debt securities:
U.S. government securities
3,052
8
—
3,060
States, municipalities and political subdivisions
—
241
—
241
U.S. corporate securities
—
15,995
13
16,008
Foreign securities
—
3,234
—
3,234
Residential mortgage-backed securities
—
1,163
—
1,163
Commercial mortgage-backed securities
—
1,949
—
1,949
Other asset-backed securities
—
4,502
—
4,502
Redeemable preferred securities
—
14
—
14
Total debt securities
3,052
27,106
13
30,171
Equity securities
54
375
250
679
Total
$
9,574
$
32,751
$
263
$
42,588
December 31, 2025
Cash and cash equivalents
$
4,030
$
4,423
$
—
$
8,453
Debt securities:
U.S. government securities
2,713
9
—
2,722
States, municipalities and political subdivisions
—
292
—
292
U.S. corporate securities
—
14,682
6
14,688
Foreign securities
—
3,028
—
3,028
Residential mortgage-backed securities
—
1,050
—
1,050
Commercial mortgage-backed securities
—
1,979
—
1,979
Other asset-backed securities
—
4,944
—
4,944
Redeemable preferred securities
—
15
—
15
Total debt securities
2,713
25,999
6
28,718
Equity securities
105
30
198
333
Total
$
6,848
$
30,452
$
204
$
37,504
During the three and nine months ended September 30, 2026 and 2025, transfers into or out of Level 3 were not material.
19
The carrying value and estimated fair value classified by level of fair value hierarchy for financial instruments carried on the unaudited condensed consolidated balance sheets at adjusted cost or contract value as of September 30, 2026 and December 31, 2025 were as follows:
Carrying
Value
Estimated Fair Value
In millions
Level 1
Level 2
Level 3
Total
September 30, 2026
Assets:
Mortgage loans
$
1,486
$
—
$
—
$
1,444
$
1,444
Equity securities
(1)
770
N/A
N/A
N/A
N/A
Liabilities:
Long-term debt
60,680
54,977
—
—
54,977
December 31, 2025
Assets:
Mortgage loans
$
1,524
$
—
$
—
$
1,524
$
1,524
Equity securities
(1)
555
N/A
N/A
N/A
N/A
Liabilities:
Long-term debt
64,570
62,321
—
—
62,321
_____________________________________________
(1)
It was not practical to estimate the fair value of these investments as they represent shares of unlisted companies.
Separate Accounts
Separate accounts assets relate to the Company’s large case pensions products and represent funds maintained to meet specific objectives of contract holders. Since contract holders bear the investment risk of these assets, a corresponding separate accounts liability has been established equal to the assets. Separate accounts assets and liabilities are carried at fair value and are included in other assets and other long-term liabilities, respectively, on the unaudited condensed consolidated balance sheets. During the nine months ended September 30, 2026, changes in separate accounts assets and liabilities were not material.
Separate accounts assets as of September 30, 2026 and December 31, 2025 were as follows:
September 30, 2026
December 31, 2025
In millions
Level 1
Level 2
Level 3
Total
Level 1
Level 2
Level 3
Total
Cash and cash equivalents
$
1
$
149
$
—
$
150
$
1
$
155
$
—
$
156
Debt securities
12
313
1
326
30
361
2
393
Equity securities
28
—
—
28
—
—
—
—
Common/collective trusts
—
1,397
—
1,397
—
1,445
—
1,445
Total
(1)
$
41
$
1,859
$
1
$
1,901
$
31
$
1,961
$
2
$
1,994
_____________________________________________
(1)
Excludes $
70
million of other receivables as of September 30, 2026.
20
4.
Insurance Liabilities
Health Care Costs Payable
The following table shows the components of the change in health care costs payable during the nine months ended September 30, 2026 and 2025:
Nine Months Ended
September 30,
In millions
2026
2025
Health care costs payable, beginning of the period
$
15,399
$
15,064
Less: Reinsurance recoverables
90
81
Less: Impact of discount rate on long-duration insurance reserves
(1)
(
20
)
(
1
)
Health care costs payable, beginning of the period, net
15,329
14,984
Add: Components of incurred health care costs
Current year
94,302
93,496
Prior years
(
1,371
)
(
1,926
)
Total incurred health care costs
(2)
92,931
91,570
Less: Claims paid
Current year
80,123
79,687
Prior years
11,378
11,567
Total claims paid
91,501
91,254
Health care costs payable, end of the period, net
16,759
15,300
Add: Premium deficiency reserves
13
728
Add: Reinsurance recoverables
107
94
Add: Impact of discount rate on long-duration insurance reserves
(1)
(
21
)
(
24
)
Health care costs payable, end of the period
$
16,858
$
16,098
_____________________________________________
(1)
Reflects the difference between the current discount rate and the locked-in discount rate on long-duration insurance reserves which is recorded within accumulated other comprehensive income (loss) on the unaudited condensed consolidated balance sheets.
(2)
Total incurred health care costs for the nine months ended September 30, 2026 and 2025 in the table above exclude $
80
million and $
41
million, respectively, of health care costs recorded in the Health Care Benefits segment that are included in other insurance liabilities on the unaudited condensed consolidated balance sheets and $
135
million and $
133
million, respectively, of health care costs recorded in the Corporate/Other segment that are included in other insurance liabilities on the unaudited condensed consolidated balance sheets. Total incurred health care costs for the nine months ended September 30, 2026 also exclude a $
13
million premium deficiency reserve related to
one
state in the Company’s Medicaid product line. Total incurred health care costs for the nine months ended September 30, 2025 also exclude $
728
million for premium deficiency reserves related to the Company’s individual exchange and Group Medicare Advantage product lines.
The Company’s estimates of prior years’ health care costs payable decreased by $
1.4
billion and $
1.9
billion, respectively, in the nine months ended September 30, 2026 and 2025, because claims were settled for amounts less than originally estimated (i.e., the amount of claims incurred was lower than originally estimated), primarily due to lower health care cost trends as well as the actual claim submission time being faster than originally assumed (i.e., the Company’s completion factors were higher than originally assumed) in estimating health care costs payable at the end of the prior year.
As of September 30, 2026, the Company’s liabilities for the ultimate cost of (i) services rendered to the Company’s Insured members but not yet reported to the Company and (ii) claims which have been reported to the Company but not yet paid (collectively, “IBNR”) plus expected development on reported claims totaled approximately $
10.3
billion. Substantially all of the Company’s liabilities for IBNR plus expected development on reported claims as of September 30, 2026 related to the current year.
Future Policy Benefits
Future policy benefits consist primarily of reserves for products for which the Company no longer solicits or accepts new customers, including limited payment pension and annuity contracts (referred to as “large case pensions”) and long-term care insurance contracts. Contracts are grouped into cohorts by contract type and issue year. The liability for future policy benefits is
21
adjusted for differences between actual and expected experience. During the nine months ended September 30, 2026 and 2025, changes in the liability for future policy benefits were not material.
The weighted-average interest rates used in the measurement of the long-duration insurance liabilities as of September 30, 2026 and 2025 were as follows:
September 30,
2026
September 30,
2025
Large case pensions
Interest accretion rate
4.21
%
4.21
%
Current discount rate
6.23
%
5.07
%
Long-term care
Interest accretion rate
5.11
%
5.11
%
Current discount rate
6.48
%
5.42
%
The weighted-average durations (in years) of the long-duration insurance liabilities as of September 30, 2026 and 2025 were as follows:
September 30,
2026
September 30,
2025
Large case pensions
7.2
7.2
Long-term care
10.9
11.3
5.
Shareholders’ Equity
Share Repurchase Programs
The following share repurchase programs have been authorized by CVS Health Corporation’s Board of Directors (the “Board”):
In billions
Authorization Date
Authorized
Remaining as of
September 30, 2026
November 17, 2022 (“2022 Repurchase Program”)
$
10.0
$
10.0
December 9, 2021 (“2021 Repurchase Program”)
10.0
1.5
Each of the share repurchase programs was effective immediately and permit the Company to effect repurchases from time to time through a combination of open market repurchases, privately negotiated transactions, accelerated share repurchase (“ASR”) transactions, and/or other derivative transactions. Both the 2022 and 2021 Repurchase Programs can be modified or terminated by the Board at any time.
During the nine months ended September 30, 2026 and 2025, the Company did
not
repurchase any shares of its common stock.
Dividends
The quarterly cash dividend declared by the Board was $
0.665
per share in both the three months ended September 30, 2026 and 2025. Cash dividends declared by the Board were $
1.995
per share in both the nine months ended September 30, 2026 and 2025. CVS Health Corporation has paid cash dividends every quarter since becoming a public company. Future dividend payments will depend on the Company’s earnings, capital requirements, financial condition and other factors considered relevant by the Board.
22
6.
Other Comprehensive Income (Loss)
Shareholders’ equity included the following activity in accumulated other comprehensive income (loss) for the three and nine months ended September 30, 2026 and 2025:
Three Months Ended
September 30,
Nine Months Ended
September 30,
In millions
2026
2025
2026
2025
Net unrealized investment gains (losses):
Beginning of period balance
$
(
47
)
$
4
$
206
$
(
399
)
Other comprehensive income (loss) before reclassifications (
$(
968
), $
209
, $(
1,321
), $
533
pretax)
(
1,029
)
175
(
1,300
)
498
Amounts reclassified from accumulated other comprehensive income (loss) (
$
64
, $
19
, $
87
, $
106
pretax)
(1)
69
17
87
97
Other comprehensive income (loss)
(
960
)
192
(
1,213
)
595
End of period balance
(
1,007
)
196
(
1,007
)
196
Change in discount rate on long-duration insurance reserves:
Beginning of period balance
259
255
215
265
Other comprehensive income (loss) before reclassifications (
$
234
, $(
65
), $
290
, $(
77
) pretax)
181
(
50
)
225
(
60
)
Other comprehensive income (loss)
181
(
50
)
225
(
60
)
End of period balance
440
205
440
205
Foreign currency translation adjustments:
Beginning of period balance
6
—
7
(
4
)
Other comprehensive income (loss) before reclassifications
—
6
(
1
)
10
Other comprehensive income (loss)
—
6
(
1
)
10
End of period balance
6
6
6
6
Net cash flow hedges:
Beginning of period balance
208
224
216
229
Other comprehensive income before reclassifications
($
0
, $
0
, $
0
, $
5
pretax)
—
—
—
3
Amounts reclassified from accumulated other comprehensive income
($(
5
), $(
5
), $(
16
), $(
17
) pretax)
(2)
(
4
)
(
4
)
(
12
)
(
12
)
Other comprehensive loss
(
4
)
(
4
)
(
12
)
(
9
)
End of period balance
204
220
204
220
Pension and other postretirement benefits:
Beginning of period balance
(
238
)
(
211
)
(
238
)
(
211
)
Other comprehensive income
—
—
—
—
End of period balance
(
238
)
(
211
)
(
238
)
(
211
)
Total beginning of period accumulated other comprehensive income (loss)
188
272
406
(
120
)
Total other comprehensive income (loss)
(
783
)
144
(
1,001
)
536
Total end of period accumulated other comprehensive income (loss)
$
(
595
)
$
416
$
(
595
)
$
416
_____________________________________________
(1)
Amounts reclassified from accumulated other comprehensive income (loss) for specifically identified debt securities are included in net investment income in the unaudited condensed consolidated statements of operations.
(2)
Amounts reclassified from accumulated other comprehensive income for specifically identified cash flow hedges are included in interest expense in the unaudited condensed consolidated statements of operations. The Company expects to reclassify approximately $
16
million, net of tax, in net gains associated with its cash flow hedges into net income within the next 12 months.
23
7.
Earnings (Loss) Per Share
Earnings (loss) per share is computed using the treasury stock method. For periods in which the Company reports net income, diluted earnings per share is determined using the weighted average number of common and dilutive common equivalent shares outstanding during the period, unless the effect is antidilutive. Stock options and stock appreciation rights to purchase
1
million and
3
million shares of common stock were outstanding, but were excluded from the calculation of diluted earnings per share for the three and nine months ended September 30, 2026, respectively, because their exercise prices were greater than the average market price of the common shares and, therefore, the effect would be antidilutive. For the same reason, stock options and stock appreciation rights to purchase
9
million and
10
million shares of common stock were outstanding, but were excluded from the calculation of diluted loss per share for the three and nine months ended September 30, 2025, respectively. In addition, due to the net loss attributable to CVS Health in the three and nine months ended September 30, 2025,
3
million of potentially dilutive common equivalent shares were excluded from the calculation of diluted earnings (loss) per share, as the impact of these shares was antidilutive for each of those periods.
The following is a reconciliation of basic and diluted earnings (loss) per share for the three and nine months ended September 30, 2026 and 2025:
Three Months Ended
September 30,
Nine Months Ended
September 30,
In millions, except per share amounts
2026
2025
2026
2025
Numerator for earnings (loss) per share calculation:
Net income (loss) attributable to CVS Health
$
2,172
$
(
3,975
)
$
8,094
$
(
1,175
)
Denominator for earnings (loss) per share calculation:
Weighted average shares, basic
1,282
1,269
1,278
1,266
Restricted stock units and performance stock units
7
—
6
—
Stock options and stock appreciation rights
2
—
2
—
Weighted average shares, diluted
1,291
1,269
1,286
1,266
Earnings (loss) per share:
Basic
$
1.70
$
(
3.13
)
$
6.33
$
(
0.93
)
Diluted
$
1.68
$
(
3.13
)
$
6.29
$
(
0.93
)
8.
Commitments and Contingencies
Lease Guarantees
Between 1995 and 1997, the Company sold or spun off a number of subsidiaries, including Linens ‘n Things and Marshalls. In many cases, when a former subsidiary leased a store, the Company provided a guarantee of the former subsidiary’s lease obligations for the initial lease term and any extension thereof pursuant to a renewal option provided for in the lease prior to the time of the disposition. When the subsidiaries were disposed of and accounted for as discontinued operations, the Company’s guarantees remained in place, although each initial purchaser agreed to indemnify the Company for any lease obligations the Company was required to satisfy. If any of the purchasers or any of the former subsidiaries fail to make the required payments under a store lease, the Company could be required to satisfy those obligations. As of September 30, 2026, the Company guaranteed
57
such store leases (excluding the lease guarantees related to Linens ‘n Things, which have been recorded as a liability on the unaudited condensed consolidated balance sheets), with the maximum remaining lease term extending through 2036.
Guaranty Fund Assessments, Market Stabilization and Other Non-Voluntary Risk Sharing Pools
Under guaranty fund laws existing in all states, insurers doing business in those states can be assessed (in most states up to prescribed limits) for certain obligations of insolvent insurance companies to policyholders and claimants. The life and health insurance guaranty associations in which the Company participates that operate under these laws respond to insolvencies of long-term care insurers and life insurers as well as health insurers. The Company’s assessments generally are based on a formula relating to the Company’s health care premiums in the state compared to the premiums of other insurers. Certain states allow assessments to be recovered over time as offsets to premium taxes. Some states have similar laws relating to health
24
maintenance organizations (“HMOs”) and/or other payors such as not-for-profit consumer-governed health plans established under the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010. It is reasonably possible that in the future the Company may record a liability and expense relating to insolvencies which could have a material adverse effect on the Company’s operating results, financial condition and cash flows. While historically the Company has ultimately recovered more than half of guaranty fund assessments through statutorily permitted premium tax offsets, significant increases in assessments could lead to legislative and/or regulatory actions that limit future offsets.
HMOs in certain states in which the Company does business are subject to assessments, including market stabilization and other risk-sharing pools, for which the Company is assessed charges based on incurred claims, demographic membership mix and other factors. The Company establishes liabilities for these assessments based on applicable laws and regulations. In certain states, the ultimate assessments the Company pays are dependent upon the Company’s experience relative to other entities subject to the assessment, and the ultimate liability is not known at the financial statement date. While the ultimate amount of the assessment is dependent upon the experience of all pool participants, the Company believes it has adequate reserves to cover such assessments.
Litigation and Regulatory Proceedings
The Company has been involved or is currently involved in numerous legal and regulatory proceedings, which may include claims of or relating to bad faith, medical or professional malpractice, breach of fiduciary duty, claims processing and billing, dispensing of medications, the use of medical testing devices in the in-home evaluation setting, non-compliance with state and federal regulatory regimes, marketing misconduct, denial of or failure to timely or appropriately pay or administer claims and benefits, provider network structure (including the use of performance-based networks and termination of provider contracts), rescission of insurance coverage, improper disclosure or use of personal information, anticompetitive practices, including antitrust violations, the Company’s participation in the 340B program, general contractual matters, product liability, intellectual property litigation, and discrimination and employment litigation. Some of these other legal proceedings are or are purported to be class actions or derivative claims. The Company is defending itself against the claims brought in these matters.
The Company is also a party to government investigations, audits, reviews, claims enforcement actions and litigation. These include routine, regular and special investigations, audits, subpoenas, civil investigative demands (“CIDs”) and reviews by
CMS, state insurance and health and welfare departments,
the U.S. Department of Justice (the “DOJ”),
state Attorneys General, the U.S. Drug Enforcement Administration (the “DEA”), the U.S. Federal Trade Commission (the “FTC”) and other governmental authorities.
Legal proceedings, in general, and securities, class action and multi-district litigation, in particular, and governmental special investigations, audits, reviews, litigation and enforcement proceedings can be expensive and disruptive. Some of the litigation matters may purport or be determined to be class actions, mass actions and/or involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. The Company also may be named from time to time in
qui tam
actions initiated by private third parties that could also be separately pursued by a governmental body. The results of legal proceedings, including government investigations, are often uncertain and difficult to predict, and the costs incurred in these matters can be substantial, regardless of the outcome.
The Company records accruals for outstanding legal matters when it believes it is probable that a loss will be incurred and the amount can be reasonably estimated. The Company evaluates, on a quarterly basis, developments in legal matters that could affect the amount of any accrual and developments that would make a loss contingency both probable and reasonably estimable. If a loss contingency is not both probable and reasonably estimable, the Company does not establish an accrued liability. Other than the controlled substances litigation accruals described below and as otherwise noted, none of the Company’s accruals for outstanding legal matters are material individually or in the aggregate to the Company’s unaudited condensed consolidated balance sheets. The Company recognizes gain contingencies when the contingency becomes realizable. Refunds requested and received in 2026 from the U.S. Customs and Border Protection for International Emergency Economic Powers Act tariffs paid on imports were not material to the Company’s consolidated operating results, financial condition or cash flows.
Except as otherwise noted, the Company cannot predict with certainty the timing or outcome of the legal matters described below, and the Company is unable to reasonably estimate a possible loss or range of possible loss in excess of amounts already accrued for these matters. The Company believes that its defenses and assertions in pending legal proceedings have merit and does not believe that any of these pending matters, after consideration of applicable reserves and rights to indemnification, will have a material adverse effect on the Company’s financial position. Substantial unanticipated verdicts, fines and rulings, however, do sometimes occur, which could result in judgments against the Company, entry into settlements or a revision to its expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on its results
25
of operations. In addition, as a result of governmental investigations or proceedings, the Company may be subject to damages, civil or criminal fines or penalties, or other sanctions including possible suspension or loss of licensure and/or exclusion from participating in government programs. The outcome of such governmental investigations or proceedings could be material to the Company.
Usual and Customary Pricing Litigation
The Company is named as a defendant in a number of lawsuits that allege that the Company’s retail pharmacies overcharged for prescription drugs by not submitting the correct usual and customary price during the claims adjudication process. These actions are brought by a number of different types of plaintiffs, including private payors and government payors, and are based on different legal theories. Some of these cases are brought as putative class actions in which classes have been certified, and one of the cases asserts state false claims act claims by several state attorneys general in an intervened complaint filed in April 2025 and unsealed in May 2025. The Company is defending itself against these claims.
PBM Litigation and Investigations
The Company is named as a defendant in a number of lawsuits and is subject to a number of investigations concerning its PBM practices.
The Company is facing multiple lawsuits, including by state Attorneys General, governmental subdivisions, private parties and several putative class actions, regarding drug pricing and its rebate arrangements with drug manufacturers. These complaints, brought by a number of different types of plaintiffs under a variety of legal theories, generally allege that rebate agreements between the drug manufacturers and PBMs caused inflated prices for certain drug products. The majority of these cases have now been transferred into a multi-district litigation in the U.S. District Court for the District of New Jersey. The Company is defending itself against these claims. The Company is also facing multiple lawsuits brought by hospital systems regarding reimbursement under the 340B program. The Company has also received subpoenas, CIDs, and other requests for documents and information from, and is being investigated by, the DOJ, the U.S. Department of Health and Human Services (“HHS”), the FTC and Attorneys General of several states and the District of Columbia regarding its PBM practices, including pharmacy contracting practices and reimbursement, pricing and rebates. The Company has been providing documents and information in response to these subpoenas, CIDs and requests for information. In September 2024, the FTC filed an administrative complaint against the three largest PBMs (the “PBM Group”) and their affiliated group purchasing organizations, including subsidiaries of the Company. The complaint alleged that the PBM Group and their affiliated group purchasing organizations engaged in anti-competitive and unfair practices that “artificially” increased insulin costs. In July 2026, the Company and the FTC announced a proposed settlement agreement that would resolve all of the FTC’s outstanding investigations related to the Company’s PBM and affiliated pharmacy businesses, including rebate, pharmacy network, contracting, and vertical integration issues. The public comment period has ended and the settlement is now contingent upon the FTC’s issuance of a final order approving the settlement. The FTC has halted its litigation against the Company pending the outcome of this process.
United States ex rel. Behnke v. CVS Caremark Corporation, et al.
(U.S. District Court for the Eastern District of Pennsylvania). In April 2018, the Court unsealed a complaint filed in February 2014. The government has declined to intervene in this case. The relator alleges that the Company submitted, or caused to be submitted, to Part D of the Medicare program Prescription Drug Event data and/or Direct and Indirect Remuneration reports that misrepresented true prices paid by the Company’s PBM to pharmacies for drugs dispensed to Part D beneficiaries with prescription benefits administered by the Company’s PBM. Following a two-week trial, the Court issued a split decision and ruled that the Company was liable under the False Claims Act as to certain claims. After trebling damages and assessing penalties, the court entered judgment for $
291
million, for which the Company recorded a litigation reserve in the year ended December 31, 2025. The Company has appealed to the Third Circuit Court of Appeals.
Roofers Union Welfare Trust Fund v. CaremarkPCS Health, LLC, et al.
(U.S. District Court for the Northern District of Illinois). In March 2026, a putative class of Caremark clients filed a new complaint alleging that Caremark breached the parties’ contracts, unjustly enriched itself and violated the federal Racketeer Influenced and Corrupt Organizations (“RICO”) Act when it failed to pass through to clients certain payments received by Zinc Health Services, LLC from manufacturers. This complaint was initially filed in the U.S. District Court for the District of Rhode Island, but has since been transferred to the U.S. District Court for the Northern District of Illinois.
26
Controlled Substances Litigation, Audits and Subpoenas
Forty-five
states, the District of Columbia, and all eligible United States territories are participating in a settlement resolving substantially all opioid claims against Company entities by participating states and political subdivisions but not private plaintiffs. A high percentage of eligible subdivisions within the participating states also have elected to join the settlement. The settlement agreement is available at nationalopioidsettlement.com. The Company has separately entered into settlement agreements with
four
states – Florida, West Virginia, New Mexico and Nevada – and a high percentage of eligible subdivisions within those states also have elected to participate. The Company has also finalized an agreement to resolve claims by third-party payors; approval of the class settlement remains subject to appeal.
The final settlement agreements contain certain contingencies related to payment obligations. Because these contingencies are inherently unpredictable, the assessment requires judgments about future events. As of September 30, 2026, the Company’s remaining accrual related to these opioid litigation matters was approximately $
3.4
billion. The amount of ultimate loss may differ from the amount accrued by the Company.
The State of Maryland has elected not to participate, and thus subdivisions within the State of Maryland may not participate, in the settlement. The State of Maryland has issued multiple subpoenas for information from the Company, and litigation is pending with certain subdivisions within the State of Maryland as well as other non-participating subdivisions in other geographies, including the City of Philadelphia, and private parties such as hospitals. The Company is defending itself against the claims made in these cases.
Because of the many uncertainties associated with any settlement arrangement or other resolution of opioid-related litigation matters, and because the Company continues to actively defend ongoing litigation for which it believes it has defenses and assertions that have merit, the Company is not able to reasonably estimate the range of ultimate possible loss for all opioid-related litigation matters at this time. The outcome of these legal matters could have a material effect on the Company’s business, financial condition, operating results and/or cash flows.
In December 2024, the DOJ intervened in a previously sealed
qui tam
action and filed an amended complaint in the U.S. District Court for the District of Rhode Island, alleging, among other claims, violations of the federal Controlled Substances Act and the federal False Claims Act based on the filling of opioid and other controlled substance prescriptions at CVS Pharmacy locations nationwide. In October 2026, the Company executed settlement of these claims for $
315
million, which had been previously accrued. Separately, the Company has been served with subpoenas issued by the U.S. Attorney’s Office for the Western District of Virginia, seeking records related to, among other things, commercial arrangements between the Company’s PBM and opioid manufacturers.
Prescription Processing Litigation and Investigations
The Company is named as a defendant in a number of lawsuits and is subject to a number of investigations concerning its prescription processing practices, including related to billing government payors for prescriptions, and the following:
U.S. ex rel. Bassan et al. v. Omnicare, Inc. and CVS Health Corp.
(U.S. District Court for the Southern District of New York). In December 2019, the U.S. Attorney’s Office for the Southern District of New York filed a complaint-in-intervention in this previously sealed
qui tam
case. The complaint alleges that for certain non-skilled nursing facilities, Omnicare improperly filled prescriptions where a valid prescription did not exist and that these dispensing events violated the federal False Claims Act. In April 2025, the jury found both Omnicare and CVS Health Corporation liable. The jury awarded approximately $
136
million due to Omnicare’s conduct. This amount is automatically required to be tripled by statute to approximately $
407
million. Accordingly, a litigation reserve was recorded related to this matter in the three months ended March 31, 2025. The jury found no damages attributable to CVS Health Corporation. In July 2025, the Court awarded penalties against Omnicare for $
542
million, for which the Company recorded an incremental litigation reserve in the three months ended June 30, 2025. The Court also found CVS Health Corporation to be jointly and severally liable for $
165
million of the $
542
million in penalties. The Company has filed an appeal to the Second Circuit. On September 22, 2025, Omnicare initiated a voluntary court-supervised Chapter 11 bankruptcy process and was deconsolidated in the three months ended September 30, 2025.
In July 2026, CVS Health Corporation entered into agreements with the DOJ and the Unsecured Creditors’ Committee, which were approved by the Bankruptcy Court in August 2026. The effectiveness of the agreements remains subject to the closing of the sale of Omnicare’s assets, among other conditions. These agreements provide that the DOJ will receive a minimum of $
440
million from Omnicare and CVS Health Corporation. CVS Health Corporation will pay $
130
million to the DOJ within two weeks of the agreements’ effective date, at which point CVS Health Corporation’s and Omnicare’s appeals will be
27
dismissed. Omnicare will transfer to the DOJ any proceeds from the sale or liquidation of assets in its estate that remain after payment of all senior claims. In the event that the DOJ does not receive at least $
310
million in payments from Omnicare by March 15, 2028, CVS Health Corporation will guarantee the DOJ’s collection of any remaining portion of the $
310
million by March 31, 2028.
As of September 30, 2026, the Company determined that the sale of Omnicare’s assets is probable of occurring in the fourth quarter of 2026, and accordingly recorded an estimated contingent guarantee liability of $
193
million during the three and nine months ended September 30, 2026. The liability reflects the Company’s estimated obligation to ensure that the DOJ receives a minimum of $
440
million from Omnicare and CVS Health Corporation in accordance with the agreements.
U.S. ex rel. Gill et al. v. CVS Health Corp. et al.
(U.S. District Court for the Northern District of Illinois). In July 2022, the Delaware Attorney General’s Office moved for partial intervention as to allegations under the Delaware false claims act related to not escheating alleged overpayments in this previously sealed
qui tam
case. The federal government and the remaining states declined to intervene on other additional theories in the relator’s complaint, except that the federal government filed a notice of intervention for the limited purpose of defending the constitutionality of the
qui tam
provisions of the False Claims Act. The Company is defending itself against all of the claims.
Provider Proceedings
The Company is named as a defendant in purported class actions and individual lawsuits arising out of its practices related to the payment of claims for services rendered to its members by providers with whom the Company has a contract and with whom the Company does not have a contract (“out-of-network providers”). Among other things, these lawsuits allege that the Company paid too little to its health plan members and/or providers for out-of-network services (including COVID-19 testing) and/or otherwise allege that the Company failed to timely or appropriately pay or administer claims and benefits (including the Company’s post payment audit and collection practices).
The Company also has received subpoenas and/or requests for documents and other information from, and been investigated by, the DOJ, state Attorneys General and other state and/or federal regulators, legislators and agencies relating to claims payments, and the Company is involved in other litigation regarding its out-of-network benefit payment and administration practices. It is reasonably possible that others could initiate additional litigation or additional regulatory action against the Company with respect to its out-of-network benefit payment and/or administration practices.
The Company is facing multiple lawsuits, including by state Attorneys General, private parties and putative class action plaintiffs, regarding Aetna’s use of third-party vendors, including Claritev (formerly MultiPlan), for the repricing of claims for reimbursement by out-of-network providers. These complaints, brought by a number of different types of plaintiffs under a variety of legal theories, generally allege that Claritev engages in a price-fixing conspiracy among Claritev and health insurers to set artificially low reimbursement rates for facilities and professionals not participating in the insurers’ networks. The majority of these cases have now been transferred into a multi-district litigation in the U.S. District Court for the Northern District of Illinois. The Company is defending itself against these claims.
CMS Actions
CMS regularly audits the Company’s performance to determine its compliance with CMS’s regulations and its contracts with CMS and to assess the quality of services it provides to Medicare beneficiaries. CMS uses various payment mechanisms to allocate and adjust premium payments to the Company’s and other companies’ Medicare plans by considering the applicable health status of Medicare members as supported by information prepared, maintained and provided by providers. The Company collects claim and encounter data from providers and generally relies on providers to appropriately code their submissions to the Company and document their medical records, including the diagnosis data submitted to the Company with claims. CMS pays increased premiums to Medicare Advantage plans and Medicare PDP plans for members who have certain medical conditions identified with specific diagnosis codes. Federal regulators review and audit the providers’ medical records to determine whether those records support the related diagnosis codes that determine the members’ health status and the resulting risk-adjusted premium payments to the Company. In that regard, CMS has instituted risk adjustment data validation (“RADV”) audits of various Medicare Advantage plans, including the Company’s plans, to validate coding practices and supporting medical record documentation maintained by providers and the resulting risk-adjusted premium payments to the plans. CMS may require the Company to refund premium payments if the Company’s risk-adjusted premiums are not properly supported by medical record data. The Office of the Inspector General of the U.S. Department of Health and Human Services (the “OIG”) also is auditing the Company’s risk adjustment-related data and that of other companies. The Company expects CMS and the OIG to continue these types of audits. CMS has announced its intention to audit all contracts as a standard practice. CMS’
28
auditing methodology is subject to pending litigation, so the Company is not able to determine the methodology, and potential extrapolation, that would be used for future audits.
Medicare and Medicaid Litigation and Investigations
The Company faces litigation and is subject to investigations concerning practices that relate to billing government payors.
The Company has received CIDs from the Civil Division of the DOJ in connection with investigations of the Company’s identification and/or submission of diagnosis codes related to risk adjustment payments, including patient chart review processes, under Parts C and D of the Medicare program. The Company is cooperating with the government and providing documents and information in response to these CIDs.
In May 2017, the Company received a CID from the U.S. Attorney’s Office for the Southern District of New York requesting documents and information concerning possible false claims submitted to Medicare in connection with reimbursements for prescription drugs under the Medicare Part D program. The Company has been cooperating with the government and providing documents and information in response to this CID.
U.S. ex rel. Andrew Shea v. Aetna Life Insurance Company, et al.
(U.S. District Court for the District of Massachusetts). In May 2025, the U.S. Attorney’s Office for the District of Massachusetts filed a complaint-in-intervention in this previously sealed
qui tam
case. The complaint alleges that the Company and two other large health insurance companies paid kickbacks to insurance brokers to induce them to direct patients to their Medicare Advantage plans and, as a result, claims made to the government in connection with those plans violated the federal False Claims Act and Anti-Kickback Statute. The complaint also alleges that the Company engaged in discriminatory conduct. The Company is defending itself against these claims.
In addition, awards to the Company and others of certain government contracts, particularly Medicaid contracts and other contracts with government customers in the Company’s Health Care Benefits segment, frequently are subject to protests by unsuccessful bidders. These protests may result in awards to the Company being reversed, delayed, or modified. The loss or delay in implementation of any government contract could adversely affect the Company’s operating results. The Company will continue to defend contract awards it receives.
Stockholder Matters
The Company has received several demands for inspection of books and records pursuant to Delaware General Corporation Law Section 220 (“Section 220 demands”) and other demands addressed to the Board requesting that certain actions be taken (“Board demands”). Section 220 demands and Board demands often relate to potential breaches of fiduciary duties by the Company’s directors and officers in relation to its oversight of certain matters, such as opioids and PBM and retail practices. While evaluating and responding to such demands may consume Company resources, the demands themselves are not material to the Company unless they lead to formal complaints or legal actions.
Beginning in February 2019, multiple class action complaints, as well as a derivative complaint, were filed by putative plaintiffs against the Company and certain current and former officers and directors. The plaintiffs in these cases assert a variety of causes of action under federal securities laws that are premised on allegations that the defendants made certain omissions and misrepresentations relating to the performance of the Company’s former LTC business unit. Since filing, several of the cases have been consolidated, and three have resolved. In February 2025, the District of Rhode Island granted the Company’s motion to dismiss
In re CVS Health Corp. Securities Act Litigation
(formerly known as
Waterford
) and in March 2025 plaintiffs filed a notice of appeal of that decision to the First Circuit. A derivative case in the District of Rhode Island,
Lovoi v. Aguirre
, had been stayed pending the outcome of the
Waterford
case, and will remain stayed pending the resolution of the appeal. The Company and its current and former officers and directors are defending themselves against remaining claims.
Beginning in July 2024,
two
purported class action complaints, as well as multiple derivative complaints, were filed by putative plaintiffs against the Company and certain current and former officers and directors. The plaintiffs in these cases assert a variety of causes of action under federal securities laws and state law that are premised on allegations that the defendants made certain omissions and misrepresentations relating to the profitability of the Health Care Benefits segment.
Two
purported class actions were filed and have been consolidated in the U.S. District Court for the Southern District of New York. In August 2026, the court denied in part and granted in part the defendants’ motion to dismiss the amended consolidated class action complaint captioned as
Louisiana Sheriffs’ Pension and Relief Fund, et al. v. CVS Health Corp., et al.
Two
derivative cases were also filed in the Southern District of New York and have been consolidated as
In re
CVS Health Corporation Derivative Litigation
.
Two
derivative cases filed in the District of Rhode Island
were consolidated as
In re CVS Health Corporation Stockholder Derivative Litigation
.
Three
additional derivative cases
were filed in Rhode Island Superior Court: two have been consolidated
29
as
In re CVS Health Corporation Stockholder Derivative Litigation
and the third is
Davidow v. Lynch, et al
. All of these derivative actions were stayed pending the outcome of any motion to dismiss in the consolidated
Louisiana Sheriffs’
securities class action and the stay in each of the actions terminated in September 2026. The parties in each of these derivative actions have filed proposals for a continuation of the stay. The Company and the individual defendants are defending themselves against these claims. In January 2025, the Board received a stockholder demand containing allegations substantially similar to those made in the class action and derivative matters, and requesting that it take certain actions, including investigating whether any Board members or officers breached their fiduciary duties related to those allegations, and bringing litigation to recover the Company’s damages if any such misconduct is found. The Board has determined to defer a decision on the demand pending developments in the related litigation. In October 2026, the Board received a supplement to the previous demand, which it intends to consider in due course.
9.
Segment Reporting
The Company has
four
reportable segments: Health Care Benefits, Health Services, Pharmacy & Consumer Wellness and Corporate/Other. The Company’s segments maintain separate financial information, and the Chief Operating Decision Maker (the “CODM”), the Company’s Chief Executive Officer, evaluates the segments’ operating results on a regular basis in deciding how to allocate resources among the segments and in assessing segment performance. The CODM evaluates the performance of the Company’s segments based on adjusted operating income. Total assets by segment are not used by the CODM to assess the performance of, or allocate resources to, the Company’s segments, therefore total assets by segment are not disclosed.
Adjusted operating income (loss) is defined as operating income (loss) (GAAP measure) excluding the impact of amortization of intangible assets, net realized capital gains or losses and other items, if any, that neither relate to the ordinary course of the Company’s business nor reflect the Company’s underlying business performance. The CODM uses adjusted operating income as its principal measure of segment performance as it enhances the CODM’s ability to compare past financial performance with current performance and analyze underlying business performance and trends. Non-GAAP financial measures the Company discloses, such as consolidated adjusted operating income, should not be considered a substitute for, or superior to, financial measures determined or calculated in accordance with GAAP.
30
The following are reconciliations of financial measures of the Company’s segments to the consolidated totals:
Three Months Ended September 30, 2026
In millions
Health Care
Benefits
Health
Services
(1)
Pharmacy &
Consumer
Wellness
Corporate/
Other
Consolidated
Totals
Revenues from external customers
$
36,367
$
47,077
$
24,295
$
13
$
107,752
Intersegment revenues
33
6,887
11,203
—
18,123
Net investment income
455
—
—
192
647
Total revenues
36,855
53,964
35,498
205
126,522
Intersegment eliminations
(2)
(
18,123
)
Total consolidated revenues
$
108,399
Less: Net realized capital gains (losses)
(
23
)
—
—
26
Cost of products sold
—
49,711
28,700
—
Health care costs
31,556
1,346
—
45
Operating expenses, excluding other segment items
(3)
4,410
801
5,163
593
Adjusted operating income (loss)
$
912
$
2,106
$
1,635
$
(
459
)
$
4,194
Reconciliation of principal measure of segment performance to consolidated operating income:
Amortization of intangible assets
(4)
425
Net realized capital gains
(5)
(
3
)
Acquisition-related integration costs
(6)
13
Omnicare guarantee
(7)
193
Operating income (GAAP measure)
3,566
Interest expense
(
747
)
Other income
30
Income before income tax provision
$
2,849
Depreciation and amortization
$
351
$
251
$
418
$
112
$
1,132
31
Three Months Ended September 30, 2025
In millions
Health Care
Benefits
Health
Services
(1)
Pharmacy &
Consumer
Wellness
Corporate/
Other
Consolidated
Totals
Revenues from external customers
$
35,431
$
42,354
$
24,441
$
13
$
102,239
Intersegment revenues
49
6,913
11,773
—
18,735
Net investment income (loss)
513
(
1
)
—
120
632
Total revenues
35,993
49,266
36,214
133
121,606
Intersegment eliminations
(2)
(
18,735
)
Total consolidated revenues
$
102,871
Less: Net realized capital gains (losses)
33
—
—
(
44
)
Cost of products sold
—
45,230
29,647
—
Health care costs
31,319
1,291
—
47
Operating expenses, excluding other segment items
(3)
4,327
695
5,089
513
Adjusted operating income (loss)
$
314
$
2,050
$
1,478
$
(
383
)
$
3,459
Reconciliation of principal measure of segment performance to consolidated operating loss:
Amortization of intangible assets
(4)
500
Net realized capital losses
(5)
11
Acquisition-related integration costs
(6)
27
Goodwill impairment
(8)
5,725
Health Care Delivery clinic closure charge
(9)
83
Opioid litigation charge
(10)
320
Operating loss (GAAP measure)
(
3,207
)
Gain on deconsolidation of subsidiary
(14)
483
Interest expense
(
784
)
Other income
26
Loss before income tax provision
$
(
3,482
)
Depreciation and amortization
$
375
$
260
$
396
$
103
$
1,134
32
Nine Months Ended September 30, 2026
In millions
Health Care
Benefits
Health
Services
(1)
Pharmacy &
Consumer
Wellness
Corporate/
Other
Consolidated
Totals
Revenues from external customers
$
108,843
$
135,075
$
69,101
$
40
$
313,059
Intersegment revenues
96
18,922
32,202
—
51,220
Net investment income (loss)
1,425
(
1
)
—
438
1,862
Total revenues
110,364
153,996
101,303
478
366,141
Intersegment eliminations
(2)
(
51,220
)
Total consolidated revenues
$
314,921
Less: Net realized capital losses
(
20
)
—
—
(
6
)
Cost of products sold
—
142,338
81,772
—
Health care costs
90,827
3,998
—
135
Operating expenses, excluding other segment items
(3)
13,178
2,332
15,224
1,862
Adjusted operating income (loss)
$
6,379
$
5,328
$
4,307
$
(
1,513
)
$
14,501
Reconciliation of principal measure of segment performance to consolidated operating income:
Amortization of intangible assets
(4)
1,298
Net realized capital losses
(5)
26
Acquisition-related integration costs
(6)
35
Omnicare guarantee
(7)
193
Operating income (GAAP measure)
12,949
Interest expense
(
2,278
)
Other income
93
Income before income tax provision
$
10,764
Depreciation and amortization
$
1,039
$
760
$
1,239
$
335
$
3,373
33
Nine Months Ended September 30, 2025
In millions
Health Care
Benefits
Health
Services
(1)
Pharmacy &
Consumer
Wellness
Corporate/
Other
Consolidated
Totals
Revenues from external customers
$
105,667
$
120,568
$
68,460
$
40
$
294,735
Intersegment revenues
87
18,603
33,247
—
51,937
Net investment income
1,307
10
—
322
1,639
Total revenues
107,061
139,181
101,707
362
348,311
Intersegment eliminations
(2)
(
51,937
)
Total consolidated revenues
$
296,374
Less: Net realized capital gains (losses)
(
1
)
15
—
(
73
)
Cost of products sold
—
128,425
83,005
—
Health care costs
90,696
3,439
—
133
Operating expenses, excluding other segment items
(3)
12,751
2,074
14,573
1,428
Adjusted operating income (loss)
$
3,615
$
5,228
$
4,129
$
(
1,126
)
$
11,846
Reconciliation of principal measure of segment performance to consolidated operating income:
Amortization of intangible assets
(4)
1,493
Net realized capital losses
(5)
59
Acquisition-related integration costs
(6)
100
Goodwill impairment
(8)
5,725
Health Care Delivery clinic closure charge
(9)
83
Opioid litigation charge
(10)
320
Legacy litigation charges
(11)
1,220
Loss on Accountable Care assets
(12)
288
Office real estate optimization charges
(13)
10
Operating income (GAAP measure)
2,548
Gain on deconsolidation of subsidiary
(14)
483
Interest expense
(
2,332
)
Other income
83
Income before income tax provision
$
782
Depreciation and amortization
$
1,199
$
781
$
1,169
$
310
$
3,459
_____________________________________________
(1)
Total revenues of the Health Services segment include approximately $
2.4
billion of retail co-payments in each of the three months ended September 30, 2026 and 2025, and approximately $
9.0
billion and $
8.8
billion of retail co-payments for the nine months ended September 30, 2026 and 2025, respectively.
(2)
Intersegment revenue eliminations relate to intersegment revenue generating activities that occur between the Health Care Benefits segment, the Health Services segment, and/or the Pharmacy & Consumer Wellness segment.
(3)
Other segment items for each reportable segment consist of the impact of amortization of intangible assets and other items, if any, that neither relate to the ordinary course of the Company’s business nor reflect the Company’s underlying business performance.
(4)
The Company’s acquisition activities have resulted in the recognition of intangible assets as required under the acquisition method of accounting which consist primarily of trademarks, customer contracts/relationships, covenants not to compete, technology, provider networks and value of business acquired. Definite-lived intangible assets are amortized over their estimated useful lives and are tested for impairment when events indicate that the carrying value may not be recoverable. The amortization of intangible assets is reflected in operating expenses within each segment. Although intangible assets contribute to the Company’s revenue generation, the amortization of intangible assets does not directly relate to the underwriting of the Company’s insurance products, the services performed for the Company’s customers or the sale of the Company’s products or services. Additionally, intangible asset amortization expense typically fluctuates based on the size and timing of the Company’s acquisition activity. Accordingly, the Company believes excluding the amortization of intangible assets enhances the Company’s and investors’ ability to compare the Company’s past financial performance with its current performance and to analyze underlying business performance and trends. Intangible asset amortization excluded from the related non-GAAP financial measure represents the entire amount recorded within the Company’s GAAP financial statements, and the revenue generated by the associated intangible assets has not been excluded from the related non-GAAP financial measure. Intangible asset amortization is excluded from the related non-GAAP financial measure because the amortization, unlike the related revenue, is not affected by operations of any particular period unless an intangible asset becomes impaired or the estimated useful life of an intangible asset is revised.
34
(5)
The Company’s net realized capital gains and losses arise from various types of transactions, primarily in the course of managing a portfolio of assets that support the payment of insurance liabilities. Net realized capital gains and losses are reflected in net investment income (loss) within each segment. These capital gains and losses are the result of investment decisions, market conditions and other economic developments that are unrelated to the performance of the Company’s business, and the amount and timing of these capital gains and losses do not directly relate to the underwriting of the Company’s insurance products, the services performed for the Company’s customers or the sale of the Company’s products or services. Accordingly, the Company believes excluding net realized capital gains and losses enhances the Company’s and investors’ ability to compare the Company’s past financial performance with its current performance and to analyze underlying business performance and trends.
(6)
During the three and nine months ended September 30, 2026 and 2025, the acquisition-related integration costs relate to the acquisitions of Signify Health and Oak Street Health. The acquisition-related integration costs are reflected in operating expenses within the Corporate/Other segment.
(7)
During the three and nine months ended September 30, 2026, the Omnicare guarantee relates to an estimated contingent guarantee liability recorded in connection with agreements to resolve certain litigation and Chapter 11 bankruptcy matters involving Omnicare. Following bankruptcy court approval of the agreements in August 2026 and the determination that the sale of Omnicare’s assets is probable of occurring in the fourth quarter of 2026, the Company recorded an estimated contingent guarantee liability in the third quarter of 2026. The Omnicare guarantee is reflected in operating expenses within the Corporate/Other Segment.
(8)
During the three and nine months ended September 30, 2025, the goodwill impairment charge relates to the Health Care Delivery reporting unit within the Health Services segment.
(9)
During the three and nine months ended September 30, 2025, the Health Care Delivery clinic closure charge primarily relates to the write down of long-lived assets in connection with the closure of certain Oak Street Health clinics in 2026, as well as associated severance and employee-related costs. The Health Care Delivery clinic closure charge was reflected in operating expenses within the Health Services segment.
(10)
During the three and nine months ended September 30, 2025, the opioid litigation charge relates to a change in the Company’s accrual related to ongoing opioid litigation matters.
(11)
During the nine months ended September 30, 2025, the Company recorded legacy litigation charges related to
two
court decisions associated with its past business practices. The legacy litigation charges were reflected in operating expenses within the Pharmacy & Consumer Wellness and Health Services segments.
(12)
During the nine months ended September 30, 2025, the loss on the wind down and sale of Accountable Care assets represents the pre-tax loss on the divestiture of the Company’s MSSP operations, as well as costs incurred in connection with the wind down of the Company’s ACO REACH operations. The loss on Accountable Care assets was reflected in operating expenses within the Health Services segment.
(13)
During the nine months ended September 30, 2025, the office real estate optimization charges primarily relate to the abandonment of leased real estate and the related right-of-use assets and property and equipment in connection with the Company’s evaluation of corporate office real estate space. The office real estate optimization charges were reflected in operating expenses within each segment.
(14)
During the three and nine months ended September 30, 2025, the gain on deconsolidation of subsidiary relates to Omnicare, a wholly-owned indirect subsidiary of CVS Health Corporation, and certain of its subsidiary entities. In September 2025, the Omnicare Entities voluntarily initiated Chapter 11 proceedings under the U.S. Bankruptcy Code, at which time the Company determined that it no longer retained control of the Omnicare Entities and deconsolidated the subsidiaries.
10.
Subsequent Event
On November 4, 2026, CVS Health announced its intention to separate into two independent, publicly traded companies in a transaction that is intended to be tax-free to CVS Health and its shareholders for U.S. federal income tax purposes. The planned separation will create two companies: a healthcare solutions company comprising Aetna, CVS Caremark, CVS Specialty, Oak Street Health and Signify Health, and a retail pharmacy and community healthcare company comprising retail pharmacy, mail pharmacy, MinuteClinic (including virtual care), and the Health100 technology services business. The healthcare solutions company, in the interim, will be referred to as CVS Health. The retail pharmacy and community healthcare company will be named CVS Pharmacy. The separation is expected to be completed in the first half of 2028, subject to customary conditions, including, among others, final approval by the CVS Health Board of Directors, effectiveness of a Form 10 registration statement filed with the SEC and receipt of customary confirmation that the separation is expected to be tax-free to CVS Health and its shareholders.
35
Index to Condensed Consolidated Financial Statements
Report of Independent Registered Public Accounting Firm
To the Shareholders and the Board of Directors of CVS Health Corporation
Results of Review of Interim Financial Statements
We have reviewed the accompanying condensed consolidated balance sheet of CVS Health Corporation (the Company) as of September 30, 2026, the related condensed consolidated statements of operations and comprehensive income (loss) for the three-month and nine-month periods ended September 30, 2026 and 2025, the related condensed consolidated statements of shareholders’ equity for the three-month periods ended March 31, 2026 and 2025, June 30, 2026 and 2025 and September 30, 2026 and 2025, the related condensed consolidated statements of cash flows for the nine-month periods ended September 30, 2026 and 2025, and the related notes (collectively referred to as the “condensed consolidated interim financial statements”). Based on our reviews, we are not aware of any material modifications that should be made to the condensed consolidated interim financial statements for them to be in conformity with U.S. generally accepted accounting principles.
We have previously audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheet of the Company as of December 31, 2025, the related consolidated statements of operations, comprehensive income, shareholders’ equity and cash flows for the year then ended, and the related notes (not presented herein); and in our report dated February 10, 2026, we expressed an unqualified audit opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying condensed consolidated balance sheet as of December 31, 2025, is fairly stated, in all material respects, in relation to the consolidated balance sheet from which it was derived.
Basis for Review Results
These financial statements are the responsibility of the Company’s management. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the SEC and the PCAOB. We conducted our review in accordance with the standards of the PCAOB. A review of interim financial statements consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the PCAOB, the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.
/s/ Ernst & Young LLP
Boston, Massachusetts
November 4, 2026
36
Form 10-Q Table of Contents
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”)
Overview of Business
CVS Health Corporation, together with its subsidiaries (collectively, “CVS Health,” the “Company,” “we,” “our” or “us”), is a leading health solutions company simplifying health care one person, one family and one community at a time. As of September 30, 2026, the Company had approximately 9,000 retail locations, more than 1,000 walk-in and primary care medical clinics and a leading pharmacy benefits manager with approximately 87 million plan members and expanding specialty pharmacy solutions. The Company also serves an estimated 37 million people through a broad range of health insurance products and related services. The Company is creating new sources of value through its integrated model, allowing it to expand into personalized, technology driven care delivery and health services, increasing access to quality care, delivering better health outcomes and lowering overall health care costs.
The Company has four reportable segments: Health Care Benefits, Health Services, Pharmacy & Consumer Wellness and Corporate/Other, which are described below.
Health Care Benefits Segment
The Health Care Benefits segment operates as one of the nation’s leading diversified health care benefits providers through its Aetna
®
operations. The Health Care Benefits segment offers a broad range of health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare Supplement plans, prescription drug plans (“PDPs”) and Medicaid health care management services. The Company refers to insurance products (where it assumes all or a majority of the risk for medical and dental care costs) as “Insured” and administrative services contract products (where the plan sponsor assumes all or a majority of the risk for medical and dental care costs) as “ASC.”
Health Services Segment
The Health Services segment provides a full range of pharmacy benefit management (“PBM”) solutions through its CVS Caremark
®
operations and delivers health care services in its medical clinics, virtually, and in the home. PBM solutions include plan design offerings and administration, formulary management, retail pharmacy network management services, and specialty and mail order pharmacy services. In addition, the Company provides clinical services, disease management services, medical spend management and pharmacy and/or other administrative services for providers and federal 340B drug pricing program covered entities (“Covered Entities”). The Company operates a group purchasing organization that negotiates pricing for the purchase of pharmaceuticals and rebates with pharmaceutical manufacturers on behalf of its participants and provides various administrative, management and reporting services to pharmaceutical manufacturers. The segment also works directly with pharmaceutical manufacturers to commercialize and/or co-produce high quality biosimilar products through its Cordavis
®
subsidiary. The Health Services segment’s health care delivery assets include Signify Health, Inc. (“Signify Health”), a leader in health risk assessments, and Oak Street Health, Inc. (“Oak Street Health”), a leading multi-payor operator of value-based primary care centers serving Medicare eligible patients.
Pharmacy & Consumer Wellness Segment
The Pharmacy & Consumer Wellness segment dispenses prescriptions in its CVS Pharmacy
®
retail locations and through its infusion operations, provides ancillary pharmacy services including pharmacy patient care programs and vaccination administration, and sells a wide assortment of health and wellness products and general merchandise. The segment also provides pharmacy fulfillment services to support the Health Services segment’s specialty and mail order pharmacy offerings.
Corporate/Other Segment
The Company presents the remainder of its financial results in the Corporate/Other segment, which primarily consists of management and administrative expenses to support the Company’s overall operations and products for which the Company no longer solicits or accepts new customers, such as its large case pensions and long-term care insurance products.
See Note 1 ‘‘Significant Accounting Policies’’ included in Item 1 of this 10-Q and Part 1, Item 1 “Business” included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 (the “2025 Form 10-K”) for further information on the Company’s reportable segments.
37
CVS Health’s Intention to Separate into Two Independent, Publicly Traded Companies
On November 4, 2026, CVS Health announced its intention to separate into two independent, publicly traded companies in a transaction that is intended to be tax-free to CVS Health and its shareholders for U.S. federal income tax purposes. The planned separation will create two companies: a healthcare solutions company comprising Aetna, CVS Caremark, CVS Specialty, Oak Street Health and Signify Health, and a retail pharmacy and community healthcare company comprising retail pharmacy, mail pharmacy, MinuteClinic (including virtual care), and the Health100 technology services business. The healthcare solutions company, in the interim, will be referred to as CVS Health. The retail pharmacy and community healthcare company will be named CVS Pharmacy. The separation is expected to be completed in the first half of 2028, subject to customary conditions, including, among others, final approval by the CVS Health Board of Directors, effectiveness of a Form 10 registration statement filed with the SEC and receipt of customary confirmation that the separation is expected to be tax-free to CVS Health and its shareholders.
38
Operating Results
The following discussion explains the material changes in the Company’s operating results for the three and nine months ended September 30, 2026 and 2025, and the significant developments affecting the Company’s financial condition since December 31, 2025. We strongly recommend that you read our audited consolidated financial statements and notes thereto and Management’s Discussion and Analysis of Financial Condition and Results of Operations, which are included in the 2025 Form 10-K.
Summary of Consolidated Financial Results
Change
Three Months Ended
September 30,
Nine Months Ended
September 30,
Three Months Ended
September 30,
2026 vs 2025
Nine Months Ended
September 30,
2026 vs 2025
In millions
2026
2025
2026
2025
$
%
$
%
Revenues:
Products
$
69,225
$
64,590
$
197,670
$
182,866
$
4,635
7.2
%
$
14,804
8.1
%
Premiums
34,566
33,719
103,474
100,734
847
2.5
%
2,740
2.7
%
Services
3,961
3,930
11,915
11,135
31
0.8
%
780
7.0
%
Net investment income
647
632
1,862
1,639
15
2.4
%
223
13.6
%
Total revenues
108,399
102,871
314,921
296,374
5,528
5.4
%
18,547
6.3
%
Operating costs:
Cost of products sold
61,185
57,045
175,491
162,107
4,140
7.3
%
13,384
8.3
%
Health care costs
32,316
32,020
93,159
92,472
296
0.9
%
687
0.7
%
Operating expenses
11,332
11,288
33,322
33,522
44
0.4
%
(200)
(0.6)
%
Goodwill impairment
—
5,725
—
5,725
(5,725)
(100.0)
%
(5,725)
(100.0)
%
Total operating costs
104,833
106,078
301,972
293,826
(1,245)
(1.2)
%
8,146
2.8
%
Operating income (loss)
3,566
(3,207)
12,949
2,548
6,773
211.2
%
10,401
408.2
%
Gain on deconsolidation of subsidiary
—
483
—
483
(483)
(100.0)
%
(483)
(100.0)
%
Interest expense
(747)
(784)
(2,278)
(2,332)
37
4.7
%
54
2.3
%
Other income
30
26
93
83
4
15.4
%
10
12.0
%
Income (loss) before income tax provision
2,849
(3,482)
10,764
782
6,331
181.8
%
9,982
1276.5
%
Income tax provision
678
508
2,641
1,977
170
33.5
%
664
33.6
%
Net income (loss)
2,171
(3,990)
8,123
(1,195)
6,161
154.4
%
9,318
779.7
%
Net (income) loss attributable to noncontrolling interests
1
15
(29)
20
(14)
(93.3)
%
(49)
(245.0)
%
Net income (loss) attributable to CVS Health
$
2,172
$
(3,975)
$
8,094
$
(1,175)
$
6,147
154.6
%
$
9,269
788.9
%
Commentary - Three Months Ended September 30, 2026 vs. 2025
Revenues
•
Total revenues increased $5.5 billion, or 5.4%, in the three months ended September 30, 2026 compared to the prior year primarily driven by growth in the Health Services and Health Care Benefits segments.
•
Please see “Segment Analysis” later in this report for additional information about the revenues of the Company’s segments.
Operating expenses
•
Operating expenses increased slightly in the three months ended September 30, 2026 compared to the prior year primarily due to continued business investments and a contingent guarantee liability recorded in connection with agreements to resolve certain litigation and Chapter 11 bankruptcy matters involving Omnicare, LLC (“Omnicare”) in the three months ended September 30, 2026. These increases were largely offset by the absence of a $320 million opioid litigation charge recorded in the prior year.
39
•
Please see “Segment Analysis” later in this report for additional information about the operating expenses of the Company’s segments.
Operating income (loss)
•
During the three months ended September 30, 2026, the Company generated operating income of $3.6 billion compared to an operating loss of $3.2 billion in the prior year. The difference was primarily driven by the absence of a $5.7 billion goodwill impairment charge related to the Health Care Delivery reporting unit recorded in the prior year, as well as improved operating performance across all operating segments.
•
Please see “Segment Analysis” later in this report for additional information about the operating results of the Company’s segments.
Gain on deconsolidation of subsidiary
•
During the three months ended September 30, 2025, the gain on deconsolidation of subsidiary relates to Omnicare, a wholly-owned indirect subsidiary of CVS Health Corporation, and certain of its subsidiary entities (collectively, the “Omnicare Entities”). See Note 1 ‘‘Significant Accounting Policies’’ to the unaudited condensed consolidated financial statements for further information on the deconsolidation of the Omnicare Entities.
Income tax provision
•
The effective income tax rate was 23.8% for the three months ended September 30, 2026 compared to (14.6)% for the three months ended September 30, 2025. The change in the effective income tax rate was primarily due to the absence of the $5.7 billion goodwill impairment charge recorded in the prior year, which was not deductible for income tax purposes.
Commentary - Nine Months Ended September 30, 2026 vs. 2025
Revenues
•
Total revenues increased $18.5 billion, or 6.3%, in the nine months ended September 30, 2026 compared to the prior year primarily driven by growth in the Health Services and Health Care Benefits segments.
•
Please see “Segment Analysis” later in this report for additional information about the revenues of the Company’s segments.
Operating expenses
•
Operating expenses decreased $200 million, or 0.6%, in the nine months ended September 30, 2026 compared to the prior year primarily due to the absence of $1.2 billion in legacy litigation charges, the $320 million opioid litigation charge and $288 million in pre-tax losses on the wind down and sale of Accountable Care assets, all recorded in the prior year. These decreases were partially offset by continued business investments, operating expenses to support increased volume from the Rite Aid asset acquisitions and the Omnicare contingent guarantee liability described above recorded in the nine months ended September 30, 2026.
•
Please see “Segment Analysis” later in this report for additional information about the operating expenses of the Company’s segments.
Operating income
•
Operating income increased $10.4 billion, or 408.2%, in the nine months ended September 30, 2026 compared to the prior year primarily due to the absence of the $5.7 billion goodwill impairment charge and the $1.2 billion in legacy litigation charges, both recorded in the prior year, as well as improved operating performance across all operating segments.
•
Please see “Segment Analysis” later in this report for additional information about the operating results of the Company’s segments.
Gain on deconsolidation of subsidiary
•
During the nine months ended September 30, 2025, the gain on deconsolidation of subsidiary relates to Omnicare and certain of its subsidiary entities.
Income tax provision
•
The effective income tax rate was 24.5% for the nine months ended September 30, 2026 compared to 252.8% for the nine months ended September 30, 2025. The change in the effective income tax rate was primarily due to the absence of the impact of the goodwill impairment charge and the legacy litigation charges recorded in the prior year, both of which were not deductible for income tax purposes.
40
Trends and Uncertainties
The Company believes you should consider the following business and regulatory trends and uncertainties:
Business Trends and Uncertainties
•
Utilization persisted at elevated levels in the third quarter of 2026. Although the level of utilization is difficult to accurately predict, utilization beyond current elevated levels may pressure the Company’s Health Care Benefits segment and its health care delivery assets in its Health Services segment in 2026.
•
The Company continues to share with clients a larger portion of rebates, fees and/or discounts received from pharmaceutical manufacturers, and typically offers clients minimum pricing guarantees that cannot always be achieved. The Company also faces increasing pressure from pharmaceutical manufacturers with respect to the calculation and collection of rebates. In addition, marketplace dynamics and regulatory changes have limited the Company’s ability to offer plan sponsors pricing that includes retail network “differential” or “spread.” The Company expects these trends to continue.
•
The environment for the federal 340B drug pricing program remains dynamic and may continue to impact the Company’s Health Services segment.
•
Changes in the economic environment, including inflation, the implementation of new tariffs or changes in tariffs, including the impact of tariffs on trade relations between the U.S. and foreign countries, and labor and other market dynamics could create exposure for increased costs and supply chain disruptions that can adversely impact consumer demand, the ability to deliver client savings or the Company’s financial results.
•
Consumer confidence and a decline in consumer discretionary spending, as well as a shift to value, grocery and digital retailers, could drive lower front store sales in the Pharmacy & Consumer Wellness segment.
•
Heightened geopolitical tensions could contribute to an increase in likelihood of factors that may negatively impact the Company’s financial results, including an economic slowdown, a recession, financial market volatility, increased supply chain costs or supply chain disruptions, fluctuations in interest rates or other monetary and fiscal policy measures and cyberattacks.
Regulatory Trends and Uncertainties
•
The Company is exposed to funding and regulation of, and changes in government policy with respect to and/or funding or regulation of, the various Medicare and Medicaid programs in which the Company participates, including changes in the amounts payable to us under those programs and/or new reforms or surcharges on existing programs, including changes to applicable risk adjustment mechanisms.
•
Legislation and/or regulations seeking to regulate PBM activities in a comprehensive manner have been proposed or enacted in a majority of states and on the federal level. In addition, some states have recently enacted or are considering legislation related to prohibiting pharmacy licensure for pharmacies affiliated with a PBM. This legislative and regulatory activity could adversely affect the Company’s ability to conduct business on commercially reasonable terms and the Company’s ability to standardize its PBM products and services across state lines and/or could limit the Company’s ability to provide both pharmacy and PBM services within the same state.
For additional information regarding these and other trends and uncertainties, see Item 1A, “Risk Factors” and Part I, Item 1 “Business - Government Regulation” included in the 2025 Form 10-K.
41
Segment Analysis
The following discussion of segment operating results is presented based on the Company’s reportable segments in accordance with the accounting guidance for segment reporting and is consistent with the segment disclosure in Note 9 ‘‘Segment Reporting’’ to the unaudited condensed consolidated financial statements.
The Company has four reportable segments: Health Care Benefits, Health Services, Pharmacy & Consumer Wellness and Corporate/Other. The Company’s segments maintain separate financial information, and the Chief Operating Decision Maker (the “CODM”) evaluates the segments’ operating results on a regular basis in deciding how to allocate resources among the segments and in assessing segment performance. The Company’s CODM is the Chief Executive Officer. The CODM evaluates the performance of the Company’s segments based on adjusted operating income. Adjusted operating income (loss) is defined as operating income (loss) as measured by accounting principles generally accepted in the United States of America (“GAAP”) excluding the impact of amortization of intangible assets, net realized capital gains or losses and other items, if any, that neither relate to the ordinary course of the Company’s business nor reflect the Company’s underlying business performance. See the reconciliations of operating income (loss) (GAAP measure) to adjusted operating income (loss) below for further context regarding the items excluded from operating income (loss) in determining adjusted operating income (loss). The CODM uses adjusted operating income as its principal measure of segment performance as it enhances the CODM’s ability to compare past financial performance with current performance and analyze underlying business performance and trends. Non-GAAP financial measures the Company discloses, such as consolidated adjusted operating income, should not be considered a substitute for, or superior to, financial measures determined or calculated in accordance with GAAP.
The following are reconciliations of financial measures of the Company’s segments to the consolidated totals:
In millions
Health Care
Benefits
Health
Services
(1)
Pharmacy &
Consumer
Wellness
Corporate/
Other
Intersegment
Eliminations
(2)
Consolidated
Totals
Three Months Ended
September 30, 2026
Total revenues
$
36,855
$
53,964
$
35,498
$
205
$
(18,123)
$
108,399
Adjusted operating income (loss)
912
2,106
1,635
(459)
—
4,194
September 30, 2025
Total revenues
$
35,993
$
49,266
$
36,214
$
133
$
(18,735)
$
102,871
Adjusted operating income (loss)
314
2,050
1,478
(383)
—
3,459
Nine Months Ended
September 30, 2026
Total revenues
$
110,364
$
153,996
$
101,303
$
478
$
(51,220)
$
314,921
Adjusted operating income (loss)
6,379
5,328
4,307
(1,513)
—
14,501
September 30, 2025
Total revenues
$
107,061
$
139,181
$
101,707
$
362
$
(51,937)
$
296,374
Adjusted operating income (loss)
3,615
5,228
4,129
(1,126)
—
11,846
_____________________________________________
(1)
Total revenues of the Health Services segment include approximately $2.4 billion of retail co-payments in each of the three months ended September 30, 2026 and 2025, and approximately $9.0 billion and $8.8 billion of retail co-payments for the nine months ended September 30, 2026 and 2025, respectively.
(2)
Intersegment revenue eliminations relate to intersegment revenue generating activities that occur between the Health Care Benefits segment, the Health Services segment, and/or the Pharmacy & Consumer Wellness segment.
42
The following are reconciliations of consolidated operating income (loss) (GAAP measure) to consolidated adjusted operating income, as well as reconciliations of segment GAAP operating income (loss) to segment adjusted operating income (loss):
Three Months Ended September 30, 2026
In millions
Health Care
Benefits
Health
Services
Pharmacy &
Consumer
Wellness
Corporate/
Other
Consolidated
Totals
Operating income (loss) (GAAP measure)
$
653
$
1,980
$
1,573
$
(640)
$
3,566
Amortization of intangible assets
(1)
236
126
62
1
425
Net realized capital (gains) losses
(2)
23
—
—
(26)
(3)
Acquisition-related integration costs
(3)
—
—
—
13
13
Omnicare guarantee
(4)
—
—
—
193
193
Adjusted operating income (loss)
$
912
$
2,106
$
1,635
$
(459)
$
4,194
Three Months Ended September 30, 2025
In millions
Health Care
Benefits
Health
Services
Pharmacy &
Consumer
Wellness
Corporate/
Other
Consolidated
Totals
Operating income (loss) (GAAP measure)
$
53
$
(3,899)
$
1,414
$
(775)
$
(3,207)
Amortization of intangible assets
(1)
294
141
64
1
500
Net realized capital (gains) losses
(2)
(33)
—
—
44
11
Acquisition-related integration costs
(3)
—
—
—
27
27
Goodwill impairment
(5)
—
5,725
—
—
5,725
Health Care Delivery clinic closure charge
(6)
—
83
—
—
83
Opioid litigation charge
(7)
—
—
—
320
320
Adjusted operating income (loss)
$
314
$
2,050
$
1,478
$
(383)
$
3,459
Nine Months Ended September 30, 2026
In millions
Health Care
Benefits
Health
Services
Pharmacy &
Consumer
Wellness
Corporate/
Other
Consolidated
Totals
Operating income (loss) (GAAP measure)
$
5,650
$
4,930
$
4,118
$
(1,749)
$
12,949
Amortization of intangible assets
(1)
709
398
189
2
1,298
Net realized capital losses
(2)
20
—
—
6
26
Acquisition-related integration costs
(3)
—
—
—
35
35
Omnicare guarantee
(4)
—
—
—
193
193
Adjusted operating income (loss)
$
6,379
$
5,328
$
4,307
$
(1,513)
$
14,501
Nine Months Ended September 30, 2025
In millions
Health Care
Benefits
Health
Services
Pharmacy &
Consumer
Wellness
Corporate/
Other
Consolidated
Totals
Operating income (loss) (GAAP measure)
$
2,729
$
(1,570)
$
3,014
$
(1,625)
$
2,548
Amortization of intangible assets
(1)
881
426
184
2
1,493
Net realized capital (gains) losses
(2)
1
(15)
—
73
59
Acquisition-related integration costs
(3)
—
—
—
100
100
Goodwill impairment
(5)
—
5,725
—
—
5,725
Health Care Delivery clinic closure charge
(6)
—
83
—
—
83
Opioid litigation charge
(7)
—
—
—
320
320
Legacy litigation charges
(8)
—
291
929
—
1,220
Loss on Accountable Care assets
(9)
—
288
—
—
288
Office real estate optimization charges
(10)
4
—
2
4
10
Adjusted operating income (loss)
$
3,615
$
5,228
$
4,129
$
(1,126)
$
11,846
43
_____________________________________________
(1)
The Company’s acquisition activities have resulted in the recognition of intangible assets as required under the acquisition method of accounting which consist primarily of trademarks, customer contracts/relationships, covenants not to compete, technology, provider networks and value of business acquired. Definite-lived intangible assets are amortized over their estimated useful lives and are tested for impairment when events indicate that the carrying value may not be recoverable. The amortization of intangible assets is reflected in operating expenses within each segment. Although intangible assets contribute to the Company’s revenue generation, the amortization of intangible assets does not directly relate to the underwriting of the Company’s insurance products, the services performed for the Company’s customers or the sale of the Company’s products or services. Additionally, intangible asset amortization expense typically fluctuates based on the size and timing of the Company’s acquisition activity. Accordingly, the Company believes excluding the amortization of intangible assets enhances the Company’s and investors’ ability to compare the Company’s past financial performance with its current performance and to analyze underlying business performance and trends. Intangible asset amortization excluded from the related non-GAAP financial measure represents the entire amount recorded within the Company’s GAAP financial statements, and the revenue generated by the associated intangible assets has not been excluded from the related non-GAAP financial measure. Intangible asset amortization is excluded from the related non-GAAP financial measure because the amortization, unlike the related revenue, is not affected by operations of any particular period unless an intangible asset becomes impaired or the estimated useful life of an intangible asset is revised.
(2)
The Company’s net realized capital gains and losses arise from various types of transactions, primarily in the course of managing a portfolio of assets that support the payment of insurance liabilities. Net realized capital gains and losses are reflected in net investment income (loss) within each segment. These capital gains and losses are the result of investment decisions, market conditions and other economic developments that are unrelated to the performance of the Company’s business, and the amount and timing of these capital gains and losses do not directly relate to the underwriting of the Company’s insurance products, the services performed for the Company’s customers or the sale of the Company’s products or services. Accordingly, the Company believes excluding net realized capital gains and losses enhances the Company’s and investors’ ability to compare the Company’s past financial performance with its current performance and to analyze underlying business performance and trends.
(3)
During the three and nine months ended September 30, 2026 and 2025, the acquisition-related integration costs relate to the acquisitions of Signify Health and Oak Street Health. The acquisition-related integration costs are reflected in operating expenses within the Corporate/Other segment.
(4)
During the three and nine months ended September 30, 2026, the Omnicare guarantee relates to an estimated contingent guarantee liability recorded in connection with agreements to resolve certain litigation and Chapter 11 bankruptcy matters involving Omnicare. Following bankruptcy court approval of the agreements in August 2026 and the determination that the sale of Omnicare’s assets is probable of occurring in the fourth quarter of 2026, the Company recorded an estimated contingent guarantee liability in the third quarter of 2026. The Omnicare guarantee is reflected in operating expenses within the Corporate/Other Segment.
(5)
During the three and nine months ended September 30, 2025, the goodwill impairment charge relates to the Health Care Delivery reporting unit within the Health Services segment.
(6)
During the three and nine months ended September 30, 2025, the Health Care Delivery clinic closure charge primarily relates to the write down of long-lived assets in connection with the closure of certain Oak Street Health clinics in 2026, as well as associated severance and employee-related costs. The Health Care Delivery clinic closure charge was reflected in operating expenses within the Health Services segment.
(7)
During the three and nine months ended September 30, 2025, the opioid litigation charge relates to a change in the Company’s accrual related to ongoing opioid litigation matters.
(8)
During the nine months ended September 30, 2025, the Company recorded legacy litigation charges related to two court decisions associated with its past business practices. The legacy litigation charges were reflected in operating expenses within the Pharmacy & Consumer Wellness and Health Services segments.
(9)
During the nine months ended September 30, 2025, the loss on the wind down and sale of Accountable Care assets represents the pre-tax loss on the divestiture of the Company’s Medicare Shared Savings Program (“MSSP”) operations, as well as costs incurred in connection with the wind down of the Company’s ACO REACH operations. The loss on Accountable Care assets was reflected in operating expenses within the Health Services segment.
(10)
During the nine months ended September 30, 2025, the office real estate optimization charges primarily relate to the abandonment of leased real estate and the related right-of-use assets and property and equipment in connection with the Company’s evaluation of corporate office real estate space. The office real estate optimization charges were reflected in operating expenses within each segment.
44
Health Care Benefits Segment
The following table summarizes the Health Care Benefits segment’s performance for the respective periods:
Change
Three Months Ended
September 30,
Nine Months Ended
September 30,
Three Months Ended
September 30,
2026 vs 2025
Nine Months Ended
September 30,
2026 vs 2025
In millions, except percentages and basis points (“bps”)
2026
2025
2026
2025
$
%
$
%
Revenues:
Premiums
$
34,569
$
33,739
$
103,480
$
100,731
$
830
2.5
%
$
2,749
2.7
%
Services
1,831
1,741
5,459
5,023
90
5.2
%
436
8.7
%
Net investment income
455
513
1,425
1,307
(58)
(11.3)
%
118
9.0
%
Total revenues
36,855
35,993
110,364
107,061
862
2.4
%
3,303
3.1
%
Health care costs
31,556
31,319
90,827
90,696
237
0.8
%
131
0.1
%
MBR (Health care costs as a % of premium revenues)
91.3
%
92.8
%
87.8
%
90.0
%
(150)
bps
(220)
bps
Operating expenses
$
4,646
$
4,621
$
13,887
$
13,636
$
25
0.5
%
$
251
1.8
%
Operating expenses as a % of total revenues
12.6
%
12.8
%
12.6
%
12.7
%
Operating income
$
653
$
53
$
5,650
$
2,729
$
600
1,132.1
%
$
2,921
107.0
%
Operating income as a % of total revenues
1.8
%
0.1
%
5.1
%
2.5
%
Adjusted operating income
(1)
$
912
$
314
$
6,379
$
3,615
$
598
190.4
%
$
2,764
76.5
%
Adjusted operating income as a % of total revenues
2.5
%
0.9
%
5.8
%
3.4
%
Premium revenues (by business):
Government
$
28,108
$
25,968
$
84,385
$
76,800
$
2,140
8.2
%
$
7,585
9.9
%
Commercial
6,461
7,771
19,095
23,931
(1,310)
(16.9)
%
(4,836)
(20.2)
%
_____________________________________________
(1)
See “Segment Analysis” above in this report for a reconciliation of Health Care Benefits segment operating income (GAAP measure) to adjusted operating income, which represents the Company’s principal measure of segment performance.
Commentary - Three Months Ended September 30, 2026 vs. 2025
Revenues
•
Total revenues increased $862 million, or 2.4%, in the three months ended September 30, 2026 compared to the prior year primarily driven by an increase in the Government business, partially offset by a decline as a result of the Company’s exit of the individual exchange business in 2026.
Medical Benefit Ratio (“MBR”)
•
Medical benefit ratio is calculated by dividing the Health Care Benefits segment’s health care costs by premium revenues and represents the percentage of premium revenues spent on medical benefits for the segment’s Insured members. Management uses MBR to assess the underlying business performance and underwriting of its insurance products, understand variances between actual results and expected results and identify trends in period-over-period results. MBR provides management and investors with information useful in assessing the operating results of the Health Care Benefits segment’s Insured products.
•
The MBR decreased to 91.3% in the three months ended September 30, 2026 compared to 92.8% in the prior year primarily driven by improved underlying performance in the Government business.
Operating expenses
•
Operating expenses in the Health Care Benefits segment include selling, general and administrative expenses and depreciation and amortization expenses.
•
Operating expenses remained consistent in the three months ended September 30, 2026 compared to the prior year.
45
Adjusted operating income
•
Adjusted operating income increased $598 million, or 190.4%, in the three months ended September 30, 2026 compared to the prior year primarily driven by improved underlying performance in the Government business.
Commentary - Nine Months Ended September 30, 2026 vs. 2025
Revenues
•
Total revenues increased $3.3 billion, or 3.1%, in the nine months ended September 30, 2026 compared to the prior year primarily driven by an increase in the Government business, partially offset by a decline as a result of the Company’s exit of the individual exchange business in 2026.
Medical Benefit Ratio
•
The MBR decreased to 87.8% in the nine months ended September 30, 2026 compared to 90.0% in the prior year primarily driven by improved underlying performance in the Government business and the absence of the premium deficiency reserves recorded as health care costs in the prior year, partially offset by lower favorable prior period development.
Operating expenses
•
Operating expenses increased $251 million, or 1.8%, in the nine months ended September 30, 2026 compared to the prior year primarily driven by increased business investments.
Adjusted operating income
•
Adjusted operating income increased $2.8 billion, or 76.5%, in the nine months ended September 30, 2026 compared to the prior year primarily driven by improved underlying performance in the Government business and the absence of the premium deficiency reserves recorded in the prior year, partially offset by lower favorable prior period development.
The following table summarizes the Health Care Benefits segment’s medical membership for the respective periods:
September 30, 2026
June 30, 2026
December 31, 2025
September 30, 2025
In thousands
Insured
ASC
Total
Insured
ASC
Total
Insured
ASC
Total
Insured
ASC
Total
Medical membership:
Commercial
2,565
15,839
18,404
2,487
15,833
18,320
3,447
15,350
18,797
3,536
15,314
18,850
Medicare Advantage
4,229
—
4,229
4,202
—
4,202
4,267
—
4,267
4,266
—
4,266
Medicare Supplement
1,164
—
1,164
1,176
—
1,176
1,202
—
1,202
1,221
—
1,221
Medicaid
1,961
362
2,323
1,964
361
2,325
1,952
373
2,325
1,978
388
2,366
Total medical membership
9,919
16,201
26,120
9,829
16,194
26,023
10,868
15,723
26,591
11,001
15,702
26,703
Supplemental membership information:
Medicare Prescription Drug Plan (stand-alone)
3,858
3,870
4,041
4,056
Medical Membership
•
Medical membership represents the number of members covered by the Health Care Benefits segment’s Insured and ASC medical products and related services at a specified point in time. Management uses this metric to understand variances between actual medical membership and expected amounts as well as trends in period-over-period results. This metric provides management and investors with information useful in understanding the impact of medical membership on the Health Care Benefits segment’s total revenues and operating results.
•
Medical membership as of September 30, 2026 of 26.1 million remained consistent compared with June 30, 2026.
•
Medical membership as of September 30, 2026 of 26.1 million decreased approximately 600,000 members compared with September 30, 2025 reflecting the Company’s exit of the individual exchange business in 2026, partially offset by an increase in Commercial ASC membership.
Medicare Update
On April 6, 2026, the U.S. Centers for Medicare & Medicaid Services (“
CMS”)
issued its final notice detailing final 2027 Medicare Advantage payment rates. Final 2027 Medicare Advantage rates resulted in an expected average increase in revenue for the Medicare Advantage industry of 2.48%, excluding the CMS estimate of Medicare Advantage risk score trend.
The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 (collectively, the “ACA”) ties a portion of each Medicare Advantage plan’s reimbursement to the plan’s “star ratings.” Plans must have a star rating of four or higher (out of five) to qualify for bonus payments. CMS released the Company’s 2027 star ratings in October 2026. The Company’s 2027 star ratings will be used to determine which of the Company’s Medicare Advantage plans have
46
ratings of four stars or higher and qualify for bonus payments in 2028. Based on the Company’s membership as of September 2026, more than 69% of the Company’s Medicare Advantage members were in plans with 2027 star ratings of at least 4.0 stars, compared to more than 81% of the Company’s Medicare Advantage members being in plans with 2026 star ratings of at least 4.0 stars based on the Company’s membership as of September 2025.
47
Health Services Segment
The following table summarizes the Health Services segment’s performance for the respective periods:
Change
Three Months Ended
September 30,
Nine Months Ended
September 30,
Three Months Ended
September 30,
2026 vs 2025
Nine Months Ended
September 30,
2026 vs 2025
In millions, except percentages
2026
2025
2026
2025
$
%
$
%
Revenues:
Products
$
51,491
$
46,767
$
146,433
$
132,125
$
4,724
10.1
%
$
14,308
10.8
%
Services
2,473
2,500
7,564
7,046
(27)
(1.1)
%
518
7.4
%
Net investment income (loss)
—
(1)
(1)
10
1
100.0
%
(11)
(110.0)
%
Total revenues
53,964
49,266
153,996
139,181
4,698
9.5
%
14,815
10.6
%
Cost of products sold
49,711
45,230
142,338
128,425
4,481
9.9
%
13,913
10.8
%
Health care costs
1,346
1,291
3,998
3,439
55
4.3
%
559
16.3
%
Operating expenses
927
919
2,730
3,162
8
0.9
%
(432)
(13.7)
%
Operating expenses as a % of total revenues
1.7
%
1.9
%
1.8
%
2.3
%
Goodwill impairment
$
—
$
5,725
$
—
$
5,725
$
(5,725)
(100.0)
%
$
(5,725)
(100.0)
%
Operating income (loss)
1,980
(3,899)
4,930
(1,570)
5,879
150.8
%
6,500
414.0
%
Operating income (loss) as a % of total revenues
3.7
%
(7.9)
%
3.2
%
(1.1)
%
Adjusted operating income
(1)
$
2,106
$
2,050
$
5,328
$
5,228
$
56
2.7
%
$
100
1.9
%
Adjusted operating income as a % of total revenues
3.9
%
4.2
%
3.5
%
3.8
%
Revenues (by distribution channel):
Pharmacy network
(2)
$
28,258
$
26,408
$
80,024
$
74,187
$
1,850
7.0
%
$
5,837
7.9
%
Mail & specialty
(3)
23,153
20,392
66,236
58,071
2,761
13.5
%
8,165
14.1
%
Net investment income (loss)
—
(1)
(1)
10
1
100.0
%
(11)
(110.0)
%
Other
2,553
2,467
7,737
6,913
86
3.5
%
824
11.9
%
Pharmacy claims processed
(4)
481.7
475.6
1,419.4
1,408.8
6.1
1.3
%
10.6
0.8
%
_____________________________________________
(1)
See “Segment Analysis” above in this report for a reconciliation of Health Services segment operating income (GAAP measure) to adjusted operating income, which represents the Company’s principal measure of segment performance.
(2)
Pharmacy network revenues relate to claims filled at retail and specialty retail pharmacies, including pharmacies owned by the Company, as well as activity associated with Maintenance Choice, which permits eligible client plan members to fill their maintenance prescriptions through mail order delivery or at a CVS pharmacy retail store for the same price as mail order.
(3)
Mail & specialty revenues relate to specialty mail claims inclusive of Specialty Connect
®
claims picked up at a retail pharmacy, as well as mail order and specialty claims fulfilled by the Pharmacy & Consumer Wellness segment.
(4)
Includes an adjustment to convert 90-day prescriptions to the equivalent of three 30-day prescriptions. This adjustment reflects the fact that these prescriptions include approximately three times the amount of product days supplied compared to a normal prescription.
Commentary - Three Months Ended September 30, 2026 vs. 2025
Revenues
•
Total revenues increased $4.7 billion, or 9.5%, in the three months ended September 30, 2026 compared to the prior year primarily driven by pharmacy drug mix and brand inflation, partially offset by continued pharmacy client price improvements.
Operating expenses
•
Operating expenses in the Health Services segment include selling, general and administrative expenses, as well as depreciation and amortization expense.
•
Operating expenses remained consistent in the three months ended September 30, 2026 compared to the prior year.
48
Goodwill impairment
•
During the three months ended September 30, 2025, the Company recorded a $5.7 billion goodwill impairment charge related to the Health Care Delivery reporting unit within the Health Services segment.
Adjusted operating income
•
Adjusted operating income increased $56 million, or 2.7%, in the three months ended September 30, 2026 compared to the prior year primarily driven by improved purchasing economics and pharmacy drug mix, partially offset by continued pharmacy client price improvements.
Pharmacy claims processed
•
Pharmacy claims processed represents the number of prescription claims processed through the Company’s pharmacy benefits manager and dispensed by either its retail network pharmacies or the Company’s mail and specialty pharmacies. Management uses this metric to understand variances between actual claims processed and expected amounts as well as trends in period-over-period results. This metric provides management and investors with information useful in understanding the impact of pharmacy claim volume on segment total revenues and operating results.
•
Pharmacy claims processed
increased 1.3%
on a 30-day equivalent basis in the three months ended September 30, 2026 compared to the prior year.
Commentary - Nine Months Ended September 30, 2026 vs. 2025
Revenues
•
Total revenues increased $14.8 billion, or 10.6%, in the nine months ended September 30, 2026 compared to the prior year primarily driven by pharmacy drug mix and brand inflation, partially offset by continued pharmacy client price improvements.
Operating expenses
•
Operating expenses decreased $432 million, or 13.7%, in the nine months ended September 30, 2026 compared to the prior year primarily due to the absence of a $291 million legacy litigation charge and $288 million in pre-tax losses on the wind down and sale of Accountable Care assets, both recorded in the prior year.
Goodwill impairment
•
During the nine months ended September 30, 2025, the Company recorded a $5.7 billion goodwill impairment charge related to the Health Care Delivery reporting unit within the Health Services segment.
Adjusted operating income
•
Adjusted operating income increased $100 million, or 1.9%, in the nine months ended September 30, 2026 compared to the prior year primarily driven by improved purchasing economics, pharmacy drug mix and modest improvement in the Company’s health care delivery business. These increases were partially offset by continued pharmacy client price improvements.
Pharmacy claims processed
•
The Company’s pharmacy claims processed increased 0.8% on a 30-day equivalent basis in the nine months ended September 30, 2026 compared to the prior year.
49
Pharmacy & Consumer Wellness Segment
The following table summarizes the Pharmacy & Consumer Wellness segment’s performance for the respective periods:
Change
Three Months Ended
September 30,
Nine Months Ended
September 30,
Three Months Ended
September 30,
2026 vs 2025
Nine Months Ended
September 30,
2026 vs 2025
In millions, except percentages
2026
2025
2026
2025
$
%
$
%
Revenues:
Products
$
34,807
$
35,503
$
99,298
$
99,730
$
(696)
(2.0)
%
$
(432)
(0.4)
%
Services
691
711
2,005
1,977
(20)
(2.8)
%
28
1.4
%
Total revenues
35,498
36,214
101,303
101,707
(716)
(2.0)
%
(404)
(0.4)
%
Cost of products sold
28,700
29,647
81,772
83,005
(947)
(3.2)
%
(1,233)
(1.5)
%
Operating expenses
5,225
5,153
15,413
15,688
72
1.4
%
(275)
(1.8)
%
Operating expenses as a % of total revenues
14.7
%
14.2
%
15.2
%
15.4
%
Operating income
$
1,573
$
1,414
$
4,118
$
3,014
$
159
11.2
%
$
1,104
36.6
%
Operating income as a % of total revenues
4.4
%
3.9
%
4.1
%
3.0
%
Adjusted operating income
(1)
$
1,635
$
1,478
$
4,307
$
4,129
$
157
10.6
%
$
178
4.3
%
Adjusted operating income as a % of total revenues
4.6
%
4.1
%
4.3
%
4.1
%
Revenues (by major goods/service lines):
Pharmacy
$
29,725
$
30,428
$
83,629
$
84,135
$
(703)
(2.3)
%
$
(506)
(0.6)
%
Front Store
5,164
5,192
15,830
15,803
(28)
(0.5)
%
27
0.2
%
Other
609
594
1,844
1,769
15
2.5
%
75
4.2
%
Prescriptions filled
(2)
470.0
461.4
1,378.2
1,335.0
8.6
1.9
%
43.2
3.2
%
Same store sales increase (decrease):
(3)
Total
(0.6)
%
14.3
%
1.5
%
14.6
%
Pharmacy
(0.6)
%
16.8
%
1.7
%
17.5
%
Front Store
(0.6)
%
1.5
%
0.5
%
1.5
%
Prescription volume
(2)
3.9
%
8.9
%
5.8
%
7.3
%
_____________________________________________
(1)
See “Segment Analysis” above in this report for a reconciliation of Pharmacy & Consumer Wellness segment operating income (GAAP measure) to adjusted operating income, which represents the Company’s principal measure of segment performance.
(2)
Includes an adjustment to convert 90-day prescriptions to the equivalent of three 30-day prescriptions. This adjustment reflects the fact that these prescriptions include approximately three times the amount of product days supplied compared to a normal prescription.
(3)
Same store sales and prescription volume represent the change in revenues and prescriptions filled in the Company’s retail pharmacy stores that have been operating for greater than one year and digital sales initiated online or through mobile applications and fulfilled through the Company’s distribution centers, expressed as a percentage that indicates the increase or decrease relative to the comparable prior period. Same store metrics exclude revenues and prescriptions from infusion services operations and long-term care pharmacies. Management uses these metrics to evaluate the performance of existing stores on a comparable basis and to inform future decisions regarding existing stores and new locations. Same-store metrics provide management and investors with information useful in understanding the portion of current revenues and prescriptions resulting from organic growth in existing locations versus the portion resulting from opening new stores.
Commentary - Three Months Ended September 30, 2026 vs. 2025
Revenues
•
Total revenues decreased $716 million, or 2.0%, in the three months ended September 30, 2026 compared to the prior year primarily driven by regulatory-related price reductions on certain drugs, the impact of recent generic drug introductions and pharmacy reimbursement pressure. These decreases were partially offset by pharmacy drug mix, increased prescription volume, including contributions from the Company’s Rite Aid asset acquisitions which were completed during the third quarter of 2025, and brand inflation.
•
Pharmacy same store sales decreased 0.6% in the three months ended September 30, 2026 compared to the prior year. The decrease was primarily driven by regulatory-related price reductions on certain drugs, the impact of recent generic drug
50
introductions and pharmacy reimbursement pressure. These decreases were largely offset by pharmacy drug mix, the 3.9% increase in pharmacy same store prescription volume on a 30-day equivalent basis and brand inflation.
•
Front store same store sales decreased 0.6% in the three months ended September 30, 2026 compared to the prior year.
Operating expenses
•
Operating expenses in the Pharmacy & Consumer Wellness segment consist of selling, general and administrative expenses which include payroll, employee benefits and occupancy costs associated with the segment’s stores and pharmacy fulfillment operations, advertising expenses, as well as depreciation and amortization expense.
•
Operating expenses increased $72 million, or 1.4%, in the three months ended September 30, 2026 compared to the prior year primarily due to continued business investments.
Adjusted operating income
•
Adjusted operating income increased $157 million, or 10.6%, in the three months ended September 30, 2026 compared to the prior year primarily driven by core pharmacy strength and contributions from the Company’s Rite Aid asset acquisitions. These increases were partially offset by continued business investments and the impact of consumer dynamics.
Prescriptions filled
•
Prescriptions filled represents the number of prescriptions dispensed through the Pharmacy & Consumer Wellness segment’s retail pharmacies and infusion services operations, as well as through the Omnicare long-term care pharmacies prior to their deconsolidation during the third quarter of 2025. Management uses this metric to understand variances between actual prescriptions dispensed and expected amounts as well as trends in period-over-period results. This metric provides management and investors with information useful in understanding the impact of prescription volume on segment total revenues and operating results.
•
Prescriptions filled increased 1.9% on a 30-day equivalent basis in the three months ended September 30, 2026 compared to the prior year primarily driven by increased utilization and incremental volume resulting from the Company’s Rite Aid prescription file acquisitions, partially offset by the absence of long-term care pharmacy prescription volume following the deconsolidation of Omnicare in September 2025.
Commentary - Nine Months Ended September 30, 2026 vs. 2025
Revenues
•
Total revenues decreased slightly in the nine months ended September 30, 2026 compared to the prior year primarily driven by regulatory-related price reductions on certain drugs, the impact of recent generic drug introductions and pharmacy reimbursement pressure. These decreases were largely offset by pharmacy drug mix, increased prescription volume, including contributions from the Company’s Rite Aid asset acquisitions, and brand inflation.
•
Pharmacy same store sales increased 1.7% in the nine months ended September 30, 2026 compared to the prior year. The increase was primarily driven by pharmacy drug mix, the 5.8% increase in pharmacy same store prescription volume on a 30-day equivalent basis and brand inflation. These increases were partially offset by regulatory-related price reductions on certain drugs, the impact of recent generic drug introductions and pharmacy reimbursement pressure.
•
Front store same store sales increased 0.5% in the nine months ended September 30, 2026 compared to the prior year.
Operating expenses
•
Operating expenses decreased $275 million, or 1.8%, in the nine months ended September 30, 2026 compared to the prior year primarily due to the absence of $929 million in legacy litigation charges recorded in the prior year, partially offset by continued business investments and operating expenses to support increased volume from the Rite Aid asset acquisitions.
Adjusted operating income
•
Adjusted operating income increased $178 million, or 4.3%, in the nine months ended September 30, 2026 compared to the prior year primarily driven by core pharmacy strength and contributions from the Company’s Rite Aid asset acquisitions. These increases were partially offset by continued business investments and the impact of consumer dynamics.
Prescriptions filled
•
Prescriptions filled increased 3.2% on a 30-day equivalent basis in the nine months ended September 30, 2026 compared to the prior year primarily driven by increased utilization and incremental volume resulting from the Company’s Rite Aid prescription file acquisitions, partially offset by the absence of long-term care pharmacy prescription volume following the deconsolidation of Omnicare.
51
Corporate/Other Segment
The following table summarizes the Corporate/Other segment’s performance for the respective periods:
Change
Three Months Ended
September 30,
Nine Months Ended
September 30,
Three Months Ended
September 30,
2026 vs 2025
Nine Months Ended
September 30,
2026 vs 2025
In millions, except percentages
2026
2025
2026
2025
$
%
$
%
Revenues:
Premiums
$
11
$
11
$
34
$
34
$
—
—
%
$
—
—
%
Services
2
2
6
6
—
—
%
—
—
%
Net investment income
192
120
438
322
72
60.0
%
116
36.0
%
Total revenues
205
133
478
362
72
54.1
%
116
32.0
%
Health care costs
45
47
135
133
(2)
(4.3)
%
2
1.5
%
Operating expenses
800
861
2,092
1,854
(61)
(7.1)
%
238
12.8
%
Operating loss
(640)
(775)
(1,749)
(1,625)
135
17.4
%
(124)
(7.6)
%
Adjusted operating loss
(1)
(459)
(383)
(1,513)
(1,126)
(76)
(19.8)
%
(387)
(34.4)
%
_____________________________________________
(1)
See “Segment Analysis” above in this report for a reconciliation of Corporate/Other segment operating loss (GAAP measure) to adjusted operating loss, which represents the Company’s principal measure of segment performance.
Commentary - Three Months Ended September 30, 2026 vs. 2025
Revenues
•
Revenues primarily relate to products for which the Company no longer solicits or accepts new customers, such as large case pensions and long-term care insurance products.
•
Total revenues increased $72 million, or 54.1%, in the three months ended September 30, 2026 compared to the prior year driven by an increase in net investment income, reflecting net realized capital gains in the three months ended September 30, 2026 compared to net realized capital losses in the prior year.
Adjusted operating loss
•
Adjusted operating loss increased $76 million, or 19.8%, in the three months ended September 30, 2026 compared to the prior year primarily driven by increased business investments.
Commentary - Nine Months Ended September 30, 2026 vs. 2025
Revenues
•
Total revenues increased $116 million, or 32.0%, in the nine months ended September 30, 2026 compared to the prior year driven by an increase in net investment income, reflecting lower net realized capital losses and increased income from private equity and equity fund investments in the nine months ended September 30, 2026.
Adjusted operating loss
•
Adjusted operating loss increased $387 million, or 34.4%, in the nine months ended September 30, 2026 compared to the prior year primarily driven by the retroactive effect of a change in a state law related to non-income taxes and increased business investments.
52
Liquidity and Capital Resources
Cash Flows
The Company maintains a level of liquidity sufficient to allow it to meet its cash needs in the short-term. Over the long term, the Company manages its cash and capital structure to maximize shareholder return, maintain its financial condition and maintain flexibility for future strategic initiatives. The Company continuously assesses its regulatory capital requirements, working capital needs, debt and leverage levels, debt maturity schedule, capital expenditure requirements, dividend payouts, potential share repurchases and future investments or acquisitions. The Company believes its operating cash flows, commercial paper program, credit facilities, as well as any potential future borrowings, will be sufficient to fund these future payments and long-term initiatives. As of September 30, 2026, the Company had approximately $11.7 billion in cash and cash equivalents, approximately $5.9 billion of which was held by the parent company or nonrestricted subsidiaries.
The net change in cash, cash equivalents and restricted cash during the nine months ended September 30, 2026 and 2025 was as follows:
Nine Months Ended
September 30,
Change
In millions, except percentages
2026
2025
$
%
Net cash provided by operating activities
$
15,318
$
7,249
$
8,069
111.3
%
Net cash used in investing activities
(5,545)
(3,873)
(1,672)
(43.2)
%
Net cash used in financing activities
(6,537)
(2,908)
(3,629)
(124.8)
%
Net increase in cash, cash equivalents and restricted cash
$
3,236
$
468
$
2,768
591.5
%
Commentary
•
Net cash provided by operating activities
increased by $8.1 billion in the nine months ended September 30, 2026 compared to the prior year. The increase was primarily due to the timing of receipts and payments and improved operating performance in the Health Care Benefits segment in the nine months ended September 30, 2026.
•
Net cash used in investing activities
increased by $1.7 billion in the nine months ended September 30, 2026 compared to the prior year. The increase was primarily due to higher net purchases of investments in the nine months ended September 30, 2026.
•
Net cash used in financing activities
increased by $3.6 billion in the nine months ended September 30, 2026 compared to the prior year primarily due to the absence of proceeds from the issuance of long-term senior notes in the nine months ended September 30, 2025.
Short-term Borrowings
Commercial Paper and Back-up Credit Facilities
The Company did not have any commercial paper outstanding as of September 30, 2026. In connection with its commercial paper program, the Company maintains three $2.5 billion, five-year unsecured back-up revolving credit facilities, which expire in May 2029, 2030 and 2031. The credit facilities allow for borrowings at various rates that are dependent, in part, on the Company’s public debt ratings and require the Company to pay a weighted average quarterly facility fee of approximately 0.03%, regardless of usage. As of September 30, 2026, there were no borrowings outstanding under any of the Company’s back-up credit facilities.
Federal Home Loan Bank of Boston (“FHLBB”)
A subsidiary of the Company is a member of the FHLBB. As a member, the subsidiary has the ability to obtain cash advances, subject to certain minimum collateral requirements. The maximum borrowing capacity available from the FHLBB as of September 30, 2026 was approximately $1.4 billion. As of September 30, 2026, there were no outstanding advances from the FHLBB.
Debt Covenants
The Company’s back-up revolving credit facilities and unsecured senior notes contain customary restrictive financial and operating covenants. These covenants do not include an acceleration of the Company’s debt maturities in the event of a downgrade in the Company’s credit ratings. The Company does not believe the restrictions contained in these covenants
53
materially affect its financial or operating flexibility. As of September 30, 2026, the Company was in compliance with all of its debt covenants.
Debt Ratings
As of September 30, 2026, the Company’s long-term debt was rated “BBB” by Fitch Ratings, Inc. (“Fitch”), “Baa3” by Moody’s Ratings (“Moody’s”) and “BBB” by Standard & Poor’s Financial Services LLC (“S&P”), and its commercial paper program was rated “F2” by Fitch, “P-3” by Moody’s and “A-2” by S&P. The outlook on the Company’s long-term debt is “Negative” by Fitch and “Stable” by S&P. In August 2026, Moody’s changed its outlook on the Company’s long-term debt from “Stable” to “Positive”. In assessing the Company’s credit strength, the Company believes that Fitch, Moody’s and S&P considered, among other things, the Company’s capital structure and financial policies, as well as its consolidated balance sheet, its historical acquisition activity and other financial information, including the Company’s expectations for future earnings and cash flows. Although the Company currently believes its long-term debt ratings will remain investment grade, it cannot predict the future actions of Fitch, Moody’s and/or S&P. The Company’s debt ratings have a direct impact on its future borrowing costs, access to capital markets and new store operating lease costs.
Share Repurchase Programs
The following share repurchase programs have been authorized by CVS Health Corporation’s Board of Directors (the “Board”):
In billions
Authorization Date
Authorized
Remaining as of
September 30, 2026
November 17, 2022 (“2022 Repurchase Program”)
$
10.0
$
10.0
December 9, 2021 (“2021 Repurchase Program”)
10.0
1.5
Each of the share repurchase programs was effective immediately and permit the Company to effect repurchases from time to time through a combination of open market repurchases, privately negotiated transactions, accelerated share repurchase (“ASR”) transactions, and/or other derivative transactions. Both the 2022 and 2021 Repurchase Programs can be modified or terminated by the Board at any time.
During the nine months ended September 30, 2026 and 2025, the Company did not repurchase any shares of its common stock.
Dividends
The quarterly cash dividend declared by the Board was $0.665 per share in both the three months ended September 30, 2026 and 2025. Cash dividends declared by the Board were $1.995 per share in both the nine months ended September 30, 2026 and 2025. CVS Health Corporation has paid cash dividends every quarter since becoming a public company. Future dividend payments will depend on the Company’s earnings, capital requirements, financial condition and other factors considered relevant by the Board.
Critical Accounting Policies
The Company prepares the unaudited condensed consolidated financial statements in conformity with generally accepted accounting principles, which require management to make certain estimates and apply judgment. Estimates and judgments are based on historical experience, current trends and other factors that management believes to be important at the time the unaudited condensed consolidated financial statements are prepared. On a regular basis, the Company reviews its accounting policies and how they are applied and disclosed in the unaudited condensed consolidated financial statements. While the Company believes the historical experience, current trends and other factors considered by management support the preparation of the unaudited condensed consolidated financial statements in conformity with generally accepted accounting principles, actual results could differ from estimates, and such differences could be material.
For a full description of the Company’s other critical accounting policies, see “Critical Accounting Policies” in Item 7 “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of the 2025 Form 10-K.
54
Form 10-Q Table of Contents
Cautionary Statement Concerning Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 (the “Reform Act”) provides a “safe harbor” for forward-looking statements, so long as (1) those statements are identified as forward-looking and (2) the statements are accompanied by meaningful cautionary statements that identify important factors that could cause actual results to differ materially from those discussed in the statement. We want to take advantage of these safe harbor provisions.
Certain information contained in this Quarterly Report on Form 10-Q (this “report”) is forward-looking within the meaning of the Reform Act or Securities and Exchange Commission rules. This information includes, but is not limited to the forward-looking information in Management’s Discussion and Analysis of Financial Condition and Results of Operations included in Part I, Item 2 of this report. In addition, throughout this report and our other reports and communications, we use the following words or variations or negatives of these words and similar expressions when we intend to identify forward-looking statements:
·
Anticipates
·
Believes
·
Can
·
Continue
·
Could
·
Estimates
·
Evaluate
·
Expects
·
Explore
·
Forecast
·
Guidance
·
Intends
·
Likely
·
May
·
Might
·
Outlook
·
Plans
·
Potential
·
Predict
·
Probable
·
Projects
·
Seeks
·
Should
·
View
·
Will
All statements addressing the future operating performance of CVS Health or any segment or any subsidiary and/or future events or developments, including, but not limited to, statements relating to the Company’s investment portfolio, operating results, cash flows and/or financial condition, statements relating to corporate strategy, statements relating to future revenue, operating income or adjusted operating income, earnings per share or adjusted earnings per share, Health Care Benefits segment business, sales results and/or trends, medical cost trends, medical membership, Medicare Part D membership, medical benefit ratios and/or operations, Health Services segment business, sales results and/or trends and/or operations, Pharmacy & Consumer Wellness segment business, sales results and/or trends and/or operations, incremental investment spending, interest expense, effective tax rate, weighted-average share count, cash flow from operations, net capital expenditures, cash available for debt repayment, statements regarding the Company’s proposed separation into two independent, publicly traded companies, statements related to possible, proposed, pending or completed acquisitions, joint ventures, investments or combinations that involve, among other things, the timing or likelihood of receipt of regulatory approvals, the timing of completion, integration synergies, net synergies and integration risks and other costs, enterprise modernization, transformation, leverage ratio, cash available for enhancing shareholder value, inventory reduction, turn rate and/or loss rate, debt ratings and actions taken by ratings agencies, the Company’s ability to attract or retain customers and clients, store development and/or relocations, new product development, and the impact of industry and regulatory developments, as well as statements expressing optimism or pessimism about future operating results or events, are forward-looking statements within the meaning of the Reform Act.
Forward-looking statements rely on a number of estimates, assumptions and projections concerning future events, and are subject to a number of significant risks and uncertainties and other factors that could cause actual results to differ materially from those statements. Many of these risks and uncertainties and other factors are outside our control.
Certain additional risks and uncertainties and other factors are described under “Risk Factors” included in Part I, Item 1A of the 2025 Form 10-K and under “Risk Factors” included in Part II, Item 1A of this report; these are not the only risks and uncertainties we face. There can be no assurance that the Company has identified all the risks that may affect it. Additional risks and uncertainties not presently known to the Company or that the Company currently believes to be immaterial also may adversely affect the Company’s businesses. If any of those risks or uncertainties develops into actual events, those events or circumstances could have a material adverse effect on the Company’s businesses, operating results, cash flows, financial condition and/or stock price, among other effects.
You should not put undue reliance on forward-looking statements. Any forward-looking statement speaks only as of the date of this report, and we disclaim any intention or obligation to update or revise forward-looking statements, whether as a result of new information, future events, uncertainties or otherwise.
55
Form 10-Q Table of Contents
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
The Company has not experienced any material changes in exposures to market risk since
December 31, 2025
. See the information contained in Part II, Item 7A “Quantitative and Qualitative Disclosures About Market Risk” of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 for a discussion of the Company’s exposures to market risk.
Item 4.
Controls and Procedures
Evaluation of disclosure controls and procedures:
The Company’s Chief Executive Officer and Chief Financial Officer, after evaluating the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Securities Exchange Act Rules 13a‑15(f) and 15d‑15(f)) as of September 30, 2026, have concluded that as of such date the Company’s disclosure controls and procedures were adequate and effective and designed to provide reasonable assurance that material information relating to the Company and its subsidiaries would be made known to such officers on a timely basis.
Changes in internal control over financial reporting:
There has been no change in the Company’s internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Rule 13a-15 or Rule 15d-15 that occurred in the three months ended September 30, 2026 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.
56
Form 10-Q Table of Contents
Part II.
Other Information
Item 1.
Legal Proceedings
The information contained in Note 8 ‘‘Commitments and Contingencies’’ contained in “Notes to Condensed Consolidated Financial Statements (Unaudited)” in Part I, Item 1 of this Quarterly Report on Form 10-Q is incorporated by reference herein.
Item 1A.
Risk Factors
The following information supplements the risk factors disclosed in Part I, Item 1A of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the “2025 10-K”) and should be read in conjunction with the risk factors disclosed in the 2025 10-K. If any of these risks or uncertainties develops into actual events or if the circumstances described in these risks or uncertainties occur or continue to occur (in each case as supplemented below), those events or circumstances could have a material adverse effect on the Company’s businesses, operating results, cash flows, financial condition and/or stock price, among other effects on the Company.
CVS Health is subject to risks related to its intention to separate into two independent, publicly traded companies.
On November 4, 2026, CVS Health announced its intention to separate into two independent, publicly traded companies in a transaction that is intended to be tax-free to CVS Health and its shareholders for U.S. federal income tax purposes. The planned separation will create two companies: a healthcare solutions company comprising Aetna, CVS Caremark, CVS Specialty, Oak Street Health and Signify Health, and a retail pharmacy and community healthcare company comprising retail pharmacy, mail pharmacy, MinuteClinic (including virtual care), and the Health100 technology services business. The healthcare solutions company, in the interim, will be referred to as CVS Health. The retail pharmacy and community healthcare company will be named CVS Pharmacy. The separation is expected to be completed in the first half of 2028, subject to customary conditions, including, among others, final approval by the CVS Health Board of Directors, effectiveness of a Form 10 registration statement filed with the SEC and receipt of customary confirmation that the separation is expected to be tax-free to CVS Health and its shareholders.
Executing the proposed separation will require significant time and attention from CVS Health’s senior management and employees, which could disrupt CVS Health’s ongoing business and adversely affect financial results and results of operations. The proposed separation is also complex, and completion of the proposed separation and the timing of its completion will be subject to a number of factors and conditions, including the readiness of the new company to operate as an independent public company and finalization of the capital structure of the new company. Unanticipated developments could delay, prevent or otherwise adversely affect the proposed separation, including, but not limited to, disruptions in general or financial market conditions, material adverse changes in business or industry conditions, the possibility that closing conditions for the separation may not be satisfied or waived, the risk that any consents or approvals required in connection with the separation may not be received, the possibility that the separation may not qualify for the expected tax treatment, and the risk that the separation may be more difficult, time-consuming or costly than expected. There can be no assurances that CVS Health will be able to complete the proposed separation on the terms or on the timeline that was announced, if at all, or that dis-synergy costs, costs of restructuring transactions and other costs incurred in connection with the separation will not exceed CVS Health’s estimates. In addition, if the separation is completed, the Company may not be able to achieve the anticipated benefits that are expected to result from the separation within the expected time frame or at all.
57
Form 10-Q Table of Contents
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
(c) Stock Repurchases
The following table presents the total number of shares purchased in the three months ended September 30, 2026, the average price paid per share and the approximate dollar value of shares that still could have been purchased at the end of the applicable fiscal period, pursuant to the share repurchase programs authorized by CVS Health Corporation’s Board of Directors on November 17, 2022 and December 9, 2021. See Note 5 ‘‘Shareholders’ Equity’’ contained in “Notes to Condensed Consolidated Financial Statements (Unaudited)” in Part I, Item 1 of this Quarterly Report on Form 10-Q for additional information.
Fiscal Period
Total Number
of Shares
Purchased
Average
Price Paid per
Share
Total Number of Shares
Purchased as Part of
Publicly Announced
Plans or Programs
Approximate Dollar
Value of Shares that
May Yet Be
Purchased Under the
Plans or Programs
July 1, 2026 through July 31, 2026
—
$
—
—
$
11,500,000,143
August 1, 2026 through August 31, 2026
—
$
—
—
$
11,500,000,143
September 1, 2026 through September 30, 2026
—
$
—
—
$
11,500,000,143
—
—
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not Applicable.
Item 5. Other Information
Securities Trading Plans of Directors and Executive Officers
During the three months ended September 30, 2026, none of our directors or executive officers
adopted
or
terminated
any contract, instruction or written plan for the purchase or sale of CVS Health Corporation securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement.”
58
Form 10-Q Table of Contents
Item 6. Exhibits
The exhibits listed in this Item 6 are filed as part of this Quarterly Report on Form 10-Q. Exhibits marked with an asterisk (*) are management contracts or compensatory plans or arrangements. Exhibits other than those listed are omitted because they are not required to be listed or are not applicable. Pursuant to Item 601(b)(4)(iii) of Regulation S-K, the Registrant hereby agrees to furnish to the U.S. Securities and Exchange Commission a copy of any omitted instrument that is not required to be listed.
INDEX TO EXHIBITS
15
Letter re: unaudited interim financial information
15.1
Letter from Ernst & Young LLP acknowledging awareness of the use of a report dated
November 4, 2026
related to their reviews of interim financial information.
31
Rule 13a-14(a)/15d-14(a) Certifications
31.1
Certification by the Chief Executive Officer.
31.2
Certification by the Chief Financial Officer.
32
Section 1350 Certifications
32.1
Certification by the Chief Executive Officer.
32.2
Certification by the Chief Financial Officer.
101
101
The following materials from the CVS Health Corporation Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2026 formatted in Inline XBRL: (i) the Condensed Consolidated Statements of Operations, (ii) the Condensed Consolidated Statements of Comprehensive Income (Loss), (iii) the Condensed Consolidated Balance Sheets, (iv) the Condensed Consolidated Statements of Cash Flows, (v) the Condensed Consolidated Statements of Shareholders’ Equity and (vi) the related Notes to Condensed Consolidated Financial Statements. The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
104
104
Cover Page Interactive Data File - The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, formatted in Inline XBRL (included as Exhibit 101).
59
Form 10-Q Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
CVS HEALTH CORPORATION
Date:
November 4, 2026
By:
/s/ Brian O. Newman
Brian O. Newman
Executive Vice President and Chief Financial Officer